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Chronic inflammation and immune activation are hallmarks of HIV infection, resulting in 
chronic oxidative stress with over-utilization of antioxidant defences, which may contribute to 
the loss of immune cells and faster disease progression. Low levels of antioxidants in HIV- 
infected individuals have been associated with frequent opportunistic infections and an 
increased risk of mortality. HIV infection is also associated with on-going and aberrant 
activation of both the innate and adaptive immune systems. An important aspect of innate 
immune stimulation is derived from the leakage of lipopolysaccharide (LPS) across the 
damaged mucosal lining of the gut in early HIV infection. The impact of this innate immune 
stimulation on the adaptive arm of the immune system, as represented in this study by levels 
of CD4+ T-cell activation and death, have not been explored previously in untreated HIV 
infection. Using an integrated approach of immune activation, inflammation, oxidative stress 
and ameliorating antioxidant intervention for the first time, this thesis reports the impact of 
inflammatory induced-oxidative stress on CD4+ T-cells in an in vitro HIV model. 
In a preliminary study, baseline levels of neutrophil respiratory burst as an in vitro indication 
of immune stimulation were investigated. The relationships between baseline total 
antioxidant status (TAS), Red blood cell (RBC) antioxidant enzyme activities (catalase, 
superoxide dismutase & glutathione peroxidase), lipid peroxidation and glutathione redox 
ratio and other markers of disease in asymptomatic, untreated HIV infection were also 
explored. The design and optimization of an assay that could determine the effects of LPS-
induced oxidative stress on CD4+ T-cells, was a critical part of this study. The development 
of this assay enabled the measurement of the effects of selected antioxidant interventions N-
acetyl cysteine (NAC) and vitamin C, on LPS-induced CD4+ T-cell activation and death. The 
results were also correlated with CD4 count, viral load and markers of inflammation 
(fibrinogen & D-dimers) in HIV-infected and uninfected groups.  
Neutrophils from HIV-infected persons at rest showed a ―primed‖ response to low stimulating 
agent, bacterial N-formyl peptides (fMLP), which was significantly (P = 0.04) higher than 
uninfected individuals. There was increased oxidative stress as evidenced by increased 
catalase activity, malondialdehyde (MDA) and conjugated dienes (CDs) with a corresponding 
decrease in antioxidant capacity in HIV-infected individuals with lower CD4 count. NAC in 
combination with vitamin C, significantly (P = 0.0018) reduced activation of CD4+ T-cells to a 
greater degree than with either antioxidant alone. NAC and vitamin C individually and in 
combination significantly (P = 0.05, P = 0.012 and P<0.0001) decreased the expression of 
the markers of apoptosis, Annexin V and 7-amino-actinomycin (7-AAD). Importantly, the 
antioxidant combination decreased MDA values and significantly (P = 0.01) increased the 
glutathione redox ratio in the HIV-infected group.  
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Based on these results, the respiratory burst and LPS-induced activation may be important 
contributing factors in inflammatory-associated oxidative stress in HIV infection and 
contribute to the depletion of CD4+ T-cells in the asymptomatic stage of HIV infection. These 
results also indicate the potential inhibitory effects of NAC and vitamin C in combination as 
agents that may limit immune activation and inflammation-induced oxidative stress. 
Importantly, the study showed that at this asymptomatic stage, CD4+ T-cells of the HIV-
infected group responded similarly to stimulation as the HIV negative group, indicating that 
antioxidant defences were still functional and that appropriate early intervention at this stage 
may be protective against oxidative damage to the immune cells.  
To the best of our knowledge, this study is the first to use an integrated approach involving 
not only plasma levels of antioxidant status, but also RBC antioxidant enzyme activities, 
oxidative damage (lipid peroxidation), inflammation, cellular levels of immune activation and 
potential ameliorating interventions in evaluating the problem of inflammation-induced 
oxidative stress in HIV infection. 
Based on the results of this study, it is envisaged that an insight into the immune activation, 
inflammatory and oxidative stress status of patients will enable long-term profiling of each 
patient with a view to individualized therapy. This approach may have a direct impact on 




















Chroniese inflammasie en immuunaktivering is kenmerke van MIV-infeksie. Dié twee 
prosesse lei tot chroniese oksidatiewe stres en oorbenutting van antioksidant 
verdedigingstelsels, wat lei tot die verlies van die immuun selle en vinniger siektevordering. 
Lae vlakke van antioksidante in MIV-positiewe individue stem ooreen met gereelde 
opportunistiese infeksies en 'n verhoogde risiko van mortaliteit. MIV-infeksie word ook 
geassosieer met langdurige en abnormale aktivering van beide die ingebore en aanpasbare 
immuunstelsels. 'n Belangrike aspek van ingebore immuun stimulasie in die raamwerk van 
vroeë MIV-infeksie, is die lekkasie van LPS oor die beskadigde slymvlies voering van die 
dunderm. Die impak van die ingebore immuun stimulasie op die aanpasbare arm van die 
immuunstelsel, soos aangetoon in hierdie studie deur die vlakke van CD4 T-sel aktivering en 
apoptose, is nog nie voorheen ondersoek in onbehandelde MIV-infeksie nie. Met behulp van 
'n oorspronklike, geïntegreerde benadering van immuun aktivering, inflammasie, oksidatiewe 
stres en ‗n lae vlak van antioksidant intervensie, lewer hierdie tesis verslag oor ‗n in vitro 
model van inflammasie-geïnduseerde oksidatiewe stres op CD4 T-selle. 
In 'n voorlopige studie, is basislyn vlakke van die neutrofiel respiratoriese uitbarsting as 'n in 
vitro aanduiding van immuunstimulasie ondersoek. Die verhoudinge tussen basislyn totale 
antioksidant status (TAS), rooi bloed sel (RBC) antioksidant ensiemaktiwiteit (katalase, 
superoksied dismutase, en glutatioon peroksidase), lipied peroksidasie en glutatioon redoks-
verhouding, asook ander merkers van siektevordering in asimptomatiese, onbehandelde 
MIV-infeksie is ook ondersoek. Die ontwerp en optimisering van 'n toets wat die effek van 
LPS-geïnduseerde oksidatiewe stres op CD4 T-selle kan bepaal, was 'n kritieke deel van 
hierdie studie. Die ontwikkeling van hierdie toets het ook die meting van die effek van 
toevoeging van twee geselekteerde anti-oksidante, N-asetiel sisteïen (NAC) en vitamien C, 
op LPS-geïnduseerde CD4 T-sel aktivering en apoptose ondersoek. Die resultate is ook 
gekorreleer met CD4-telling, virale lading en merkers van inflammasie (fibrinogeen en D-
dimere) in groepe met en sonder MIV-infeksie. 
Neutrofiele van asimptomatiese persone met MIV infeksie, het 'n 'voorbereide' reaksie gehad 
teen ‗n lae stimulerende agent, bakteriële N-formiel peptied (fMLP), wat beduidend (P = 0,04) 
hoër was as in individue sonder MIV infeksie. Daar was verhoogde oksidatiewe stres soos 
bewys deur verhoogde katalase aktiwiteit, malondialdehied (MDA) en gekonjugeerde diëne 
(CDs), saam met 'n ooreenstemmende afname in anti-oksidant kapasiteit in MIV-positiewe 
individue met laer CD4-tellings. NAC in kombinasie met vitamien C, het die aktivering van 
CD4 T-selle beduidend verminder (P = 0,0018), ‗n effek wat groter was in vergelyking met 
elke antioksidant alleen. NAC en vitamien C alleen, en in kombinasie het beduidend die 
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uitdrukking van die merkers van apoptose, Annexin V en 7-AAD verminder (P = 0,05, P = 
0.012 en P<0,0001). Wat belangrik is, is dat die afname in MDA waardes as gevolg van 
antioksidante in kombinasie, ‗n beduidende styging in die glutatioon redoks verhouding in die 
MIV-positiewe groep tot gevolg gehad het.  
Hierdie resultate het aangetoon dat die respiratoriese uitbarsting en LPS-geïnduseerde 
aktivering belangrike bydraende faktore mag wees in inflammasie-verwante oksidatiewe 
stres in MIV-infeksie, wat kan bydra tot die uitputting van CD4 T-selle in die asimptomatiese 
stadium van MIV-infeksie. Hierdie resultate dui ook aan dat die moontlike inhiberende effekte 
van NAC en vitamien C in kombinasie, immuun aktivering en geïnduseerde oksidatiewe stres 
kan beperk. Van belang is die feit dat hierdie studie bewys het dat in die asimptomatiese 
stadium van MIV-infeksie, CD4 T-selle weens stimulasie dieselfde gereageer het as dié van 
mense sonder MIV infeksie. Dit het aangedui dat antioksidant verdediging in hierdie stadium 
nog funksioneel was, en dat ‗n toepaslike vroeë intervensie op hierdie stadium beskermend 
teen immuun-sel oksidatiewe skade kan wees. 
Tot die beste van ons kennis, is hierdie studie die eerste om 'n geïntegreerde benadering te 
gebruik, waar plasma vlakke van antioksidant status saam met RBC antioksidant 
ensiemaktiwiteit, oksidatiewe skade (lipied peroksiidasie), inflammasie, sellulêre vlakke van 
immuunaktivering, en potensiële beskermende ingrypings ondersoek is in die evaluering van 
die probleem van oksidatiewe stres in MIV-infeksie wat tot inflammasie lei. 
Gebaseer op dié resultate, word dit in die vooruitsig gestel dat 'n insig in die status van 
immuunaktivering, inflammasie, en oksidatiewe stress van pasiënte, dit moontlik sal maak vir 
langtermyn- beplanning om vir elke pasiënt individuele terapie voor te skryf. Hierdie 
benadering kan 'n direkte impak op die sorg van pasiënte in hulpbron-beperkte gebiede soos 
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This thesis is organized in a format of five articles (written according to specific journal 
guidelines) with plans to submit them for publication in peer reviewed journals sooner rather than 
later and with an opening introduction, literature review and concluding chapters. The first 
chapter is a general overview of the research framework, which includes a brief description of 
the research problem, justification, aims and objectives of the research. The second chapter is a 
review of what other studies have reported in the field of inflammation-induced oxidative stress 
and how this has contributed to the development of the research topic. The research gaps in 
previous studies that form the basis of present study have also been discussed. The third 
chapter reports on a preliminary study that was conducted to investigate neutrophil 
respiratory/oxidative burst response in asymptomatic untreated HIV infection as an in vitro 
indication of a response to immune stimulation. The fourth chapter reports on how baseline 
antioxidant status and oxidative stress indicators relate to markers of disease and inflammation 
in untreated asymptomatic HIV infection. The fifth chapter reports on optimization of an assay 
that could determine the effects of LPS-induced oxidative stress on CD4+ T-cells, which enabled 
the measurement of the effects of selected antioxidant interventions N- acetyl cysteine (NAC) 
and vitamin C, on LPS-induced CD4+ T-cell activation and death. The sixth chapter is an article 
on modulation of LPS-induced CD4+ T-cell activation and apoptosis by antioxidants in untreated 
HIV infection. The seventh chapter is an article on modulation of LPS-induced immune activation 
and oxidative stress by vitamin C and N-acetyl cysteine in untreated asymptomatic HIV 
individuals 
The eighth chapter is the conclusions, summary and recommendations. The developed HIV 
model for intervention is also discussed in this chapter. 




Adaptive Immunity: Arm of the immune system composed of T and B-cells with antigen-
specific receptors that upon activation use multiple effector 
mechanisms to respond to antigen challenge. 
Antioxidant:  A chemical when present in small amounts reduce or prevent oxidation 
of other molecules by being oxidized. 
Apoptosis:  Programmed cell death or a genetically controlled mechanism of cell 
suicide involved in regulation of tissue homeostasis. 
Asymptomatic: A stage of disease in which there are no symptoms of the disease. 
Biomarker: A measurable biochemical indicator of a biological state, such as 
severity of presence of disease. 
CD4+T-cells:   Mature T-helper cells expressing surface protein CD4. 
Chemokine: Low molecular weight cytokine capable of inducing 
chemotaxis/movement in leukocytes. 
Chronic disease:  A long term disease that can be controlled but not cured. 
Correlation:  Any broad class of statistical relationship involving dependence. 
Cytochrome p-450: A group of hemoproteins, which form multi-component electron 
transfer chains, useful in metabolism of endogenous and exogenous 
molecules e.g. drugs and toxins in humans. 
Cytokine: Is a cell signaling molecule made by cells, which modulate immune 
response such as inflammation cell growth & proliferation, 
differentiation and apoptosis. 
Dismutation: A reaction involving two identical molecules in which one gain what the 
other loses e.g. oxidation/reduction or 
phosphorylation/dephosphorylation. 
Ex vivo:  An experiment conducted outside of the organism. 
Fenton Reaction: A non-enzymatic reaction of hydrogen peroxide with transition metals 
such as Fe3+ and Cu2+ to produce hydroxyl radicals and ferric iron. 
Flow cytometry:  Process of measuring or counting cells or a technique of quantitative 
single cell analysis. 
Flow-check 
Fluorosphere: Suspension of fluorescent microspheres used for daily verification of 
flow cytometers optical (laser) alignment and fluidic system. 
Flow-set  
Fluorospheres: Suspension of fluorospheres (fluorescent micro beads) used in 
optimizing a flow cytometer for qualitative analysis of cells: 




Free radical: A highly reactive molecule with one or more unpaired electrons in its 
outer orbit. 
Full matrix color 
Compensation: Procedure used in flow cytometry to ensure and improve inter-
instrument agreement in display and light sources measurements. 
GRADE: A type of systematic review, which separates the rating of the quality of 
evidence (by classifying it as high, moderate, low or very low) from the 
rating of the strength of recommendation. 
HIV transcription: Process by which single-stranded RNA with a base sequence 
complementary to one strand of double-strand DNA is synthesized via 
DNA-dependent RNA polymerase. 
Immune activation: State of immune stimulation characterized by high expression of CD38 
and HLA-DR. 
Immunophenotyping: Analysis of antigens expressed by cells as by flow cytometry or 
immunohistochemistry. 
In vitro: An experiment or an occurrence on isolated cell components e.g. in a 
test tube. 
In vivo:   An experiment or an occurrence in or on intact or whole organism. 
Inflammation: A protective tissue response to harmful stimuli such as pathogens, 
damaged cells or irritants. 
Innate Immunity: Arm of immune system composed of phagocytes (dendritic cells, 
macrophages & neutrophils), natural killer cells with germ line-encoded 
receptors specific for markers of perturbations (infection, damage or 
loss of exposure of self-molecules), complement and antimicrobial 
peptides. 
Interleukins: Cytokines produced by cells (WBCs) to modulate immune responses 
such as inflammation, growth, proliferation or apoptosis. 
Kinase: An enzyme that transfers phosphate groups from a high energy donor 
molecule e.g. ATP to specific substrates (phosphorylation). 
Lentivirus: A genus of virus of the retroviridae family characterized by a long 
incubation period 
Lipid peroxidation: Oxidative degradation of lipids by free radicals. 
Metalloenzymes: Enzymes containing a tightly bound metal e.g. zinc, cobalt, iron or 
magnesium as an integral part of its structure. 
Monoclonal 
Antibodies:  A single clone of antibodies derived from a single cell. 
Neutrophils: Types of white blood cells characterized by the ability to mediate 
immune responses against infectious microorganisms. 




NOX family:  A group of white blood cells with NADPH oxidase complex, which is 
capable of generating ROS. 
Optimization: Process or method of making something e.g. designs, system as fully 
perfect, functional or effective as possible. 
Oxidation:                    The loss of electrons by a substance. 
Oxidative stress:  An imbalance between free radicals formation and antioxidant defense 
mechanisms. 
Peroximes:  Cell organelles responsible for metabolism of fatty acids. 
Peroxidation:   Oxidation initiated by free radicals with the end products being 
hydroperoxides 
Phagocytosis: Engulfing/endocytosis of particulate material or cell fragment by cells 
to be killed or digested. 
Phospholipids: Any lipid containing phosphorous. 
Phosphotidylserine (PS): A phospholipid predominantly occurring in the inner leaflet of 
eukaryotic cellular membranes 
Plasma: Fluid part of blood in which the particulate components have been 
suspended. 
Polymorphism: Ability to exist in several different forms. 
Priming:  Initial exposure to antigen of cells to facilitate the action of another cell. 
Pro-inflammatory 
Cytokine:   Cytokine capable of stimulating inflammation. 
Pro-oxidant: A free radical of pathological importance or a toxic substance that can 
cause damage to biological molecules. 
Protein Kinases: A kinase enzyme that modifies other proteins by chemically adding 
phosphate groups. 
Pro viral:  Precursor or latent form of a virus that is capable of being integrated 
into the genetic material of the host cell and being replicated with it. 
P-value: Levels of significance within a statistical hypothesis test representing 
the probability of occurrence of a given event. 
Redox status:   Oxidation and reduction status. 
Regimen: A regulated course of medical treatment designed to give a positive 
result. 
Respiratory burst: Rapid release of reactive oxygen species (ROS) from different cells. 




RNS: Nitrogen containing molecules/species produced by incomplete 
reduction of oxygen and nitrogen. 
ROS: Oxygen containing molecules/species produced by incomplete 
reduction of oxygen. 
Seronegative: Absence of detectable specific antibodies to virus in the blood stream 
due to infection or immunization. 
Seropositive:  Presence of detectable specific antibodies to virus in the blood stream 
due to infection or immunization. 
Statistically 
Significant:  Statistical term that tells how reliable a difference or relationship exists. 
T-cell hybridomas: Somatic cells hybrid formed by fusion of normal T-cells and tumour 
cells resulting in cells that can produce same secretions as normal 
cells and able to proliferate indefinitely in culture medium 
Toll-like receptors: A group of pattern recognition receptors first discovered in Drosophila, 
which play a critical role in the innate immunity. 
Total antioxidant 
Capacity: The ability of antioxidants (both water-soluble and lipid-soluble) to 
clear/remove harmful free radicals in the blood or cells. 
Total antioxidant 
Status:  The sum total of endogenous and diet/food/supplements derived 
antioxidants of the extracellular fluid of an individual. 
Ubiquitination: Process of addition of ubiquitin to proteins as one step of intracellular 
breakdown. 
β-oxidation: Oxidative degradation of saturated fatty acids in which two-carbon 
units are sequentially removed from the molecule with each turn of the 
cycle. 




LIST OF SELECTED ABREVIATIONS 
°C:                             Degrees Celsius 
7-AAD:                       7- Aminoactinomycin D 
AAPH:                        2,2‘-Azobis (2-amidinopropane) hydrochloride  
ABTS:                        2,2‘-Azino-bis (3-ethylbenzothiazoline-6-sulfonic) diammonium salt 
AIDS:                         Acquired immunodeficiency syndrome 
APC:                          Allophycocyanin 
ATF-2:                       Activating transcription factor 2 
ATP:                          Adenosine triphosphate 
ARV‘s:                       Antiretroviral therapies 
AUC:                          Area under the curve 
BCL-2:                       B-cell lymphoma-2 
BHT:                          Butylated hydroxytoluene 
BMK1:                       Big mitogen activated kinase 1 
CD:                  Cluster differentiation 
CDs: Conjugated dienes 
CPUT:                       Cape Peninsula University of Technology 
DHR 123:                  Dihydrorhodamine 123 
DMACA:                    4-dimethylaminocinnamaldehyde 
DNA:                         Deoxyribonucleic acid 
DPPH:                       2,2-diphenyl-1-picrylhydrazyl 
DTNB:                       5-5'-dithiobis [2-nitrobenzoic acid] 
ERK:                          Extracellular signal-regulated kinases 
EtOH:                         Ethanol 
FACS:                        Fluorescein activated cell sorting 
FBS:                           Foetal bovine Saline 
Fe:   Iron 
FITC:                          Fluorescein isothiocyanate 
FL:    Fluorochlome 
fMLP:                          Bacterial N-formyl peptides 
FRAP:                         Ferric reducing antioxidant power/potential 
GCLC:   Glutamate cysteine ligase catalytic unit 
GPx:                           Glutathione peroxidase 
GR: Glutathione reductase 




GRADE:           Grading of recommendations assessment, development and            
evaluation 
GSH:                          Reduced Glutathione  
GSSG:                       Oxidised Glutathione  
HAART:                      Highly active antiretroviral therapy 
H2O:                           Water 
H2O2:                         Hydrogen peroxide 
HCl:                            Hydrochloric acid 
HLA-DR:                    Human leukocyte antigen D related 
HO-:                           Hydroxyl radical 
ICAM:                         Intracellular adhesion molecule- 1 
IKK:                            Inhibitor of kappa B kinase 
JAK:                           Janus kinase 
JNK:                           c-JUN N-terminal kinases 
LDL:                           Low density lipoproteins 
LPS:                           Lipopolysaccharides 
MAPK:                        Mitogen activated protein kinase 
M2VP:                        1-methyl-2-vinyl-pyridinium trifluoromethane sulfonate 
MBH:                          Membrane bound haemoglobin  
MCP-1:                       Monocyte chemotactic protein-1 
MDA:                          Malondialdehyde 
MeOH:                       Methanol 
MIP-1:                         Macrophage inflammatory protein- 1 
MPA:                           Metaphosphoric acid 
mRNA:                        Messenger ribonucleic acid 
Na2CO3:                    Sodium carbonate 
NaCl:                         Sodium chloride 
NADPH:                     Reduced nicotinamide dinucleotide phosphate 
NaOH:                        Sodium hydroxide 
NF-kB:                        Nuclear factor kappa-light chain enhancer of activated B-cells 
Nrf2:                           Nuclear factor (erythroid-derived) like 2 
O2.-:                          Superoxide radical 
ORAC:                       Oxygen radical absorbance capacity 
PE:                             Phycoerythrine 
PerCP:                       Peridinin chlorophyll protein 




PI3:   Phosphoinositide 3 kinase 
PMA:                          Phorbol myristate acetate 
PUFA‘S:                     Polyunsaturated fatty acids 
r:                 Spearman‘s correlation coefficient 
R 123:                        Rhodamine 123 
rRNA:                         Ribosomal ribonucleic acid 
RBC:              Red blood cells 
ROS:                          Reactive oxygen species 
SAPK:                        Stress associated protein kinase 
SOD:                          Superoxide dismutase 
TAC:                           Total antioxidant capacity 
TBA:                           Thiobarbituric acid 
TBARS:                      Thiobarbituric acid reactive substances 
TB:   Tuberculosis 
TE:   Trolox equivalents 
TEAC:     Trolox equivalent antioxidant capacity 
TLR:                           Toll- like receptor 
TNB:                           5-thionitrobenzoic acid 
TNF:                           Tumour necrosis factor 
TPTZ:                     2,4,6-Tri [2-pyridyl]-s-triazine 
TRAF:                         Tumour necrosis factor receptor associated factor 
TRAIL:                        Tumour necrosis factor-related apoptosis inducing ligand 
Trolox:                        6-Hydroxy-2,5,7,8- tetramethylchroman-2-carboxylic acid 
µM:   Micromole 
UNAIDS:                     United nation programme of acquired immune deficiency syndrome 
USA:                           United States of America 
V-CAM:                       Vascular cell adhesion molecules 
WHO:                         World health organisation 
ΔA:                             Absorbance difference 
  

































Although the HIV pandemic has globally stabilised since 2008 due to the introduction of the 
highly active antiretroviral therapy (HAART) in 1996 (Gil et al., 2013; UNAIDS, 2011), it still 
remains a serious health threat. This pandemic continues to devastate resource-poor countries, 
especially in sub-Saharan Africa, which bears the highest burden (WHO, 2009; UNAIDS, 2012). 
Moreover, the inability of HAART to completely eradicate HIV, in association with the on-going 
immune activation and inflammation, has resulted in inflammation-associated complications and 
non-AIDS-associated deaths, such as myocardial infarction (El-Sadr et al., 2006; Lau et al., 
2006; Kuller et al., 2008). A major characteristic of HIV infection is the continuous systemic 
immune activation and inflammation (Brenchley et al., 2006; Haynes, 2006; Nixon, 2010) which 
may result in oxidative stress, weakened immune responses, pro-inflammatory cytokine 
production, inflammation-associated complications and uncontrolled viral replication, in activated 
CD4+ T-cells (Haynes, 2006; Morris et al., 2012). Excessive immune activation, inflammation 
and oxidative stress are associated with loss of immune cells, faster disease progression and 
increased risk of mortality (Pace & Leaf, 1995; Hazenberg et al., 2003, Tan et al., 2008; Tien et 
al., 2010). Inflammation which is an important non-specific protective response of a tissue to 
harmful stimuli such as pathogens, damaged cells or irritants (Prescott et al., 2002), is 
associated with increased production of reactive oxygen species (ROS) which are associated 
with apoptosis of CD4+ T-cells in HIV infection (Hockenbery et al., 1993; Kotler, 1998; Gil et al., 
2003). Oxidative stress which has been defined as the cytopathological consequence of an 
imbalance between free radical production and the antioxidant status of the cell (Franco & 
Panayiotadis, 2009), is thought to add significantly to the depletion of CD4 + T-lymphocytes in 
HIV infection, thereby contributing to the progression to AIDS (Gil et al., 2003; Pasupathi et al., 
2009; Wanchu et al., 2009). 
Mitochondria are a major source of ROS in the cells through electron leakage from the 
mitochondrial respiratory chain. The leaking electrons react with molecular oxygen to form 
superoxide and other ROS (Andreyev et al., 2005). Other major endogenous sources of ROS 
include neutrophil respiratory burst, whereby some phagocytic cells in an oxidative burst, 
produce ROS through NADPH oxidase catalysed reaction, intentionally to destroy cells infected 
with bacteria or virus. The activated neutrophils and macrophages, during inflammation produce 
hydrogen peroxide (H2O2) and other oxidants (Kotler, 1998) during respiratory/oxidative burst 
due to increased oxygen use and ATP production, which further promotes tissue injury and 
inflammation (Israel & Israel, 2002; Prescott et al., 2002). As a result, neutrophil respiratory burst 
is thought to contribute to the overall oxidative stress, which is implicated in the massive 




depletion of CD4+ T-cells in early HIV infection (Reeves, et al., 2002). Interestingly, neutrophil 
respiratory burst levels have not been described previously in the context of asymptomatic 
untreated HIV infection nor have the effects of this oxidative stress been studied in the CD4+ T-
cell group. 
Since the human biological system constitutively produces free radicals and other oxygen-
derived radical species, cells have evolved complex antioxidant defence systems to combat this 
(Halliwell & Cross, 1994; Evans & Halliwell, 2001; Leonarduzzi et al., 2010). The antioxidant 
defence system consists of primary or preventive antioxidants, which limit the initial formation of 
oxygen-centred radicals of organic compounds. The first primary defence mechanism consists of 
antioxidant enzymes such as catalase (CAT), found in peroximes in most tissues, which catalyse 
the two stage change of H2O2 to water and oxygen; glutathione peroxidase (GPx) and 
glutathione reductase (GR), which catalyse oxidation of glutathione at the cost of H2O2 in the 
cytosol and mitochondria and superoxide dismutase (SOD) which catalyse dismutation of 
superoxide to H2O2, which can then be removed. Secondary scavenging or chain breaking 
antioxidants are present to trap intermediate ROS and thus interrupt the chain reaction. The third 
line of defence consists of repair systems for damaged nucleic acids, proteins and lipids 
(Halliwell, 1994). 
The, cells of the immune system are remarkably sensitive to oxidative stress, since their plasma 
membranes contain high levels of polyunsaturated acyl lipids, which are vulnerable to 
peroxidation. Consequently, excessive ROS causes damage to biomolecules such as DNA, 
carbohydrates, proteins and uric acids (Prior & Cao, 1999; Devasagayam et al., 2004). More 
importantly, this oxidative damage is particularly marked in the phospholipids, which constitute 
the cell membrane (Block et al., 2002; Roberts et al., 2010), therefore making lipid peroxidation 
a convenient marker of oxidative stress in living systems (Nalsen, 2006). Furthermore, 
peroxidation of the polyunsaturated acyl chain in the cell membranes leads to loss of membrane 
integrity and altered membrane fluidity, consequently leading to impairment of intracellular 
signalling and the overall cell function (Chew & Park, 2009). As a consequence, immune cells in 
HIV infection are in constantly challenged by oxidative stress (Willcox et al., 2004; Guerra et al., 
2011; Morris et al., 2012), which further damages the already compromised immune system and 
contributes to disease progression (Haynes, 2006). Therefore, maintenance of a proper 
functioning antioxidant defence system in HIV-infected patients is vital, as it protects the cells 
against oxidative damage, hence promoting their survival (Kotler, 1998; Wanchu et al., 2009; 
Morris et al., 2013). 




Several studies have linked a weakened antioxidant defence system to the increased oxidative 
stress found in HIV infection (Dobmeyer et al., 1997; Pasupathi et al., 2009; Suresh et al., 2009). 
Pasupathi and co-workers (2009). observed a markedly decreased activity of SOD, CAT, GPx, 
GR, glutathione S-transferase (GST), reduced glutathione (GSH), in HIV/AIDS patients as 
compared to healthy controls (Pasupathi et al., 2009). In this study, significantly decreased 
levels of plasma GSH, vitamin A (β-carotene), vitamin C, vitamin E, serum uric acid, albumin, 
selenium and zinc in AIDS patients compared to HIV positive patients and controls were 
reported. In addition, elevated markers of lipid peroxidation such as malondialehyde/ 
thiobarbituric acid reactive substances and conjugated dienes have been reported in previous 
studies (Allard et al., 1998; Pasupathi et al., 2009; Suresh et al., 2009). Decreased levels of 
serum vitamins and minerals have been linked to a higher risk of disease progression and 
mortality in HIV infection (Pace & Leaf, 1995; Hazenberg et al., 2003,). Supplementation with 
micronutrients was shown to delay HIV progression and reduce mortality in HIV-infected 
individuals not receiving HAART (Jaruga, et al., 2002; Drain et al., 2007). Therefore, 
maintenance of antioxidant defences in HIV infections may be important as it prolongs the 
survival of the patient by delaying the accumulation of oxidative stress-induced tissue damage. 
The role of immune activation and inflammation, as stronger indicators of HIV pathogenesis than 
CD4 count and viral load, has become an important subject of HIV research (Giorgi et al., 1993; 
Fahey et al., 1998; Liu et al., 1998; Brenchley et al., 2004; Cassol et al., 2010). The role played 
by LPS translocation and other microbial products was a key finding in understanding that other 
factors besides the viral load, may be contributing to ongoing to immune activation (Brenchley et 
al., 2006). The translocation of microbial products from the gastrointestinal tract (GIT) into the 
systemic circulation as a result of breakdown of the gut mucosal integrity (―leaky gut‖ 
phenomenon) in the acute phase of the infection induces the activation of innate immune cells 
such as neutrophils, monocytes and dendritic cells. This is likely to result in increased oxidative 
stress, depletion of antioxidant defence mechanisms and increased susceptibility to apoptosis 
(Brenchley et al., 2006; Cassol et al., 2010). Therefore, ―the leaky gut phenomenon‖ is regarded 
as an important source of on-going immune stimulation and consequently immune activation 
persists as a characteristic of HIV infection (Hazenberg et al., 2003; Cassol, 2010). Immune 
activation is associated with the depletion of CD4+ T-cells and increased risk of disease 
progression (Pace & Leaf, 1995; Hazenberg et al., 2003). This occurs during the early phases of 
HIV infection, and more specifically, stage II of HIV infection has been associated with higher 
free radical production (Bundres et al., 1993; Favier et al., 1994; Jarstrand & Akerlund, 1994; 
Pugliese et al., 2005). Some viral proteins (such as vpr) are capable of binding to mitochondria 




of infected CD4+ T-cells, directly inducing apoptosis (Jacotot et al., 2000). Figure 0.1 below 
summarizes the link between HIV, immune activation, inflammation, oxidative stress and CD4+ 
T-cell depletion. Allard et al. showed increased oxidative stress in HIV-positive patients when 
compared to seronegative control subjects and decreased plasma concentrations of various 
antioxidant vitamins and selenium (Allard et al., 1998). Previous studies have reported clinical 
improvement in AIDS patients who willingly consumed high doses (500 mg, 800 mg and 1 800 
mg) of ascorbic acid (Allard et al., 1998; Fawzi et al., 2002; Kaiser et al., 2006) and the potential 
of vitamin C to inhibit apoptosis, albeit in erythrocytes has been described (Cathcart, 1984; 
Mahmud et al., 2010). Previous studies involving LPS-induced activation of cells have utilized 
varying concentrations of LPS (100 ng/ml - 5 µg/ml), N-acetyl cysteine (NAC) (5 - 50 µM), and 
vitamin C (25 - 50 nM) therefore the current study required considerable optimization of 
conditions.(Dobmeyer et al., 1996; Shang et al., 2003; Yamanda et al., 2006). 
 
Figure 0:1: Proposed link between HIV immune activation and CD4+ T-cells depletion 
1.2 Statement of the problem 
Various studies have confirmed that HIV-infected patients are under chronic oxidative stress and 
that oxidative stress plays a key role in HIV pathogenesis (Pace & Leaf, 1995; Jaruga et al., 
2002; Gil et al., 2003; Wanchu et al., 2009; Morris et al., 2012). More importantly, all these 
studies on oxidative stress and HIV have consistently implicated changes in the antioxidant 
defence system and increased ROS production during infection. They have also concluded that 
micronutrients and dietary antioxidants, could offer a cost-effective supplementary therapy to 




HIV patients, which may prolong and improve their survival rate (Wanchu et al., 2009; Morris et 
al., 2013). However, despite the numerous studies done on HIV and oxidative stress, several 
gaps remain in the understanding of the link between oxidative stress and immune deficiency. 
Since oxidative stress is implicated in inflammation, HIV replication and apoptosis of immune 
cells and therefore the progression of HIV to AIDS (Dobmeyer et al., 1997; Kotler, 1998; 
Papasuthi et al., 2009), reducing the impact of oxidative stress in immune cells may present an 
additional strategy for slowing down HIV progression and thereby increasing the survival rate of 
infected persons. Hence, it becomes necessary to find ways of ameliorating oxidative stress 
during early HIV infection before the oxidative damage and excessive immune depletion of 
immune cells starts in order to delay the progression to AIDS. The impact of direct stimulation of 
the innate immune system on CD4+ T-cell death has not been well documented in the literature 
to date. Studies on oxidative stress levels in asymptomatic untreated HIIV infection in 
conjunction with effects of LPS-induced stimulation on CD4+ T-cell activation and death; and 
potential of antioxidants to ameliorate these effects, are still scarce and limited especially in the 
South African context. ART remains the best treatment option for HIV/AIDS. While not 
advocating antioxidant therapy in general; but rather specific, scientifically determined 
combinations with validated in vitro effects on the immune system, which might offer a 
supplementary therapeutic strategy that aims to minimize immune activation, inflammation and 
oxidative stress responses in HIV infection. 
1.3 Aims and objectives 
The general objective of this study was to investigate the impact of inflammation-induced 
oxidative stress on the integrity of CD4+ T-cells in asymptomatic untreated HIV infection and 
potential ameliorating interventions. This was based on two hypotheses; 1) that a dysfunctional 
enzymatic antioxidant defense system (SOD, CAT, GPx) will lead to an overall increase in H2O2 
levels which has been implicated in apoptosis of cells from HIV-infected individuals as H2O2 is 
membrane soluble and can easily enter the cells and cause apoptosis (Dobmeyer, et al., 1996) 
and 2) that antioxidant intervention ameliorates HIV inflammation-induced oxidative stress and 
delays apoptosis of the cells from HIV-infected individuals, thereby promoting their survival. 
Results from the current study will make an important contribution to the current knowledge in 
the field of HIV and oxidative stress, by addressing one of the underlying mechanisms by which 
dietary antioxidants (in combination) can modulate oxidative stress in specific immune cells 
(CD4+ T-cells) from HIV-infected individuals. Through data from this study, possible 
management strategies can be devised for HIV patients. 




Ethics approval was obtained from both the clinical site: University of Cape Town: REC: REF: 
417/2006 and University of Stellenbosch (laboratory site): N07/09/197. This sub-study was 
added as an addendum to the already approved original project, N07/09/197. The current study 
was divided into four phases, each addressing different aspects as mentioned below. 
1.3.1 A preliminary study of the neutrophil respiratory burst in asymptomatic untreated 
HIV individuals as an in vitro indication of response to immune stimulation 
HIV is characterized by persistent inflammation and immune activation resulting in chronic 
oxidative stress with over-utilization of endogenous antioxidant defences. The aim of this 
preliminary study was to determine the capacity of innate immune cells to produce a respiratory 
burst, which may impact on the integrity of adaptive immune cells such as the CD4+ T-cells in 
HIV infection. Specifically, the neutrophil respiratory burst response in asymptomatic untreated 
HIV-infected individuals was determined and compared with uninfected controls as an in vitro 
indication of response to immune stimulation. In this preliminary study, the neutrophil respiratory 
burst response of 14 HIV-infected and 12 uninfected controls as well as TAS, measured as 
oxygen radical absorbance capacity (ORAC), were determined. Results of the phagoburst test 
were correlated with CD4 count, viral load and other markers of immune system activation and 
inflammation in these individuals and control group. 
1.3.2 Baseline antioxidant status and oxidative stress in asymptomatic untreated HIV 
infection 
Scientific evidence suggests that HIV-infected patients are under chronic oxidative stress (Pace 
& Leaf, 1995) and that a weakened antioxidant defence system is associated with the increased 
oxidative stress found in HIV infection (Dobmeyer et al., 1998; Pasupathi et al., 2009; Suresh et 
al., 2009). In this phase of the study, the aim was to determine the baseline antioxidant status 
and oxidative stress status in untreated asymptomatic HIV-infected individuals and its 
relationship (if any) to markers of disease and inflammation. Therefore, the total antioxidant 
status, lipid peroxidation markers, activity of antioxidant enzymes and the glutathione (GSH) 
redox status, were determined and correlated with other markers of the disease. In total 20 HIV-
infected asymptomatic untreated participants and 20 uninfected controls were used in this 
preliminary study. 
1.3.3 Effects of temperature, time and concentration on LPS-induced whole blood 
activation and antioxidant intervention in asymptomatic untreated HIV infection: An 
optimization study 
Previous studies involving LPS-induced activation of cells have utilized varying concentrations of 
LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and vitamin C (25 - 50 nM) and therefore it was 




critical to optimize the conditions for the current study (Dobmeyer et al., 1996; Shang et al., 
2003; Yamanda et al., 2006). The LPS stimulation and Annexin V/7-AAD [apoptosis] assays 
were optimized before undertaking the current study. The aims of this phase of the study were to 
explore and optimize the in vitro effects of time, temperature and concentration on LPS-induced 
immune activation and apoptosis in asymptomatic, untreated HIV-infected individuals. The effect 
of varying doses of selected antioxidants (vitamin C & NAC) on LPS-induced activation was also 
explored. For the optimization phase, blood samples from 20 HIV-infected individuals and 20 
uninfected controls were utilized. 
1.3.4 LPS-induced activation, oxidative stress and modulation with antioxidants 
The general objective of this phase was to study the effects of selected antioxidants such as 
vitamin C and a glutathione precursor (NAC) on the oxidative stress status and apoptosis of 
CD4+T-cells from HIV-infected individuals. Specific aims of the study were to first develop a flow 
cytometry assay for the assessment of levels of CD4+ T-cell activation in HIV-infected 
individuals and secondly, to measure immune activation before and after stimulation with LPS 
and incubation with the selected antioxidants. The ability of selected antioxidants to modulate 
LPS-induced immune activation was also investigated in this phase. A total 20 HIV-infected 
asymptomatic untreated participants and 20 uninfected controls were analysed in this phase of 
the study. 
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UNAIDS estimates that there were 34.5 million people living with human immunodeficiency virus 
(HIV) at the end of 2011, the majority of whom (about 23.5 million or about 70% of total HIV 
burden) were from sub-Saharan Africa (UNAIDS, 2012). As the pandemic continues to 
devastate these resource-poor countries, sub-Saharan Africa bears two thirds of the total global 
HIV infections. Over 7500 people become infected with HIV daily and over 5600 people die daily 
from the disease globally, according to the 2009 joint United Nations programme on HIV/AIDS 
(UNAIDS, 2009). In 2009 alone there were 1.3 million AIDS-related deaths among adults and 
children in sub-Saharan-Africa (UNAIDS, 2010). To date, the discovery of a cure for the HIV 
pandemic remains elusive and the factors precipitating the progression of HIV infection to 
acquired immunodeficiency syndrome (AIDS) still remains unclear (Appay & Sauce, 2008). In 
addition to reviewing and analyzing the previous studies on oxidative stress and its role in the 
progression and pathogenesis of the HIV infection, this review discusses the interrelationship 
between inflammation, immune activation, oxidative stress and apoptosis and its impact on 
CD4+ T-cells in HIV infection. Potential ways to ameliorate oxidative stress using selected 
antioxidants, which could delay the progression and thereby increase the survival rate of 
infected persons have also been discussed. A brief overview of some of the 
immunohaematopoietic cells targeted by HIV has also been discussed. The review was 
conducted by searching PUBMED, MEDLINE, SCOPUS; GOOGLE SCHOLAR, 
SCIENCEDIRECT databases using the following search words; HIV, inflammation, oxidative 
stress, antioxidant defense systems, immune activation and apoptosis of CD4+ T-lymphocytes 
in asymptomatic HIV infection. The search was not limited by date, treatment or stage of 
disease, but only to HIV disease. 
2.2 HIV disease: Current and future perspectives 
The HIV infection is perhaps the most widely studied disease since its discovery in 1983 
(Papadopulos-Eleopulos, et al., 1992; Appay & Sauce, 2009). Successful vaccines and 
treatments for this small virus comprising of 9 genes, continues to elude scientists for decades 
without a remedy in sight in the near future. How this virus is capable of rapid mutation and 
evasion of the host‘s immune system still remains a mystery to scientists. However, a great body 
of information regarding HIV pathogenesis, such as depletion of both infected and ―innocent 
bystander‖ CD4+ T-cells through apoptosis, has been gathered over the last two decades 
(Appay & Sauce, 2008; Hunt, 2010). An interesting phenomenon in HIV pathogenesis has been 




the role of chronic immune activation and inflammation in disease progression (Brenchley et al., 
2004). 
The introduction of HAART regimens in the mid-1990s has resulted in a 50% decline in AIDS 
related deaths (UNAIDS, 2010), although, this is mostly in developed countries. In developing 
countries however, the access to antiretroviral therapy (ARVs) is still low due to economic 
reasons, therefore a large number of infected persons continue to die before they can benefit 
from the ARV‘s. The role out of ARV programmes has been slow. Although more than 6.2 million 
people in sub-Saharan Africa are currently receiving ARV‘s, more than 10 million people living 
with HIV and qualifying for treatment, according to the 2010 WHO guidelines, are still on a 
waiting list (UNAID, 2012). According to WHO, individuals with symptomatic HIV disease and 
those with lower CD4 count are like to benefit more for initiating ARVs. Based on increasing 
evidence supporting earlier initiation of ARVs, WHO in 2010 recommended commencement of 
ARVs for HIV-infected individuals with CD4 count of ≤350 cells/mm3 regardless of clinical stage 
and for those with clinical stages 3 or 4 regardless of CD4 count (WHO, 2012). Evidence 
gathered from systematic review of previous observational studies and randomized control trials 
using grading of recommendations, assessments, development and evaluation (GRADE) 
evidence profiles; all indicated benefits of early ARVs initiation, such as reduced risk of 
progression to AIDS and/or death, TB, development of a non-AIDS-defining illness and 
increased likelihood of immune recovery. Consequently, WHO currently recommends initiation of 
ARVs to all individuals with confirmed HIV infection with a CD4 count of ≤500 cell/mm3, 
prioritizing those with advanced clinical stages (3 or 4) or a CD4 count of ≤350 cells/mm3 (WHO, 
2013). This may be difficult to implement in resource-poor countries, since significant numbers of 
patients with CD4 count of less than 200 cells/mm3 have not yet had access to ARV‘s. 
The depletion of CD4+ T-lymphocytes is a characteristic of HIV infection (Brenchley et al., 2004; 
Brenchley et al., 2006; Appay & Sauce, 2009), which is complemented by the HIV‘s ability to 
mutate rapidly, thereby capable of evading its host‘s immune system and persistently causing 
serious damage (Hahn et al., 1986; Hunt, 2010). Another major characteristic of HIV infection, is 
the intense generation of pro-inflammatory cytokines (Morris et al., 2010) with a sustained loss 
of immune competent and experienced cells, resulting in aberrations in the host‘s immune 
integrity (Haynes, 2006; Pasupathi et al., 2009). Scientific evidence suggests that this is strongly 
associated with increased oxidative stress at cellular levels within the lymphatic and systemic 
tissues (Pace & Leaf, 1995; Dobmeyer, 1998; Pasupathi et al., 2009). More importantly, recent 
studies in developed countries have indicated that ongoing immune activation and inflammation, 
despite adequate control of viral load, increases the risk of thrombotic and inflammatory-




associated complications such as myocardial infarctions and certain cancers (Nakhla & Rumble, 
2010). As a result, the role of immune activation and inflammation as stronger indicators of HIV 
pathogenesis rather than CD4 count and viral load has become a common subject of study 
(Fahey, et al., 1998; Carbone et al., 2000; Brenchley et al., 2004).  
2.2.1 WHO clinical and immunological staging of HIV infection 
In its effort to assist in clinical management and to maximize ARV therapy, World Health 
Organization (WHO) is continuously revising its clinical and immunological classification of HIV 
guidelines (WHO, 2007; WHO, 2009). The clinical staging of HIV is used only when HIV infection 
has been confirmed, which enables the assessment at baseline (first diagnosis of HIV infection) 
or for long term HIV care and in the follow up of patients in care and treatment programmes 
(Mellors et al., 1997; Bonnet et al., 2005; WHO, 2007). Clinical staging is also useful in decision 
making, such as when to commence HIV interventions (WHO, 2007). More importantly, clinical 
stages of HIV have been shown to correlate with survival, prognosis and progression of clinical 
disease without ARVs in adults and children (Malamba et al., 1999; Dilys et al., 2002; Dunn, 
2003). WHO uses clinical (HIV-associated symptoms) and immunological classification to 
categorize HIV infection. Using HIV-associated symptoms, WHO classifies HIV infection into four 
clinical stages, depending on severity of symptoms; 1) clinical stage 1, the asymptomatic stage, 
in which there is no symptoms or there can be a persistent generalized lymphadenopathy 2) 
Clinical stage 2 in which there are mild symptoms, such as moderate unexplained weight loss, 
recurrent respiratory infection, Herpes Zoster, recurrent oral ulceration and popular pruritic 
eruptions among other symptoms; 3 clinical stage 3, which is an advanced-symptoms stage, 
with unexplained severe weight loss, unexplained chronic diarrhea (>1 month), unexplained 
persistent fever (>1 month), persistent oral candidiasis, pulmonary tuberculosis, unexplained 
anaemia, neutropenia etc. and 4) clinical stage 4, characterized by severe symptoms such as 
the HIV wasting syndrome, Pneumocystis pneumonia, extra pulmonary tuberculosis, Kaposi 
sarcoma, lymphomas, invasive cervical carcinoma among others. 
Since the pathogenesis of HIV infection is associated with depletion of CD4+ T-cells (Brenchley 
et al., 2006; Appay & Sauce, 2009), using this information, WHO has provided guidelines for 
categorizing HIV infection using immunological classification (WHO, 2007). Based on this and 
the normal CD4 count which is 500 - 1500 cells/mm3 of blood, WHO and CDC have classified 
HIV infection into four stages depending on immune deficiencies as shown in Table 2.1. As CD4 
count may vary within an individual, assessing the CD4 count over time is necessary. The 
response to therapy will also depend on the immune stage at which it is started. Better outcomes 




and response to ART at higher CD4 counts (CD4>200 – 350) have been reported (Bennett et 
al., 2002; Grabar et al., 2005; WHO, 2007). 




Table 2:1: WHO immunological classification of established HIV infection (WHO, 2007) 












mm3 or CD4+) 
None or not 
significant 
>35 >30 >25 >500 
Mild 30-35 25-30 20-25 350-499 
Advanced 25-29 20-24 15-19 200-349 
Severe <25 <20 <15 <200 or <15% 
 
2.2.2 Current ARV treatment regimens 
According to WHO and UNAIDS, at least 15 million people needed ARV treatment by 2011 
and over 8 million had access to ART in low and middle income countries (UNAIDS, 2012; 
WHO, 2012). WHO in 2010 recommended the commencement of ARV therapy for adults at 
CD4 count of ≤350 cells/mm3. However, recent studies in addition to improved understanding 
of the chronic inflammation caused by HIV, all point to clinical benefits of starting ART at 
CD4 count above 350 cells/mm3. Accordingly, the new revised WHO guidelines on use of 
ARVs for treating and preventing HIV infection, recommends beginning of treatment for all 
individuals with confirmed HIV infection with a CD4 count of ≤500 cells/mm3 (WHO, 2013). 
Unfortunately, changing the threshold from 350 to 500 cells/mm3 would further increase the 
pool of people eligible for ART to 25 million, despite most of low and middle income countries 
yet to achieve a ―universal access‖ to ART for the majority of their eligible people (WHO, 
2012). 
2.2.3 Regimen composition 
The current ARV regimens recommended for HIV treatment include two nucleoside and 
nucleotide reverse transcriptase inhibitors (NRTIs) as the backbone and either a non-
nucleoside reverse transcriptase inhibitors (NNRTIs) or a protease inhibitor (PIs) as the base 
(WHO, 2013). The main reason for combining different anti-HIV drugs in the current 
treatment regimens of HIV/AIDS is to increase synergy, reduce toxicity and prevent 
development of drug resistance (De Clercq, 2009; Gil et al., 2013; UNAIDS, 2011). Currently 
there are more than 20 ARV medications available, classified into six major classes (CDC 
report, 2009; De Clercq, 2009; UNAIDS, 2011); 
 Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) such as Abacavir, 
Stavudine, Tenoforvir etc. 
 Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) that includes Nevirapine 
Efavirenz etc. 
 Protease inhibitors (PIs) such as Amprenavir, Atazanavir, Darunavir etc. 




 Fusion inhibitors such as Enfuvirtide 
 Integrase inhibitors such as Elvitegravir 
 CCR5 or CXCR4 antagonists such as Maraviroc 
Fixed dose combinations are also available such as Zidovudine + Lamivudione or Zidovudine 
+ Lamivudine + Abacavir etc. (Lubinski et al., 2009). However, due to availability of new 
medications, formulations and dosage recommendations, ARV treatment is continuously 
being updated (De Clercq, 2009). Although adverse effects have been reported with use of 
all ARVs, the use of newer regimens has reduced these effects. Numerous factors such as 
gender, concomitant use of medications, comorbidities, drug-drug interactions and genetic 
factors influence the development of adverse effects. Women have a higher susceptibility to 
develop Steven-Johnson syndrome, rashes and hepatotoxicity from NNRTIs such as 
Nevirapine. However, all said and done, the overall benefits of ARVs outweigh the risks (El-
Sadr et al., 2006; Lichtenstein et al., 2008). 
2.3 HIV, immunobiology and pathogenesis 
2.3.1 The HIV 
The HIV belongs to the genus Lentivirus, a group of enveloped ribonucleic acid (RNA) 
viruses under the family Retroviridae. This group of viruses produces typically slow, 
progressive infections and their replication depends on the occurrence of an active reverse 
transcriptase, which transforms the viral RNA genome into a proviral deoxyribonucleic acid 
(DNA) copy that integrates into the host cell chromosome. The proviral DNA is finally 
transcribed into messenger RNA (mRNAs) that encodes the viral proteins and progeny 
genomic RNA (Gao et al., 1999). 
The HIV is sub-divided into two groups; HIV-1, which is more virulent and a less virulent, less 
transmissible, HIV-2. HIV-1 is further sub-divided into three sub-groups; M (―major‖), O 
(―outlier‖) and N (―non M/non O‖). Group M, which has evolved in humans to form at least 10 
genetic subtypes (designated by letters A to K), is responsible for the majority of global AIDS 
pandemic (Tatt et al., 2001). The majority of infections in sub-Saharan Africa, including 
Southern and Eastern Africa, are of sub type C. In Central Africa, sub-types A and D 
predominate (McCutchan, 2001). In geographical areas, where more than one HIV-1 
genetically distinct subtypes exist, recombination of subtypes currently referred to as 
circulating recombinant forms (CRFs) have been identified (McCutchan, 2000; Filho et al., 
2006). This usually occurs during replication in order to generate diversity. Several CRFs 
such as CRF 12_BF in South America, CRF-06 in West Africa and CRF16 in Kenya, just to 
mention a few are now recognized as important sub-types. Most of the CRFs have been 
discovered in sub-Saharan Africa, which also bears the greatest genetic diversity of HIV 
(Dowling et al., 2002; Montavon et al., 2002). 




A mature virion is made up of a cone-shaped protein capsid enclosing two strands of 
genomic RNA, replication enzymes and cellular proteins as shown below in Fig. 2.1, 
(Goldstein, 1996). A lipid envelop, which comprises of the viral glycoproteins and cellular 
proteins, encloses the capsid. The envelop glycoprotein consists of two sub-units, external 
gp120, which binds to the CD4 receptor and CCR-5 or CXCR5 co-receptors on the surface 
of target cells and gp41, trans membrane subunit, anchoring the spikes in the viral envelope 
to maintain their trimeric organization and help in fusion of the virus and the host cell 





Figure 2:1: A mature virion showing capsid with genomic RNA, lipid ‘envelop’, with 
viral glycoproteins gp120 and gp41. (Source: 
http://upload.wikimedia.org/wikipedia/commons/2/2b/HIV_Virion-en-2.png). 
2.3.2 HIV entry into the cells 
Entry of HIV into the host cell is via CD4-gp120 interaction and gp120-chemokine receptor 
(CCR5 and CXCR4) interactions (Dimitrov, 1997; Brelot & Alison, 2001). The gp120 binds to 
CD4 and a co-receptor, either CCR5 or CXCR4, which are present on the surface of 
susceptible cells such as T-lymphocytes or macrophages. Immunohaematopoietic cells 




expressing these receptors and co-receptors of HIV are targets for infection by the virus and 
are therefore discussed briefly below. Consequent upon the binding of the virus with CD4 
and gp120, gp41 undergoes a conformational change that facilitates fusion of the viral 
membrane and the target cell membrane (Chan & Kim, 1998). The virus loses its protein 
capsid coat and is transcribed and integrated into the hosts DNA by reverse transcriptase 
and integrase respectively. Further transcription and translation produces new viral particles, 
which are assembled at the cell membrane to make a new virion through a budding process. 
In addition, cell to cell infection or the release of viral particles during budding propagates the 
virus to other cells (Sierra et al., 2005). 
2.3.3 Immunohaematopoietic cells infected by HIV 
HIV requires its target cells to express two molecules i.e. CD4, which is the primary receptor 
for HIV and a second co-receptor either CCR5 or CXCR4 in order to infect the cell (Appay & 
Sauce, 2009). A number of cell populations occurring in various mucous membranes, such 
as the genital tract, express the required receptors for HIV infection (Hunt, 2010). These 
include CD4+ T-lymphocytes, Langerhans cells, dendritic cells and macrophages (Siliciano & 
Siliciano, 2000; Hunt, 2010). 
Most of the infected cells die quickly by cytopathic effects of the virus, apoptosis or by hosts‘ 
antiviral immune response, while a fraction of them represents a stable pool of long-lived 
memory T-cells. These memory T-cells carry the proviral DNA, but do not transcribe the viral 
genes and thus evades the hosts HIV specific cellular effectors killing (Ho et al., 1995: Hunt, 
2010). 
2.3.3.1 CD4+ T helper cells 
The hallmark of HIV infection is the massive depletion of CD4+ T-helper cells and the 
subsequent inability to fight opportunistic infections (Appay & Sauce, 2009). CD4+ T-
lymphocytes express CD4 receptors and both CCR5 and CXCR4 co-receptors making them 
perfect targets for HIV (Hunt, 2010). Thus, it is not surprising that they are the major type of 
cells infected by the virus. Furthermore, HIV directly depletes these cells through; its 
cytopathic effects, killing by activated CD8+ cytotoxic cells, or indirectly through apoptosis, 
eventually causing immunosuppression, the hall mark of HIV/AIDS (Gandhi et al., 1998; 
Cummins & Badley, 2010). Interestingly, infected CD4+ T-helper cells become targets of 
CD8+ T-cells, but can also die by other mechanisms. During acute phase of HIV infection, 
CD4+ T-helper cells mostly in the GIT mucosal are depleted. However, during chronic phase 
they generally proliferate and die due to the persistent immune activation and other reasons 
(Brenchley et al., 2004; Haynes, 2006). After activation by specific HIV antigens, the CD4+ T-
helper cells either die or become non-proliferating memory cells, which are rapidly activated 
after re-encounter with a similar antigen (Hunt, 2010). 




2.3.3.2 CD 8+ T lymphocytes 
These cells express low levels of CD4 antigens when activated and are only infected by HIV 
in small numbers during the later stages of the disease. Naïve CD8+ T-cells do not express 
CD4 antigen, therefore do not become infected by HIV, although they express the co-
receptors CCR5 and CXC4 (Hunt, 2010). 
2.3.3.3 Macrophages/monocytes 
Macrophages/monocytes express CD4 antigens, although in low amounts, and CCR5 co-
receptor and are, therefore infected by HIV in the later stages of the disease (Kedzierska et 
al., 2003; Alfano & Poli, 2005). Although only a few of them are infected by HIV, monocytes 
activation contributes significantly to pathogenesis of HIV disease by inducing ROS 
production (Elbim et al., 1999; Bailey et al., 2006; Brown et al., 2008). They are also capable 
of phagocytosing opsonized virus particles by anti-HIV antibodies via Fc or complement 
receptors e.g. C5b (Dimitrov, 1997; Hunt, 2010). In addition, macrophages provide an 
important reservoir for the virus within the hosts‘ body. They bind HIV gp120 proteins via 
syndecan and CD91 consequently becoming infectious to other cells. Non-proliferating 
mature macrophages can sustain HIV production for long periods without being killed by the 
virus (Hunt, 2010).  
Activated macrophages lead to aberrant production of pro-inflammatory cytokines in HIV 
infection, leading to a vicious cycle of secondary effects like wasting, inflammation and 
oxidative stress (Brown et al., 2008). Macrophages are also involved in the removal of CD4+ 
T-helper cells expressing phosphatidylserine (PS) on their surface, which is one of the 
specific signals for recognition and removal of apoptotic cells (Fadok et al., 1992; Verhoven 
et al., 1995). 
2.3.3.4 Natural killer cells 
Natural killer cells express CD4 antigens and interact with antigen presenting cells like 
dendritic cells. They also express the co-receptor CCR5 and thus are infected by CCR5 
specific HIV strains (Hunt, 2010). 
2.3.3.5 Dendritic cells 
Dendritic cells are antigen-processing cells (APCs) that recognize antigens and present them 
to T-cells. Although they are not promptly infected by HIV, these cells express low levels of 
HIV receptors CD4 antigen and co-receptors CCR5 and CXCR4, which make them 
candidates for infection (Alfano & Poli, 2005; Hunt, 2010). The dendritic cells trap HIV on 
their surfaces through a surface lectin, called dendritic cell-specific intercellular adhesion 
molecule 3-grabbing non-integrin (DC-SIGN) at the site of infection, migrate to lymph nodes 
and transmit the trapped virus to CD4+T-cells (Bailey et al., 2006; Gil et al., 2013). This 




ensures that no fusion of the cell membrane with the virus occurs and hence dendritic cells 
cannot get infected via this route (Israel & Israel, 2002; Hunt, 2010). However, they bind the 
virus when it enters through the mucosal route and migrates to the lymph nodes where they 
present it to the T-cells, infecting them in the process (Bailey et al., 2006; Hunt, 2010; Gil et 
al., 2013). 
2.3.3.6 Cells of the nervous system 
HIV infects oligodendrocytes, astrocytes, neurones, glial cells and brain macrophages which 
express low levels of CD4 antigens (Del la Monte et al., 1987; Ranki et al., 1995; Kruman et 
al., 1998; Clements et al., 2002). Infection of these cells causes disease of the central 
nervous system through the viral protein Tat, which binds to neural cells through CD91 
antigen (Westendorp et al., 1995; Jaworowski et al., 1999 Hunt, 2010). Although, all the cells 
discussed previously are infected by HIV, however, untreated asymptomatic HIV infection is 
characterized by massive depletion of CD4+T-cells. 
2.3.4 HIV mediated depletion of CD4+ T-cells 
The HIV is unique and different from other viruses in that it targets CD4+ T-cell pool and to a 
small extent macrophages and dendritic cells, which are key players in the immunity of the 
host (Kedzierska et al., 2003; Alfano & Poli, 2005; Hunt, 2010). Acute HIV infection is 
characterized by a temporary decrease in peripheral blood CD4+ T-cell count (Figure 2.2). 
Since the majority of CD4+ T-cells reside in the mucosal-associated lymphoid tissues 
(MALT), particularly GIT, the peripheral blood count is not representative of the total body 
CD4+ T-cell count. The CCR5 expressing mucosal CD4+ T-cells consist mostly of memory 
CD4+ T-cells, hence are the primary targets for the HIV (Brenchley et al., 2004; Harnes, 
2006; Hunt, 2010). 
 






Figure 2:2: The phase of HIV infection showing course of HIV infection in terms of the 
levels of CD4+ T cells, HIV viral load, neutralizing antibodies, and cytotoxic T 
lymphocyte levels in different phases of HIV infection (Source: Appay & Sauce, 2009). 
 
Studies done on primates, infected with Simian equivalent of HIV (SIV) and on humans, 
infected with HIV, indicated that most of the depletion of the CD4+T-cells occurs in the 
mucosal tissues during acute phase of the infection either as direct targets of the cytopathic 
effects of the virus or indirectly by apoptosis (Veazey et al., 2003; Brenchley et al., 2004; 
Haynes, 2006). Chronic HIV infection is characterized by a gradual decline of peripheral 
blood CD4+ T-cell counts and gradual increase in viral load as shown in Figure 2.2. 
Consequently, the low circulating CD4 count correlates well with the onset of AIDS, as 
minimum levels of circulating CD4+ T-cells are important for maintaining immune integrity 
(Pantaleo, 1993).  
The number of HIV-infected circulating CD4+ T-cells in peripheral blood (1 in 10 000 in acute 
phase and 1 in 40 in chronic phase) is too low to account for their depletion (Douek et al., 
2002; Lassen et al., 2004; Duoek, 2007). Therefore, the loss of uninfected CD4+ T-cells 
(bystander cells) suggests other mechanisms through which these cells are depleted. 
Several theories explaining the cause of CD4+ T-cell depletion in HIV have been proposed. 




These theories include direct effect of virion synthesis in the cell and budding from the cells, 
thus puncturing the membranes initiating their destruction (Carbonari et al., 1995; Dandekar, 
2007; Cummins & Badley, 2010; Hunt, 2010). This theory falls short, as the cells need to be 
infected and it has been confirmed that only a few of the cells are infected. The second 
theory proposed is the fusion of the HIV with the cell membrane. This fusion is thought to 
result in the formation of syncytia that can lead to the spread of the virus to other uninfected 
cells, though this is not common (Hunt, 2010).  
It is also proposed that infected cells expressing viral proteins in association with MHC I 
molecules on their surface, might become targets of cytotoxic T-cells destruction (Gil et al., 
2003 Hunt, 2010). However, this phenomenon does not explain the death of the ―innocent 
bystander‖ CD4+ T-cells. Another hypothesis about the depletion is that viral proteins such 
as gp120, Nef and Tat shed from the infected cells or from the virus particles, may bind to 
the uninfected cells through CD4 antigens, thus appearing as infected cells and are thereby 
―cleared‖ by the immune system (Westendorp et al., 1995; Schindler et al., 2006; Appay & 
Sauce, 2008; Hunt, 2010). Some viral proteins (such as vpr) are capable of binding to 
mitochondria of infected CD4+ T-cells, directly inducing apoptosis (Jacotot et al., 2000). It 
has also been suggested that HIV-related cytotoxic antibodies are produced in infected 
individuals that may target specific antigens on the surface of activated uninfected CD4+ T-
cells (Hunt, 2010). Autoimmune component targeting gp120 via anti-gp120, which is capable 
of binding to CD4+ T- cells, has also been proposed (Betts et al., 2001; Alimonti et al., 2003). 
HIV proteins have also been shown to alter the T-cell function (Hunt, 2010).  
Though not exclusive, the above theories try to elucidate why, despite only a few of CD4+ T-
cells being infected, massive depletion of these cells occurs as the disease progresses. The 
prospects of HIV-induced apoptosis of CD4+ and CD8+ T-cells as the main cause of the 
depletion of these cells has become a common theme of many studies (Gougeon, & Gougen 
& Montagnier, 1993; Dobmeyer et al., 1998; Hunt, 2010). Consequently, apoptosis of the 
cells initiated via various pathways is thought to be a major contributing factor in the 
depletion of CD4+ T-cells and the eventual progression to AIDS (Cummins & Badley, 2010). 
Immune activation, inflammation and inflammation-induced oxidative stress is thought to 
contribute significantly to the depletion of peripheral CD4+ T-cells in HIV infection and have 
become a popular research subjects (Dobmeyer et al., 1998; Brenchley et al., 2004; 
Marques et al., 2009; Plaeger et al., 2012).  
2.3.5 Inflammation and Immune activation in HIV 
Chronic inflammation and immune activation also characterises HIV infection (Haynes, 2006; 
Villinger & Ansari, 2010), which results in weakened immune responses, increased pro-
inflammatory cytokines production and uncontrolled viral replication in the activated CD4+ T-




cells (Cassol et al., 2010; Morris et al., 2012). The significant depletion of memory CD4+ T-
cells lining the GIT mucosa in early HIV infection results in loss of mucosal integrity and 
ongoing translocation of microbial products such as LPS across the epithelial surface 
(Brenchley et al., 2004). Consequently, LPS induces the activation of innate immune cells 
such as neutrophils, monocytes and dendritic cells resulting in increased oxidative stress, 
depletion of antioxidant defence mechanisms and an increased susceptibility to apoptosis 
(Bailey et al., 2006; Gendron et al., 2011). 
As a consequence, neutrophil respiratory burst contributes significantly to oxidative stress, 
inflammatory and immune activation states in living systems (Fuchs et al., 2007; Rada & 
Leto, 2008; Gonzalez-Dosal et al., 2011), which is thought to contribute to the depletion of 
CD4+T-cells in HIV infection (Aquaro et al., 2008). Although the process of recruitment and 
activation of neutrophils and macrophages at the site of infection is tightly regulated, if in 
excess or prolonged, it can lead to inflammation and damage to the surrounding tissues and 
cells (Crocker et al., 2012; Drescher & Bai, 2013). As previously mentioned, depletion of 
CD4+T-cells is characteristic of HIV infection and recent studies have linked the loss with 
chronic immune activation and inflammation (Brenchley et al., 2004; Haynes, 2006; Desail & 
Lindayl, 2010). 
As a common routine, the pathogenesis of HIV infection is linked to CD4+ T-cells and the 
immune status of an HIV-infected individual is assessed by measuring the absolute number 
per mm3 or percentage CD4+ T-cells as the golden standard of immune deficiency 
(MacDonnell et al., 1998; Vlahov et al., 1998; Vajpayee et al., 2005; WHO, 2007). However, 
peripheral blood CD4 count is not representative of the total body CD4+ T-cell count as 
discussed in section 2.3.4, the role of immune activation and inflammation as stronger 
indicators of HIV pathogenesis has become more prominent (Fahey et al, 1998; Brenchley et 
al., 2004). Inflammation is an important non-specific protective response of a tissue to 
harmful stimuli e.g. a pathogen, damaged cells or irritants (Prescott et al., 2002). Activated 
neutrophils and macrophages during inflammation produce H2O2 and other oxidants (Kotler, 
1998). This occurs during respiratory burst due to increased oxygen use and ATP 
production, which further promotes tissue injury and inflammation (Prescott et al., 2002). 
Importantly, inflammatory cytokines such as tumour necrosis factor α (TNF-α), interleukin-1 
(IL-1), interleukin-6 (IL-6), are known to stimulate HIV transcription and replication and thus 
may be important factors in the progression of HIV to AIDS (Aquaro et al., 2008). Elevated 
markers of immune activation, inflammation and apoptosis such as CD 38/8, CD 95, pro-
inflammatory cytokines e.g. TNF α, IL-1β, IL-6 in both plasma and lymph nodes, as well as 
chemokine such as macrophage inflammatory protein 1 (MIP-1 α, MIP 1β and RANTES) 
have been reported in HIV-infected patients (Giorgi et al., 1999; Gil et al., 2003; Deeks et al., 
2004). Giorgi et al. reported that T-cell activation levels as expressed by the activation 




marker CD38 on CD8+ T-cells, predicted a poor prognosis for the infected patients which 
have been confirmed by other investigators (Giogi et al., 1999; Hazenberg et al., 2003; 
Deeks et al., 2004). More specifically, HIV gene products, such as Tat, Nef, Vpr, Raf and Env 
have been shown to induce immune activation of macrophages and lymphocytes directly, 
however they cannot solely account for the complete immune activation (Kedzierska et al., 
2003; Brown et al., 2008; Hunt, 2010). In addition, HIV is capable of causing immune 
activation and inflammation indirectly through antigenic stimulation (Hunt, 2010). 
Brenchley et al. recently proposed another potential mechanism of immune activation that 
involves the innate immune system (Brenchley et al., 2006). The study suggested that the 
massive depletion of CD4+ T-cells by HIV in the MALT lining the gut, compromises the 
integrity of the mucosal barrier which usually prevents translocation of the intestinal tract 
flora, restricting them to the lamina propia and the mesenteric lymph nodes. Consequently, 
the loss of integrity of the mucosal lining results in microbial translocation from the gut to the 
systemic immune system. As a result, the translocation of microbial products such as LPS 
leads to an intense activation of the innate immune response. LPS, flagellin and CpG DNA, 
which are toll-like receptor (TLR) ligands, are capable of stimulating macrophages and 
dendritic cells to produce a range of pro-inflammatory cytokines (TNF-α, IL-6 & IL-1β) and 
ROS. As a result, increased oxidative stress, depletion of antioxidant defence mechanisms 
and increased susceptibility of the cells to apoptosis, may occur (Merrill et al., 1989: Cheung 
et al., 2008; Morris et al., 2012). The ultimate effect of this phenomenon is activation of 
―innocent bystander cells‖, differentiation of lymphocytes, monocytes and an establishment of 
a pro-inflammatory condition which characterizes HIV infection. Hence, immune activation 
has been shown to be a stronger predictor of disease progression to AIDS than CD4 count 
and viral load (Carbone et al., 2000; Giorgi et al., 1993; Fahey et al., 1998; Liu et al., 1998; 
Brenchley et al., 2004). 
HIV infection has been shown to affect levels of antioxidant enzymes such as glutathione 
peroxidase (Stephensen, 2007). In addition, HIV-tat gene has been shown to induce H2O2 
signaling, resulting in enhanced T-cell activation and death signal expression (Campbell, 
2005). Therefore, it is likely that both the depletion of endogenous antioxidants such as 
glutathione and the increased production of H2O2 as a result of chronic inflammatory 
processes, contribute to the deaths of CD4+ T-lymphocytes in HIV infection (Gil et al., 2003; 
Wanchu et al., 2009; Morris et al., 2012).  
2.3.6 The natural course of HIV infection 
Although, the clinical manifestation of full blown AIDS from the time of HIV infection takes 
about 8-10 years (Hunt 2010), this may not always be the case, as sometimes it can be less 
than two years depending on factors such as the hosts‘ immune system and dietary factors 




(Lederman & Valdez, 2000; Hunt, 2010). The acute phase of the infection lasts for 6-12 
weeks (Figure 2.3) before anti-HIV antibodies are detectable in the blood. Initially, the virus 
produces a mild disease which is self-limiting or asymptomatic. 
 
Figure 2:3: The CD4 count and viral load in HIV infection, showing the natural course 
of CD4 count viral load CD8 in different phases of HIV infection (source: Hunt, 2010). 
 
Furthermore, during early infection, an initial fall in CD4+ T-cells and a rise in CD8+ T-cells 
occur, which quickly return to normal as seen in figure 2.4 below. The virus titer levels at this 
time are very high (figure 2.4). The first two weeks of infection are marked by a massive loss 
of CD4+ T-cells of the MALT, resulting from immune activation due to translocation of 
microbes from the damaged gut mucosa and local immunodeficiency (Lifson et al., 1997; 
Brenchley et al., 2004; Hunt, 2010). 





Figure 2:4: The natural course of HIV infection in terms of the CD4 count, HIV 
antibodies, and viral load (source: Hunt, 2010). 
As a result, the cytotoxic B and T-lymphocytes intensify their defense and the virus 
disappears from the peripheral circulation as seen in figure 2.3. In addition, the cell-mediated 
immune response will also be accompanied by increased humoral antibodies (anti-HIV 
antibodies (figure 2.2 & 2.4). More specifically, high levels of virus are produced daily (10 
billion particles) but are cleared rapidly by the immune system (Hunt, 2010). Although, the 
infected cells producing the virus are destroyed by the immune system or by the virus itself, 
however, a small fraction survives as resting memory cells and make up a reservoir that is 
crucial in drug-based therapy (Martinez-Maza et al., 1987; Giorgi et al., 1999; Hunt, 2010; 
Zeng et al., 2011). Immune activation is also associated with up regulation of CCR5, which 
along with CD4 receptor allows HIV entry into more cells enhancing the virus replication and 
infection (El-Far et al., 2008) 
The strong immune response reduces the viral particles in the blood stream, although the 
particles persist elsewhere and continue to replicate and infect more cells. The patient enters 
a latent phase as seen in figure 2.3. This period vary from as little as 1 year to more than 15 
years (Pantaleo, 1993; Appay & sauce, 2009). Activated CD4+ T-cells, which are susceptible 
to apoptosis, are continuously and permanently depleted from the beginning of the infection, 




unless ARV treatment commences. Ultimately, the virus cannot be controlled, as the CD4+ 
T-cells becomes depleted and falls below 200 cell/mm3, the virus titers rise, while immune 
response falls dramatically (Fig. 2.3). 
The loss of immune competence driven by immune activation, inflammation, oxidative stress 
apoptosis-induced depletion of CD4+T-cells, marks the onset of opportunistic infections and 
HIV-associated cancers characterizing AIDS (Lederman et al., 1993; Pace & Leaf, 1995; 
Allard et al., 1998; Hazenberg et al., 2003, Hunt, 2010; Tien et al., 2010). The specific roles 
of some of the common pro-inflammatory cytokines in the inflammatory process are 
discussed below. 
2.3.7 Pro-inflammatory cytokines, Inflammation, oxidative stress and apoptosis 
The persistent systemic immune activation that characterizes HIV infection, results in 
enhanced pro-inflammatory cytokine production such as TNF-α, which have been implicated 
in the activation of extrinsic pathway of apoptosis (Ashkenazi & Dixit, 1999; Haynes, 2006). 
Pro-inflammatory cytokines refers to a group of inducible cytokines with properties that 
promote inflammatory reaction. These include; IL-1, IL-2, IL-6, TNF family (CD40 ligand, Fas 
ligand, CD27 ligand, CD30 ligand etc.) and interferon‘s (IFN‘s) (Ware et al., 1998). Although 
these cytokines stimulate increased production of ROS, thereby inducing oxidative stress, 
they assist in antigen presentation by dendritic cells in addition to promoting phagocytosis 
(Ware et al., 1998; Luiz, 2005). The pro-inflammatory cytokines drive the many processes 
underlying the inflammatory response, cell apoptosis, activation and differentiation (Tracey et 
al., 1993; Luiz, 2005). In the LPS-induced activation of innate immunity, the LPS bind to 
CD14 on macrophages or monocyte surface. This binding is enhanced by a plasma LPS-
binding protein (LPB). The LPS/CD14 complex formed activates toll like proteins 2 (TLR2) 
and 4 (TLR4) which consequently activates the nuclear factor of Kappa B (NF-kB) resulting 
in production of pro-inflammatory cytokines and ROS (Ware et al., 1998; Liu, 2005). 
More specifically, TNF which is the primary mediator of immune regulation plays a crucial 
role in various cellular processes including cell proliferation, differentiation, necrosis and 
apoptosis. TNF exerts cytotoxic effects on a wide range of tumour cells and other target cells 
(Liu, 2005). As a result, TNF is involved in both intracellular inflammatory signalling pathways 
and apoptotic signalling through its death domain of the p55 tumour necrosis factor receptor 
(TNFR). The IL-1 and TNF up-regulate the E-selectin, ICAM-1, and V-CAM adhesion 
molecules on vascular endothelial cells. Furthermore, they also stimulate production of 
chemokines such as IL-8 and MCP-1, which helps to attract and trap neutrophils to the 
inflammatory sites (Ware et al., 1998). These two cytokines (IL-1 & TNF) also produce small 
mediators, such as cyclooxygenase 2 which induces production of prostaglandin E2 or 
prostacyclin from endothelium, causing vasodilation and feeling of pain during inflammation 




(Israels & Israels, 2002). In concert with IFN-γ, they induce production of nitric oxide, a 
vasodilator from NO synthase. They also cause expression of tissue factor and platelet 
activating factor, which boosts the clotting mechanisms. IL-6, a product of IL-1 and TNF-
stimulated cells, causes production of acute phase proteins and also aids in promoting fever 
during inflammatory process. Many of the TNF super families e.g. Fas, TNFR and death 
receptor 3 are known to induce apoptosis in HIV infection (Lichtner et al., 2004; Herbein & 
Khan, 2008). The TNF-TNFR complex is known to enhance the NADPH oxidase activity that 
increases oxidative stress leading to necrotic cell death (Feldmann & Saklatvala, 2000). Due 
to its cytotoxic effects, the biosynthesis of TNF is tightly controlled and therefore produced in 
very small quantities in quiescent cells, but secreted in large amounts in activated cells (Liu, 
2005). 
Elevated markers of TNF, IL-1 & 6, in plasma and lymph nodes have been observed in HIV 
infection from the early stages of the disease (Molina et al., 1989; Weiss, 1989; Emilie, 1990; 
Lafeuillade, 1991; Wanchu, et al., 2009; Morris et al., 2012). Importantly, in HIV infection, 
activated macrophages are a major source of cytokines such as TNFα, IL-1, IL-6, IL-12, IL-
15, IL-18 and chemokines such as IL-8, MIP-1, MIP-1, MCP-1, interferons, etc. (Alfano & 
Poli, 2005; Brown et al., 2008). An association between elevated pro-inflammatory markers 
sTNFR-1, sCD27, sCD40L and CD8 T-cell activation, with disease progression in patients 
whose CD4+ T-cell counts were less than 200 cells/cm3 and who had suppressed viral 
replication but who either died, developed an AIDS-defining malignancy or other 
complications has been described previously (Kalayjian et al., 2010). As a result, these pro-
inflammatory markers may highlight important cellular pathways in pathogenesis of HIV 
independent of on-going viral replication which could be targeted for immune-based 
therapies in the future (Kalayjian et al., 2010). As previously mentioned, 
macrophages/monocytes and neutrophils are major targets and source of the pro-
inflammatory cytokines and ROS (Ware et al., 1998; Liu, 2005; Lam et al., 2010), and hence 
neutrophil respiratory burst, which is a major source of oxidative stress is an example of 
pathways that could be ideal targets in the future. 
2.3.8 Neutrophil respiratory burst 
Activated neutrophils have been shown to produce large amounts of superoxide anion 
approximated to be 1 – 4 M/L in the vacuoles (Reeves et al., 2002) therefore, identifying 
perturbations in cell redox triplets composed of mitochondrial potential, respiratory burst and 
intracellular thiol levels may help in understanding oxidative stress-related disease processes 
including HIV infection (Matteucci & Giampietro, 2008; Matteucci et al., 2009). Polymorph 
nuclear neutrophils (PMNs) are a critical component of first line defense against pathogens 
(Salmen et al., 2005; Crocker et al., 2012; Drescher & Bai, 2013) and their enrolment and 




activation at the location of infection or inflammation in order to eliminate pathogens is a key 
aspect of innate immunity (Greenberg & Grinstein, 2002; Choi & Dumler, 2003;). PMNs 
continuously traverse blood vessels scrutinizing for bacterial, viral infection and inflammation 
(Rada & Leto, 2008; Gonzalez-Dosal et al., 2011) and when they encounter an infection they 
leave circulation, migrate to the site of infection where they phagocytose and kill the invading 
microbe by releasing packaged microbial systems (Prescot, 2002; Fuchs et al., 2007; 
Papayannopoulus & Zychlinsky, 2009). At the site of infection, neutrophils kill the invading 
pathogens by a combination of two mechanisms; oxygen-independent and oxygen-
dependent response or respiratory burst (Prescott et al., 2002; Nathan, 2006; Fuchs et al., 
2007). The oxygen independent mechanism is through highly toxic cationic proteins and 
enzymes e.g. MPO, defensins, lactoferrin, lysozyme, gelatinase, etc. contained in 
azurophilic, gelatinase and specific granules (Engelich et al., 2002; Segal, 2005). The 
oxygen-dependent mechanism or the respiratory or oxidative burst involves a sequential 
reduction of oxygen by an NADPH oxidase leading to production of toxic oxygen metabolites 
such as H2O2, hydroxyl radicals and singlet oxygen according to equation 2.1 - 2.7 (Parkin & 




H2O2 is generated from the dismutation reaction of the superoxide radical catalysed by 




When the generated H2O2 reacts with a halide, hypochlorus acid is produced. This reaction is 
catalysed by myeloperoxidase enzyme. The hypochlorus acid is used to kill the ingested 
bacteria in the phagosome. 
 
Equation 2.3 




Catalase enzyme and reduced glutathione (GSH) protects the neutrophils from oxidative 
damage by these oxidants (Hunt et al., 1998, Israels & Israels, 2002). 
The NADPH oxidase system is inactive, but can be activated by chemokines, immune 
complexes, (activated complement 5) C5a, or N-formyl oligopeptides shed by microbes 
(Taylor et al., 1993; Cruse & Lewis, 2010). The NADPH oxidase system is separated into two 
compartments in a resting cell: the membrane and the cytosol. The oxidase system is a 
complex put together from five proteins, two on the plasma membrane (p22phox and gp91phox) 
and three in the cytoplasm (p47phox, p67phox and p40phox), but each group associated with 
monomeric GTP-binding (G) protein (Israel & Israel, 2002, Segal, 2005). When neutrophils 
are activated and the cytosolic protein (p47phox) is phosphorylated, cytoplasmic protein 
complex are translocated to the membrane. The gathering of the cytoplasmic proteins with 
the membrane proteins activates the oxidase enzyme (NADPH oxidase) (Segal, 2005). The 
NADPH oxidase transports electrons across the plasma membrane from the cytosolic 
NADPH to oxygen to generate the superoxide anion radical (O.-2) both in the phagosome and 
extracellular space (Israels & Israels, 2002; Fuscs et al., 2007). H2O2 is generated from the 
dismutation reaction of the superoxide radical catalyzed by superoxide dismutase (Halliwell, 
1994). When the generated H2O2 reacts with a halide, hypochlorus acid is produced, which is 
used to kill the ingested bacteria in the phagosome. 
A rapid flow cytometric screening test for abnormalities of neutrophil function (Van Eeden et 
al., 1999), whole blood PMNs oxidative burst (Alvarez-Larran et al., 2005) and apoptosis in 
physiological and pathological situations has been described previously (Emmendorffer et 
al., 1990; Bitzinger et al., 2008; Brescia & Sarti, 2008). In addition, a burst test assay for 
PMNs oxidative burst which utilises unlabeled opsonized bacteria (E. coli), phorbol 12-
myristate 13-acetate (PMA) and the chemotactic peptide N-formyl-Met-Leu-Phe (fMLP) as 
stimulants, dihydrorhodamine (DHR) 123 as a fluorogenic substrate and necessary reagents 
has been reported (Rothe et al., 1988). The assay determines the percentage of phagocytic 
cells which produce ROS (conversion of DHR 123 to R 123) and their enzymatic activity. 
Based on the fact that, when stimulated, phagocytes produce ROS to destroy bacteria inside 
the phagosome during the oxidative burst, which can be monitored by the addition and 
oxidation of DHR 123 to R 123 and can be measured using flow cytometry.  
Although, studies on neutrophil respiratory burst levels in HIV have been scarce and limited 
however, the few that exists have shown that pro-inflammatory cytokines such as TNF, GM-
CSF and IL-8 strongly prime a sub-population of PMNs to generate H2O2 in response to 
fMLP stimulation (Elbim & Lizard, 2009). This results suggests that the priming effects of 
cytokines such as TNF is required for triggering the PMN oxidative burst and that it pre-
activates resting PMNs, enabling them to produce a heightened and more powerful response 




at the site of infection (Elbim et al., 1999; Wittmann et al., 2004). Additional evidence of pre-
activation, priming and increased respiratory burst comes from a study by Bandres et al. who 
showed an enhanced respiratory burst and phagocytosis by neutrophils and monocytes of 
men with stage 1 HIV infection (Bandres et al., 1998). In a study investigating priming by 
TNF, GM-CSF & IL-8, Elbim & Gougerot-Pocidalo, showed strong priming of 
polymorphonuclear neutrophils (PMN) by these cytokines in HIV (Elbin & Gougerot-Pocidalo, 
1996). In this study, there was normal respiratory burst in both HIV positive and negative 
controls patients, however, there was enhanced oxidative burst of resting and fMLP 
stimulated neutrophils in HIV positive patients than in negative controls suggesting a 
preactivation or priming by the inflammatory cytokines (TNF, IL-1, 8). Dobmeyer et al. in 
another study showed a significant decrease in respiratory burst response of asymptomatic 
HIV infection patients in contrast to those with AIDS which correlated well with CD4 count 
(Dobmeyer et al., 1995). 
These studies and others discussed in later sections of this chapter, confirms the significant 
contribution of neutrophil respiratory burst to the overall oxidative stress indicated in HIV 
infection. 
2.4 Oxidative stress 
Zielch et al. have defined oxidative stress as ―cellular state where ROS production exceeds 
the cells ability to metabolize them resulting in excessive accumulation of ROS that 
overwhelms cellular defenses‖ (Zielch et al., 2011) whereas, Franco & Panayiotidis defined it 
as ―the cytopathological consequence of an imbalance between free radical production and 
the ability of the cell to defend against them‖ (Franco & Panayiotidis, 2009). Oxidative stress 
may result from excessive production of ROS and the failure of the antioxidant defense 
system. Importantly, the human body produces ROS and reactive nitrogen species (RNS), 
constitutively through normal physiological and metabolic processes e.g. aerobic respiration. 
ROS are defined as oxygen-containing, reactive chemical species, while RNS refers to 
nitrogen containing species e.g. nitric oxide (NO), nitric dioxide (NO2) and peroxynitrite. 
Furthermore, ROS have been categorised into two groups; the free radicals which contain 
one or more unpaired electron in their outer molecular orbitals e.g. superoxide, nitric oxide, 
and hydroxyl radicals and the non-radicals, which, although lacking unpaired electrons, they 
are chemically reactive and can be converted to free radical species e.g. (H2O2), ozone, 
peroxynitrate and hydroxide (Trachootham et al., 2009). Mitochondria are a major source of 
ROS in the cells through electron leakage from the mitochondrial respiratory chain. The 
leaking electrons react with molecular oxygen to form superoxide and other ROS (Andreyev 
et al., 2005). Other major endogenous sources of ROS include;  




i. phagocytic cells and some cancer cells, which in an oxidative burst, produces 
ROS through an NADPH oxidase complexes catalysed reaction intentionally to 
destroy cells infected with bacteria or virus infected cells as discussed 
previously. 
ii. β-oxidation of fatty acid reactions in the peroximes is a major source of ROS.  
iii. Prostaglandin synthesis and detoxification reaction by cytochrome P-450 mixed 
function oxidase system (Kehrer & Smith, 1994; Abe & Berk, 1998).  
It is a well-known fact that ROS plays a vital role in biological functions, as regulators of 
many signal transduction pathways, signalling cell growth and differentiation and regulation 
of certain enzymes (e.g. ribonucleotide reductase) (Trachootham et al., 2009). In addition, 
they mediate inflammation by stimulating cytokine production. More importantly, ROS are 
also involved in elimination of pathogens and foreign particles, particularly in oxygen-
dependent microbial killing of neutrophil respiratory burst (Israels & Israels, 2002). However, 
ROS being highly reactive molecules are capable of causing oxidative damage to 
biomolecules such as DNA, proteins and lipids, consequently altering their functions 
(Boonstra & Post, 2004; Devasagayama et al., 2004). This may result in various pathological 
conditions and diseases (Prior & Cao, 1999). Excessive increase in ROS in cells may cause 
permanent oxidative damage which could lead to loss of immune function, inflammation and 
even death of the cell (Gil et al., 2013). 
..
 
Figure 2:5: Responses to oxidative stress in proliferating cells. (Source: Davies, 2005). 




2.4.1 Antioxidants defense system, oxidative stress and HIV 
The human biological system constantly produce ROS as products of normal physiological 
processes to serve important functions such as electron transfer in mitochondrion and as 
signalling molecules (Devasagayam et al., 2004; Valko et al., 2007 Gil et al., 2013). 
However, as mentioned previously, activated immune system such as activated phagocytes 
may generate excessive amounts of ROS both locally and in systemic circulation (Gil et al.,  
2013), which might lead to oxidative modifications and damage to proteins, nucleic acids, 
carbohydrates and lipids (Block et al., 2002; Kohen & Nyska, 2002). As a result, cells have 
evolved complex antioxidant defence systems to combat this (Halliwell & Cross, 1994; Evans 
& Halliwell, 2001; Leonarduzzi et al., 2010). Antioxidants have been defined by Becker et al. 
as substances that at low concentrations prevent or retard oxidation of biomolecules such as 
lipids, proteins and DNA (Becker et al., 2004). The antioxidant defence system consists of 
primary or preventive antioxidants, which limit the initial formation of oxygen-centred radicals 
of organic compounds. Secondary scavenging or chain breaking antioxidants are present to 
trap intermediate ROS and thus breaking the chain reaction. The third line of defence 
consists of repair systems for damaged nucleic acids, proteins and lipids (Halliwell, 1994; 
Masella et al., 2005; Halliwell, 2006 Ratnam et al., 2006).  
More specifically, the first primary defence mechanism consists of antioxidant enzymes such 
as CAT, GPx, GR and SOD. Catalase is a ubiquitous antioxidant enzyme found in peroximes 
in most tissues, which catalyse the two stage change of H2O2 to water and oxygen. It is so 
efficient as an enzyme that it cannot be saturated by H2O2 at any concentration. Most 
important, catalase protects the cells from H2O2 generated within them therefore, playing a 
vital role in acquiring tolerance to oxidative stress in the adaptive response of cells (Hunt et 
al., 1998). Catalase has a peroxidatic activity in which low molecular weight alcohols can 
serve as electron donors. Catalase is found in high levels in human liver, kidneys and 
erythrocytes, where it accounts for the bulk of its H2O2 decomposition, therefore essential in 
the protection of cells against severe oxidative stress (Yan & Harding, 1997). A significant 
decrease in activity of erythrocyte‘s catalase has been observed in AIDS patients when 
compared to HIV infection and healthy subjects (Pasupathi et al., 2009)  
GPx and GR catalyse oxidation of glutathione at the cost of H2O2 in the cytosol and 
mitochondria (Equation 2.4). 
 
Equation 2.4 
GPx is a selenium containing peroxidase, which catalyse the reduction of various 
hydroperoxides at the expense of glutathione, thus protecting mammalian cells from 




oxidative damage. At least five isoenzymes of GPx have been identified in mammals (De 
Haan et al., 1998; Mates & Sanchez-Jimenez, 1999), which occur in the cytosol and 
mitochondria (e.g. cGPx or GPx1 which reduces fatty acid hydroperoxides and H2O2 at the 
expense of glutathione in mitochondria). GPx1 and phospholipid hydroperoxide peroxidase 
occurs in most tissues, while GPx4 occurs both in the cytosol and membranes. GPx1 occurs 
predominantly in erythrocytes, kidneys and liver. GPx4 occurs in high quantities in renal 
epithelial cells and testes with cytosolic GPx2 and extracellular GPx3, only detectable in 
gastrointestinal tract and kidneys. GPx contains one selenocystein residue, which is 
important for its enzymatic activity. The glutathione redox cycle, protects against low levels 
oxidative stress, while catalase is more significant in protecting against severe oxidative 
stress (De Haan et al., 1998). GPx and GR catalyse oxidation of glutathione at the cost of 
H2O2 in the cytosol and mitochondria and thus protects the cell from oxidative damage. A 
reduction of erythrocyte GPx activity has been observed in HIV-infected individuals than in 
health individuals (Gil et al., 2003; Pasupathi et al., 2009). 
SOD is a metalloenzyme that forms a fundamental component of the cellular antioxidant 
defense system. SOD catalyse the dismutation of superoxide anion to molecular oxygen and 
H2O2 as a vital part of cellular enzymatic antioxidant defence system as shown in equation 
2.2 (Mates & Sanchez-Jimenez, 1999; Benov & Fridovich, 1998). Importantly, SOD also 
protects dehydratases (dihydroxy acid dehydratase, aconitase, 6-phosphogluconate and 
fumarase A and B) from inactivation by the superoxide radical (Benov & Fridovich, 1998). In 
humans, it is found in high concentration in brain, liver, kidneys, heart and erythrocytes. The 
amount of SOD present in the cellular and extracellular environments is important for the 
prevention of oxidative stress related damage.  
In humans, three classes of SOD have been identified: the cytosolic copper superoxide 
dismutase (CU-SOD), zinc superoxide dismutase (zn-SOD), mitochondrial manganese 
superoxide dismutase (Mn-SOD) and extracellular superoxide dismutase (EC-SOD) which 
accounts for the majority of SOD in plasma, lymph and synovial fluid (Adachi & Wang, 1998). 
The mitochondrial Mn-SOD is a nuclear encoded primary antioxidant enzyme that functions 
to remove superoxide radicals in the mitochondria, where the respiratory chain serves as a 
major source of oxygen radicals. The expression of Mn-SOD is vital for the survival of 
aerobic life and cellular resistance to oxygen radical mediated toxicity. Copper and zinc-
SOD, play a major role in the first line of antioxidant defense by catalyzing the dismutation of 
superoxide anion radicals, to form H2O2 and molecular oxygen. Extracellular-SOD occurs in 
the interstitial spaces of tissues and in extracellular fluids accounting for the majority of SOD 
activity of plasma, lymph and synovial fluid (Adachi & Wang, 1998). EC-SOD is not induced 
by its substrates as its regulation in mammalian tissues is coordinated by cytokines.  




A significant decrease in the activity of erythrocyte SOD has been observed in AIDS patients 
when compared to HIV infection and healthy individuals (Pasupathi et al., 2009; Suresh et 
al., 2009). 
As previously mentioned, the secondary defence system includes chain-breaking 
antioxidants, exogenous in source and derived from dietary intakes, are small molecules that 
prevent further interaction of free radicals with other molecules (this may generate secondary 
radicals). These chain-breaking antioxidants function by receiving electrons from a radical or 
by donating an electron to a radical to form a stable by-product (De Zwart et al., 1999). 
These antioxidants are classified into water soluble and lipid soluble antioxidants. Lipid 
phase antioxidants, such as vitamin E and carotenoids, scavenge free radicals in 
membranes and lipoprotein particles, thus preventing lipid peroxidation. Vitamin E is a major 
lipid soluble antioxidant in body tissues, which provides the first line of protection against free 
radicals in cell membranes, by trapping peroxyl radicals (Lien et al., 1999). The water soluble 
antioxidants such as vitamin C, uric acid, phenolic compounds and bilirubin scavenges free 
radicals present in the aqueous phase section of blood plasma (Evans & Halliwell, 2001). 
Vitamin C is an important water soluble antioxidant that is involved in the recycling of free 
radicals produced by oxidation of vitamin E. However, vitamin C under certain circumstances 
can function as pro-oxidant and therefore, damage the cells (Bayday et al., 2007). 
In addition to the primary and secondary antioxidant defence system, other endogenous 
non–enzymatic antioxidants such as reduced glutathione (GSH), bilirubin, ceruloplasmin, uric 
acid, nicotinamide adenine dinucleotide phosphate (NADPH), albumin, thiols, ubiquinol-10, 
melatonin, and metals and metal binding proteins such as, transferrin, manganese and 
copper exists. The mechanism of metal binding proteins (e.g. ferritin, transferrin and 
lactoferrin) involves capturing or seizing the iron and copper so that they are unavailable to 
form hydroxyl radicals, thus forming an essential constituent of the antioxidant defence 
system (Papas, 1999).  
2.4.1.1 Glutathione redox status imbalance- reduced glutathione: oxidized glutathione 
ratio 
Glutathione (GSH), a free radical scavenger, is one of the major endogenous antioxidant, 
which plays key role in the cellular redox homeostasis and whose importance in redox 
balance and cell apoptosis is well established in various cell types (Circu et al., 2008; Ushio, 
2009). It is a tripeptide of glycine, glutamine (glutamic acid) and cysteine that is present in all 
eukaryotic cells, which exists in two forms; reduced GSH responsible for its antioxidant 
activity and GSSG which is a by-product of GSH free radical scavenging activity but lacking 
antioxidant activity (Zhang et al., 2005; Heisterkamp et al., 2008). Importantly, the cysteine 
residual in GSH provides an exposed sulphydryl group that is available for free radical attack, 




conferring the strong antioxidant activity of this molecule. Although free radicals oxidises 
GSH, the oxidised form (GSSG) is recycled back to its reduced form (GSH) by GR and an 
electron acceptor NADPH (Masella et al., 2005) (Equation 2.4).  
As a consequence, the main form of GSH in the body is the reduced form, however an 
oxidised form (GSSG), although in much lower concentrations also exist. Glutathione 
reductase oxidises GSH to GSSG and then recycled back to GSH by NADPH in the GPx 






Under normal conditions the ratio of GSH is about 90% to 10% GSSG in humans. A change 
in this ratio or decrease in GSH indicates an increase in GSSG, which in turn indicates lipid 
peroxidation and thus cellular oxidative stress (Sen, 1997; Schafer & Buettner, 2001).  
2.4.1.2 Glutathione redox status and HIV 
More specifically, glutathione being a major intercellular free radical scavenger is thought to 
inhibit activation of NF-kB which is involved in the transcription of HIV-1 (Walmsleyet al., 
1997). In its inactive form NF-kB is bound to IkB in the cytoplasm, however factors like TNF-α 
and ROS can cause its release from IkB to the nucleus where it binds with DNA (Greenspan 
& Aruoma, 1994). Interestingly, intracellular GSH is known to control T-lymphocyte function. 
In addition, T-cells lack both the ability to synthesize cysteine, a primary component of 
glutathione and the ability to take up cysteine the form in which cysteine is present in 
circulation. As a result, intracellular glutathione levels depend on the presence and uptake of 
extracellular cysteine (Droge et al., 1991; Droge et al., 1992). 
The measurement of GSH and GSSG has been used as an indicator of oxidative status and 
as an indicator of disease risk in humans (Pastore et al., 2003; Rossi et al., 2006). Recent 
studies have reported glutathione redox imbalance in HIV infection resulting from oxidative 
damage, viral replication, chronic inflammation and micronutrient deficiencies (Stephenson et 
al., 2007; Awodele et al., 2012; Morris et al., 2012), which is implicated in apoptosis and 




reduced immune proliferation (Morris et al., 2012). In addition, deficiencies of intracellular 
GSH in red blood cells (RBCs) and in T-cells, natural killer cells and monocytes of HIV-
infected individuals have been reported (Venketaraman et al., 2006; Morris et al, 2012). 
Supporting this theory, Staal et al. observed significantly lower GSH levels in CD4+ and 
CD8+ T-cells from HIV-infected individuals than from uninfected controls, the greatest 
decrease occurring in the later stages of the infection (Staal et al., 1992). These prior studies 
show that intracellular GSH levels could be a key aspect in HIV infection and progression to 
AIDS (Staal et al., 1992). Morris et al. hypothesized that chronic HIV infection promotes 
excessive production of pro-inflammatory cytokines, leading to generation of ROS which 
leads to depletion of GSH as it scavenges for the free radicals. In addition, they suggested 
that elevated TGF-β block GCLC reducing production of GSH and that elevated levels of IL-1 
lead to loss of intracellular cysteine, further inhibiting production of new GSH molecules 
(Morris et al., 2009). In addition, N-acetyl cysteine (NAC), a cysteine analogue that 
replenishes intracellular GSH and glutathione peroxidase, antioxidants that scavenge 
peroxides have been shown to inhibit apoptosis (Hockenbery et al., 1993). NAC acts directly 
as a free radical scavenger by reducing hypochlorus acid produced by neutrophils to kill 
target pathogens and cells. Although, this direct antioxidant activity of NAC could inhibit the 
natural mechanisms of neutrophils cytolysis, however, cell studies have indicated that NAC 
essentially boosts intracellular killing of bacteria by protecting the neutrophils and 
macrophages from free radical generated during phagocytosis (Oddera et al., 1994). 
Various studies support the hypothesis that oxidative stress is implicated in the progression 
of HIV disease (Dobmeyer et al., 1997; Kotler, 1998; Pasupathi et al., 2009). Disturbances in 
glutathione and antioxidant defence system in HIV-infected persons, decreased levels of 
other antioxidants e.g. ascorbic acid, tocopherols, carotenoids and selenium, altered 
activities of enzymes of the oxidant defence system and higher levels of serum markers of 
oxidative stress including malondialdehyde and hydroperoxides and higher oxygen 
consumption rates supports the conclusion that HIV-infected persons are exposed to chronic 
oxidative stress (Pace & Leaf, 1995; Kotler, 1998). The discovery that NAC or glutathione 
can protect T-cell hybridomas from activation-induced apoptosis, imply that HIV-linked 
CD4+T-cell activated apoptosis may be prevented by either replacement of intracellular 
reduced glutathione or by addition of other internal antioxidants (Sandstrom et al., 1994). 
The above antioxidant defence mechanisms, however, are not entirely efficient and thus 
repair enzymes also exist intracellularly to destroy proteins damaged by free radicals, 
remove oxidised fatty acids from membranes and repair free radical-damaged DNA 
(Halliwell, 1994; Masella et al., 2005). In addition other extracellular antioxidant defence 
mechanisms exist, which includes; transferrin (the plasma iron transport protein), the iron 
binding protein lactoferrin, ceruloplasmin (transport form of copper), hemopexin and 




haptoglobin (which binds free heme and heme proteins to decrease their capability to 
catalyse free radical damage), albumin and urate (end products of purine metabolism which 
scavenges several free radicals) (Morrissey & O‘Brien, 1998; Halliwell, 1989). 
Several studies have linked a weakened antioxidant defence system to the increased 
oxidative stress found in HIV infection (Dobmeyer, 1998; Pasupathi et al., 2009; Suresh et 
al., 2009). This could be as a result of increased utilization of the antioxidant defense system 
or reduced intakes of antioxidant micronutrients (Allard et al., 1998; Pasupathi et al., 2009). A 
depleted TAS leading to increased oxidative stress in HIV infection, has been previously 
reported (Mates et al., 2000;Gil et al., 2005; Pasupathi et al., 2009). Pasupathi, et al. 
reported a markedly decreased activity of superoxide dismutase, catalase, glutathione 
peroxidase, glutathione reductase, glutathione S-transferase, and reduced levels of GSH, in 
HIV/AIDS patients as compared to healthy controls (Pasupathi et al., 2009). They also 
observed significantly decreased levels of plasma GSH, vitamin A (β-carotene), vitamin C, 
vitamin E, serum uric acid, albumin, selenium and zinc in AIDS patients than in HIV positive 
patients and controls. Elevated markers of lipid peroxidation such as malondialdehyde/ 
thiobarbituric acid reactive substances (MDA/TBARS) and conjugated dienes have been 
reported in previous HIV studies (Allard et al., 2009; Pasupathi et al., 2009; Suresh et al., 
2009). Therefore, maintenance of the antioxidant defence system in HIV infections is critical 
as it prolongs the survival of the patient. This is due to the fact that accumulation of tissue 
damage due to oxidative stress takes long to manifest (Kotler, 1998).  
2.4.2 Oxidative stress and disease development 
All eukaryotic cells with the exception of red blood cells (RBC‘s) contain mitochondria, the 
principal organelle that generates ROS (Shanoun et al., 1997: Roberts et al., 2010), which is 
not only important for the normal physiological processes such as differentiation and cell 
signalling, but also in pathological processes (Halliwell, 2006; Kondo et al., 2009; Gil et al., 
2013). Cells are capable of dealing with mild oxidative stress via their antioxidant defence 
mechanisms, however, severe oxidative stress causes damage to biomolecules, cells and 
tissues. Prevention of oxidative stress is therefore paramount for good health and modulation 
of disease (Morrissey & O‘Brien, 1998; Young & Woodside, 2001). In healthy tissue, ROS 
and RNS generation involves a well and tightly regulated mechanism that helps to maintain 
redox homeostasis at cellular level (Yoshikawa et al., 2000). However, excessive ROS 
causes oxidation of nucleic acids, chromosome breaks, and peroxidation of unsaturated fatty 
acids in the cell membrane (Devasagayam et al., 2004), causing a loss of cell function, which 
might lead to apoptosis and in the process promote pathology of diseases (Kotler, 1998; 
Roberts et al., 2010). Furthermore, extensive DNA damage induced by oxidative stress not 
only promotes apoptosis of the affected cell, but also results in cell necrosis, which releases 




lysosomal enzymes, further producing ROS (Greenspan & Aruoma, 1994; Devasagayama et 
al., 2004).  
As previously mentioned, the body has developed a repair mechanism which includes both 
non-enzymatic antioxidants and enzymatic antioxidants to deal with the slight imbalance 
(Morrissey & O‘Brien, 1998; Young & Woodside, 2001; Leonarduzzi et al., 2010). The body 
can derive antioxidants such vitamin C, E, carotenoids, polyphenols and micronutrients such 
as zinc, magnesium and selenium from dietary intakes (Podsedec, 2007; Valko et al., 2007). 
Consequently, the body also uses a type of negative feedback regulation mechanism in a 
process referred to as redox homeostasis which produces endogenous antioxidants to 
correct this imbalance (Valko et al., 2007). The interrelationships between the effect of the 
imbalance in ROS, oxidative stress and human disease and their consequences on cell 
growth and differentiation and function are illustrated in figure 2.6. Several studies indicate 
that oxidative stress may be implicated in the progression of numerous disorders, which 
include HIV/AIDS, atherosclerosis, diabetes, inflammatory conditions, certain cancers and 
the aging process (Lipinsky, 2001; Barja, 2004; Devasagayam et al., 2004; Kondo et al., 
2009). However, according to other studies, oxidative stress may be a secondary 
phenomenon and not the primary cause of the disease (Gutteridge, 1993).  





Figure 2:6: ROS induced oxidative damage. The figure shows the interrelationship 
between ROS, oxidative damage and human disease (Compiled by author according to 
Mates et al., 1999. 
2.4.3 Oxidative stress and HIV/AIDS 
There is sufficient evidence suggesting HIV-infected patients are under chronic oxidative 
stress (Pace & Leaf, 1995; Allard et al., 1998; Jaruga et al., 2002; Gil et al., 2003; Wanchu et 
al., 2009), which might be related to increased activation of polymorphonuclear leukocytes or 
from pro-inflammatory cytokines produced by activated macrophages during the infection, or 
decreased intake of antioxidants (Peterhans et al., 1987; Valko et al., 2007; Coaccioli et al., 
2010; Morris et al., 2012). Furthermore, a role of viral protein Tat in intracellular increases of 
ROS, that is thought to induce apoptosis via FAS/CD95 interactions, thereby contributing to 
depletion of CD4+ T-cells, has been reported (Gil et al., 2003). 




Several studies have reported depleted levels of antioxidants such as glutathione, ascorbic 
acid, tocopherols, carotenoids, selenium and antioxidant enzymes (SOD, GPx & catalase) in 
HIV-infected individuals (Gil et al., 2003; Pasupathi et al., 2009: Suresh et al., 2009; Morris et 
al., 2012). Increased levels of lipid peroxidation products such as MDA/TBARS and 
conjugated dienes and more importantly, increased free radical production by neutrophils, 
have also been observed (Reeves, et al., 2002). The subsequent overload of H2O2, together 
with deficiencies in the antioxidant glutathione and antioxidant enzymes such as, CAT and 
GPx lead to overproduction of hydroxyl radicals and lipid peroxides, which are thought to 
promote apoptosis of CD4+T-lymphocytes in HIV infection (Hockenbery et al., 1993; Kotler, 
1998; Gil et al., 2003; Reinehr et al., 2008; Morris et al., 2012). Dobmeyer et al. presented 
the evidence that oxidative stress plays a fundamental role in initiation of apoptosis in HIV 
infection (Dobmeyer et al., 1996). This study reported that ROS generated under 
circumstances similar to those that occur during opportunistic infections, promotes apoptosis 
and that this effect could be ameliorated by antioxidants and/or antioxidant enzymes such as 
catalase, SOD, GSH, NAC and anti-TNF-α. Gougen & Montagnier theorized that the majority 
of the T-helper (CD4+) cell depletion occurs essentially via apoptosis and not by direct HIV 
infection (Gougen & Montagnier, 1993). This has been confirmed in subsequent studies in 
HIV-infected individuals (Dobmeyer et al., 1996). 
Oxidative stress is thought to significantly contribute to the reduction of CD4+ lymphocyte 
count in HIV-infected individuals, aiding in the progression to AIDS (Wanchu, et al., 2009). 
Moreover, lymphocytes of AIDS patients have been shown to be deficient of glutathione, an 
important endogenous antioxidant, (Venketaraman et al., 2006; Wanchu et al., 2009; Morris 
et al, 2012), making them susceptible to oxidative stress (Willcox et al., 2004). Furthermore, 
changes in the antioxidant defence system including depleted levels of ascorbic acid, vitamin 
E, superoxide dismutase and glutathione have been reported in lymphocytes including the T-
cell subsets of HIV-infected persons (Staal et al., 1992; Pasupathi et al., 2009; Suresh et al., 
2009; Gil et al., 2011). Suresh et al. noted elevated levels of serum malondialdehyde and 
hydroperoxides in these persons, suggesting oxidative stress during HIV infection (Suresh et 
al., 2009). A change in the levels and in the normal activity of superoxide dismutase, 
catalase, and glutathione peroxidise have also been noted in HIV-infected persons (Polyakov 
et al., 1994). 
Several studies have reported a severely disturbed redox balance in untreated HIV-infected 
individuals (Israel & Gougerot-Pocidalo, 1997; Romero-Avira & Roche, 1998; Allard et al., 
1998; Gil et al., 2003). In one of the studies, Gil et al. investigated the relationship between 
redox status indices of GSH, MDA, peroxidation potential, total antioxidant status, glutathione 
peroxidase, superoxide dismutase, total hydroperoxide (TH), DNA fragmentation and relative 
CD4, CD95, CD38/CD8 T-lymphocytes counts in HIV/AIDS patients in comparison with 




healthy individuals (Gil et al., 2003). The study indicated both a reduction of GSH levels and 
an increase in MDA and TH levels in the plasma of HIV-infected patients. The authors also 
reported that increased oxidative stress occurs in addition to persistent redox imbalance 
during successful HAART in a similar study (Gil et al., 2011). An increase of DNA 
fragmentation in lymphocytes and significant differences in global indices of total antioxidant 
status was noted in these patients. Furthermore, reduction of GPx and an increase in SOD 
activity in erythrocytes of the HIV-infected patients was also noted (Gil et al., 2003). Morris et 
al. in their study on causes of decreased glutathione levels in HIV infection, attributed this to 
increased pro-inflammatory cytokines, which increases ROS production, depleting 
intracellular GSH levels observed in the disease (Morris et al., 2012). Wanchu et al. in a 
study on oxidative stress in HIV-infected individuals, found decreased GSH levels and 
increased lipid peroxidation in infected individuals when compared to uninfected healthy 
control individuals (Wanchu et al., 2009) 
In another study, Pace & Leaf reported that oxidative stress was thought to contribute to the 
pathogenesis of HIV disease, including viral replication, inflammatory responses, decreased 
immune cell proliferation, loss of immune cell function, apoptosis, chronic weight loss and 
increased sensitivity to drug toxicity (Pace & Leaf, 1995). Of specific significance, is the fact 
that HIV has only been isolated from in vitro cultures and that no HIV can be isolated, unless 
the cultures are subjected to oxidative stress. Therefore, oxidation is a prerequisite for HIV 
expression (Papadopulos-Eleopulus et al., 1992). More importantly, ROS are known to 
activate NF-kB that is obligatory for HIV replication, therefore enhancing pathogenesis of the 
disease (Sen & Packer, 1996). It has been demonstrated that HIV replication is enhanced 
under oxidative conditions in vitro (Nabel & Baltimore, 1987; Sen & Packer, 1996). ROS are 
capable of directly activating (inhibitor of kappa B) IkB kinase (IKK), which phosphorylates 
the C-terminal ankylin repeats of the IkBα proteins bound to NF-kB at serine residuals 32 and 
36 (Hayden & Ghosh, 2008). This leads to ubiquitination and degradation of the IkBα, 
unmasking the DNA binding sites subsequently causing translocation of the NF-kB to the 
nucleus, where it binds to kB sites activating transcription of genes involved in cellular 
processes such as production of pro-inflammatory cytokines, inflammation, thereby 
promoting oxidative stress (Bonizzi & Karin, 2004). In vitro inhibition of viral replication has 
been established by experiments with both water and lipid soluble antioxidants (Kalebic et 
al., 1991; Harakeh & Jariwalla, 1991; Suzuki et al., 1992). The activity of antioxidants 
nonetheless, differs with different cell culture systems and thus do not emerge as strong anti-
HIV agents based on the high concentrations used in vitro (Pace & Leaf, 1995). More 
specifically, antioxidants such as vitamin C and NAC have been shown to inhibit NF-kB 
activation in vivo and in vitro, thereby ameliorating oxidative stress (Aillet et al., 1994; 
Baeuerle et al., 1994; Harakey & Jariwalla, 1997; Bellezzo et al., 1997). Several 




observations, including depletion of anti-apoptotic/antioxidant protein Bcl-2 in HIV-infected 
CD4+ T-cells, reduced apoptosis in HIV-infected cells treated with antioxidants and presence 
of apoptotic cytokines such as TNF-α, IL-1 & IL-6 secreted by activated macrophages in 
AIDS patients, all strengthen the proposition that apoptosis is involved in depletion of CD4+ 
T-cells in HIV/AIDS infection (Romero-Alvira & Roche, 1998). 
2.4.4 The mechanism of apoptosis 
Apoptosis or programmed cell death is a normal physiological process involved in tissue 
homeostasis, but is increased during oxidative stress (Pace & Leaf, 1995; Kotler, 1998).The 
physiological importance and quantitative significance of ROS-dependent receptor-mediated 
apoptosis in relation to the classical receptor/ligand-induced apoptotic signalling are poorly 
understood and requires further investigation (Circu & Aw, 2010). Apoptosis involves several 
biochemical proceedings culminating in cell membrane blebbing, shrinkage, nuclear 
fragmentation, chromatin condensation and chromosomal DNA fragmentation. Apoptosis is 
regulated by various cell signals, originating either extracellularly or intracellularly and 
activated through two separate pathways: the extrinsic (death receptor pathway) and intrinsic 
(mitochondrial) pathways. The extrinsic pathway is activated by the binding of death 
receptors FAS/CD95, TNFR1, DR4 and DR5 with their respective ligands i.e. Fas ligand 
(FasL), TNF, and TNF-related apoptosis-inducing ligand (TRAIL/Apo-2) ligands as shown in 
figure 2.7. The binding of receptors to their ligands, lead to protein-protein interactions at cell 
membranes, initiating a cascade of activation of membrane-proximal or initiator caspases 
(caspase-8 and caspase-10), which in turn activates caspase-3 and caspase-7 (executor 
caspases) (Ashkenazi & Dixit, 1999). Apoptotic signalling begins with the linking of death 
domains, containing adaptor protein within the death domain occurring at the c-terminal 
domain of the receptor.  
Emerging evidence indicates a possible direct role of ROS in mediating death receptor 
activation and apoptosis stimulation via ROS-induced receptor clustering and formation of 
lipid-raft-derived signaling platforms as shown in figure 2.7 (Circu & Aw, 2010). Oxidative 
stress-induced apoptosis mechanisms involve loss of mitochondrial transmembrane 
potential, release of cytochrome c to the cytoplasm, loss of Bcl-2, down-regulation and 
degradation of mitochondrially encoded mRNA, rRNA, and diminished transcription of the 
mitochondrial genome (Zamzani et al., 1997). Likewise, apoptosis may be initiated by genes 
in response to DNA damage or endoplasmic reticulum stress, death signals (Fas ligand) 
received at the membrane or when proteolytic enzymes such as granzymes enters the cells 
directly (Israels & Israels, 2002). 
The intrinsic pathway is activated by the disruption of mitochondrial membrane and 
subsequent release of mitochondrial proteins such as cytochrome c into the cytoplasm 




(Figure 2.7), which is vital for the assembly of the caspase–activating complex or 
apoptosome comprising of cytochrome c, Apaf-1, dATP & procaspase. As a result, caspase-
activating complex activates caspase-9, which initiates the apoptotic caspase cascade 
(Danial & Korsmeyer, 2004). The release of cytochrome c from the cytosol is regulated by 
Bcl-2 family proteins. The Bcl-2 family proteins are classified depending on their roles in 
apoptosis into proapoptotic (Bid and Bax) and antiapoptotic Bcl-2 & Bcl-xL (Ryter et al., 
2007; Circu Aw, 2010). 
Apoptosis is characterized by certain morphological features which include loss of plasma 
membrane asymmetry. In apoptotic cells, the membrane phospholipid PS is translocated 
from the inner to the outer leaflet of the plasma membrane, as a result exposing the PS to 
the external environment. Annexin V which is a 35-36 kDa Ca2+ dependent phospholipid-
binding protein has a high affinity for PS, and binds to cells with exposed PS. Annexin V, 
which can be conjugated to fluorochromes, therefore can serve as a sensitive probe for flow 
cytometry analysis of cells undergoing early apoptosis, since externalization of PS occurs in 
the earlier stages of apoptosis (Vermes et al., 1995). Various mediators including ROS, pro-
inflammatory cytokines, metals, radiation, pro-apoptotic genes etc. are known to activate 
various pathways of apoptosis (Circu & Aw, 2010).  
 
Figure 2:7: Death receptor mediated and mitochondrial pathways of apoptosis. 
(Source; Circu & Aw, 2010). 
Depending on where they exert their effects, mediators of apoptosis, can be broadly 
classified into five categories; 1) cell surface mediators, 2) the cytosol mediators, 3) the 




cytoskeleton mediators, 4) the mitochondrion and 5) the nucleus mediators (Kanna & Jain, 
2002). Table 2.2 summarises example of mediators of apoptosis.  
The cell surface mediators are the death receptors that include; Fas (CD 95), TNF-R1, 
CAR1, DR3, DR4 and DR5. Figure 2.7 illustrates the interactions between these death 
receptors with their ligands which lead to activation of various pathways ultimately leading to 
apoptosis. The interaction of these death receptors with their ligands may lead to initiation of 
a death signal depending on the presence of intracellular death domains and association 
with Fas-associated death domain (FADD) (Circu & Aw, 2010). Another key player in 
apoptosis is a class of cysteine-dependent and glutathione redox status sensitive enzymes 
called caspases. Importantly, they are synthesized as precursors and one of their functions is 
to inactivate proteins that are important for cell survival. FADD is capable of communicating 
with caspase-8, which triggers a cascade of caspases activation, therefore committing the 
cell to apoptosis. So far 13 different caspases have been identified (Israels & Israels, 2002). 
Table 2:2: Mediators of apoptosis (Source: Kanna & Jain, 2000) 
Inducers of oxidative stress Examples 
ROS Superoxide, hydroxyl, hydrogen peroxide radicals 
Metals Iron, cadmium, mercuric chloride 
Pathophysiologic conditions Hyperglycaemia, ischemic heart disease, 
Alzheimer‘s and Parkinson‘s 
Inducers of apoptosis involving 
oxidative stress 
Examples 
Pro-oxidants H2O2, diamide, etoposide and semiquinones 
Ionizing radiation Gamma UV radiation 
Protein synthesis inhibitor Cycloheximide 
Apoptotic stimuli Fas (CD95), TNF α, ceramide, glutamate, growth 
factor withdrawal (IL-2, IL-3, nerve growth factor and 
serum starvation) 
Physiologic stimuli Glucocorticosteroids, calcium, TNF α, glutamate 
Pathophysiological conditions Serum starvation, IL-2 and IL-3 withdrawal, 
hyperglycaemia, ischemia and reperfusion 
Pro- apoptotic genes P53, Bax, c-myc 
Organic solvents and metabolites Benzene and their metabolites and 2,5-hexanedione 
Pesticides DDT, endosulfan, dieldrin and  2,3,7,8 
tetrachrolodibenzo-p-dioxin 
Drugs Actinomycin D, cisplatin, camptothecin and 
staurosporine 
2.4.5 Oxidative stress, immune activation and immune response 
The chronic immune activation during HIV infection promotes increased ROS generation (Gil 
et al., 2003; Awodele et al., 2012), which activates nuclear transcription factors such as NF-
kB leading to viral gene expression, initiating a vicious cycle of activation, oxidative stress 
and viral replication (Ma, 2010; Gendron et al., 2011). In addition, the cells of the immune 
system are remarkably sensitive to oxidative stress since their plasma membranes contain 
high levels of polyunsaturated acyl lipids, which is vulnerable to peroxidation (Kotler, 1998; 




Block et al., 2002; Roberts et al., 2010). As a result, ROS may modify protein structures, 
making them susceptible to spontaneous fragmentation, proteolysis and ultimately impairing 
their function (Gil et al., 2013). Peroxidation of the polyunsaturated acyl chain in the cell 
membranes leads to loss of membrane integrity and altered membrane fluidity, consequently 
leading to impairment of intracellular signalling and the overall cell function (Chew & Park, 
2009). The subsequent oxidative modifications of DNA leads to gene mutations and 
deletions, which has been implicated in pathophysiology of many diseases involving 
mitochondrion dysfunction, aging (Devasagayama, 2004) and cellular senescence (Block et 
al., 2002; Roberts et al., 2010). Pasupathi et al. associated the increased production of ROS 
to chronic immune system activation, which depleted antioxidant defences, causing damage 
to cellular components as indicated by increased lipid peroxidation products, oxidized 
proteins and altered DNA sequences (Pasupathi et al., 2009). A higher incidence of diseases 
associated with oxidative stress such as cancer, cardiovascular disorders, 
neurodegeneration and waste syndrome have been reported in HIV patients (Gil et al., 
2013).  
Translocation of microbial products from GIT to the systemic circulation is thought to activate 
the innate immune system resulting in generation of pro-inflammatory cytokines and ROS, 
increased oxidative stress, depletion of antioxidant defences and susceptibility to apoptosis 
(Brenchley et al., 2006; Haynes, 2006; Morris et al., 2012). Interestingly, a unique feature of 
HIV infection is that it targets mainly the CD4+ T-cell pool and to a lesser extent 
macrophages and dendritic cells, which are vital immune cells (Hunt, 2010). More 
specifically, during the chronic phase of HIV infection, the main target of the virus is the 
CCR5+ CD4+ activated T-lymphocytes (Siliciano & Siliciano, 2000; Veazey et al., 2000). The 
majority of these cells (about 80%) inhabit the lymphoid tissues such as lymph nodes in 
particular MALT such as GIT associated lymphoid tissue (GALT) (Haynes, 2006; Hunt, 
2010). Importantly, these mucosal  CD4+T-cells consist primarily of memory CD4+ T-cells 
expressing the HIV co-receptor CCR5, therefore are perfect targets for the HIV virus 
(Veazey, et al., 2000; Appay et al., 2008). The ―leaky gut‖ phenomenon during early HIV 
infection, results in loss of mucosal integrity leading to translocation of microbial products 
such as LPS, flagellin and CpG DNA (toll like receptor ligands) across the epithelial surface 
(Brenchley et al., 2006). These microbial products are known to activate innate immune cells 
such as neutrophils, macrophages/monocytes and dendritic cells directly to produce ROS 
and pro-inflammatory cytokines e.g. TNF-α, IL-6 and IL-1β. In the early stages of HIV 
infection, ROS e.g. H2O2 production is markedly increased, which is thought to contribute to 
the increased depletion of CD4+ T-cells via apoptosis (Pugliese et al., 2005).  
Considerably high plasma levels of LPS correlating directly with markers of immune 
activation have been demonstrated in HIV infection, indicating microbial translocation and 




immune activation (Brenchley et al., 2006). LPS induces activation of innate immune cells 
such as neutrophils, monocytes and dendritic cells via toll like receptor 4 (TLR4) resulting in 
increased oxidative stress, depletion of antioxidant defense mechanisms and increased 
susceptibility to apoptosis (Brenchley et al., 2004; Haynes, 2006). 
It is a well-established fact that chronic activation of CD8 and CD4+ T-cells characterises 
HIV-1 infection and that this consistent activation is associated with depletion of CD4+ T-cells 
and increased risk of faster disease progression to AIDS (Hazenberg et al., 2003). 
Importantly, markers of immune activation are now considered more valuable predictors of 
disease progression to AIDS than the CD4 count and viral load (Giorgi et al., 1993; Liu et al., 
1997; Fahey et al., 1998). In addition, a complex interplay between HIV replication, immune 
activation, inflammation and oxidative stress exists (Le douce et al., 2010) making these 
conditions closely intertwined and interlinked (Gendron et al., 2010; Ma, 2010). Oxidative 
imbalance in the early phase of HIV infection, which is characterised by low serum and tissue 
antioxidants and antioxidant enzymes such as low GSH and SOD and high lipid peroxidation 
products (MDA) has been reported (Friis-Moller, 2007: Awodele et al., 2011). The immune 
system‘s function is influenced by its glutathione redox status and potential. As a 
consequence, oxidative stress and decreased glutathione levels in lymphocytes in vitro, 
cause changes in cell function, abnormal cytokine production, and a dysfunctional 
proliferation response (Fidelus, 1990; Maly, 1990; Hamilos, 1992). The increased activation 
of polymorphonuclear leukocytes during infections or due to the effect of TNF-α produced by 
activated macrophages during HIV infection is closely associated with increased production 
of ROS and oxidative stress (Das et al., 1990). Therefore, chronic oxidative stress is 
associated with an abnormal T-lymphocyte function in HIV-infected patients (Droge, et al., 
1991; Droge, 1993).  
Oxidative stress leads to over expression of TNF-α which activates HIV replication in T-
lymphocytes, and mononuclear cells, which leads to up regulation of interleukin-2 (IL-2) 
receptor, and other cytokines, resulting in decreased immune cell proliferation (Hamilos, 
1992; Droge, 1993). However, various glutathione-replenishing agents have been shown to 
restore in vitro proliferative response in HIV-infected cells and in cells in which glutathione 
had been depleted chemically in cell cultures (Zmuda & Friedenson, 1983; Hamilos et al., 
1989; Eylar et al., 1992; Iwata et al., 1994). ROS are known to activate 
monocytes/macrophages potentiating them to produce increased pro-inflammatory cytokines 
therefore playing an important role in inflammatory process in HIV infection (Chaudri & Clark, 
1989; Morris et al., 2013). 




2.4.6 Oxidative stress and inflammation  
Inflammation has been shown to directly induce oxidative stress and endothelial dysfunction 
in HIV-infected individuals, which might predispose them to thrombotic complications (Baliga 
et al., 2005). Although inflammation is an important non-specific defence response to tissue 
injury by either a pathogen or a wound, however if not properly regulated it can be 
detrimental (Janeway et al., 2005). It is well know that excessive ROS are produced during 
inflammation (McGregor et al., 2006), which are linked to the pathophysiology of chronic 
diseases such as atherosclerosis and chronic inflammatory diseases (Mayne, 2003). 
The inflammatory response is divided into two phases; an acute phase which forms part of 
innate immunity and a chronic phase forming part of adaptive immunity (Medzhitov et al., 
2008). Acute inflammation is the immediate response of the body to injury or cell death and it 
begins when injured tissue cells releases chemical signals that activate the endothelium of 
the nearby capillaries (Israels & Israels, 2002; Prescott et al., 2002). As a result, the 
activated endothelial cells display selectin or cell adhesion molecules, P-selectin and E-
selectin, which randomly attract and attach neutrophils to the endothelial cells slowing them 
down. The neutrophils encounter the inflammatory mediators that activate adhesion 
receptors (integrins) on the cells. Importantly, the neutrophil integrins attach tightly to 
endothelial adhesion molecules and stops rolling (Prescott et al., 2002). As a result, 
neutrophils undergo changes in shape, squeeze through the endothelial wall into interstitial 
tissue fluid, migrate to the site of injury, and attack the pathogen or the cause of tissue injury.  
The recruited activated neutrophils and macrophages shed arachidonic acid (A A) from the 
membrane phospholipids mediated by the action of phospholipase A2. Consequently, A A 
after undergoing a series of eicosanoids conversions is ultimately converted to 
prostaglandins responsible for typical pain, vasodilation, erythema and fever that are 
associated with inflammatory reaction (Israels & Israels, 2002). Depending on the severity 
and nature of tissue damage other leukocytes e.g. lymphocytes, monocytes, and 
macrophages may follow the neutrophils (Prescott et al., 2002). The phagocytic cells 
(monocytes, tissue macrophages and neutrophils) are important early defence against 
invading pathogens. Once the invading pathogens are ingested by the phagocytes, they are 
taken to lysosomes where they are destroyed. Macrophages and neutrophils also contain 
oxygen-dependent enzymes (NADPH oxidase system) that produce noxious ROS which are 
efficient in killing the attacking pathogen (Kotler, 1998). The expression of NADPH oxidase 
NOX2 (gp91 phox) responsible for ROS production during inflammatory process is induced 
by NF-kB (Israels & Israels, 2002). This occurs during respiratory burst due to increased 
oxygen use and ATP production and further promotes oxidative stress, tissue injury and 
inflammation (Prescott et al., 2002). Inflammatory cytokines such as TNF-α, IL-1, IL-6, are 
known to stimulate HIV transcription, replication and rapid depletion of CD4+ T-cells via 




apoptosis, making them important factors in the progression of HIV to AIDS (Roederer et al., 
1990; Staal et al., 1990; Villinger & Ansari, 2010; Morris et al., 2012). In addition, excessive 
TNF-α may cause inflammatory damage and toxicity impairing the hosts‘ immune responses 
independent of CD4 depletion. As a result, the chronic inflammatory state in HIV infection 
causes prolonged production of ROS leading to chronic oxidative stress (Merrill et al., 1989; 
Cheung et al., 2008). 
Inflammation has been associated with a higher mortality risk in HIV infection even in 
patients with high CD4 count (Julg & Goebel, 2006; Fichtenbaum, 2010). In their study, Tien 
et al. found that inflammatory biomarkers fibrinogen and C-reactive proteins (CRP) were 
strong and independent predictors of mortality in HIV-infected patients (Tien et al., 2010). 
Furthermore, excessive production of pro-inflammatory cytokines such as TNF-α may induce 
inflammatory damage and toxicity, ultimately leading to dysfunctional immune response 
according to Morris et al. (Morris et al., 2012). More specifically, the chronic infection 
characteristic of HIV infection, leads to a sustained production of ROS and a chronic state of 
inflammation, which promotes chronic oxidative stress (Merrill et al., 1989; Cheung et al., 
2008). The complexity of inflammation and oxidative stress in HIV is summarised in figure 
2.8.





Figure 2:8: Oxidative stress and inflammation in HIV infection. The figure shows the 
proposed link between inflammation, oxidative stress and HIV (compiled by the author 
according to Appay & Sauce, 2008; Haynes, 2006; Brenchley et al., 2004. 
 
2.5 Consequences of oxidative stress in HIV 
2.5.1 Oxidative stress and signaling pathways 
In order to understand the consequences of oxidative stress and apoptosis in HIV, it is 
important to comprehend the signalling pathways activated by oxidative stress. Apoptosis or 
programmed cell death is regulated by various molecules including cytokines such TNF-α, 
Fas ligand (FasL), ROS and mitogen-activated protein kinesis (MAPK) such as extracellular 
signal-related protein kinase (ERK), c-Jun N-terminal kinase/ stress activated (JNK) (Akgul & 
Edwards, 2003). Some of the pathways activated by oxidative stress are summarised in 
Figure 2.9. Oxidative stress is proposed to activate an intracellular mediator, the small G 
protein Ras (Figure 2.9), which in turn activates MAPK via a network of protein kinases 
(enzymes that modify other proteins by chemically adding phosphate groups to them) such 
as ERK kinase, (MEK) kinase (MEKK) and subsequently activating MEK1, a regulator of the 































may be regulated by oxidative stress (Kyaw et al., 2004; Circu & Aw, 2010). Among the 
targets of these MAP kinases are various transcription factors including Elk-1 (ternary 
complex factor, TCF), c-Jun, ATF-2, and CHOP. It has also been reported that ROS 
activates tyrosine kinases and non-receptor protein kinases (Src family & JAK) initiating 
MAPK, NF-kB, nuclear erythroid 2-related factor-2 (Nrf2) and PI3K signalling pathways 
(Kyaw et al., 2004). Of specific importance to this study is the NF-kB signalling pathway and 
the fact that GSSG (oxidised form of GSH during oxidative stress) has been shown to 
actívate stress-activated protein kinase (SAPK), JNK and MAPK pathways, thereby directly 
inducing apoptosis (Filomeni et al., 2005). 
NF-kB is an inducible and ubiquitously expressed transcription factor that regulates the 
expression of hundreds of genes involved in cell survival, differentiation, growth, apoptosis 
and inflammation (Amiri & Richmond, 2005). It occurs as an inactive complex in the cytosol, 
bound to IkBα, which mask the NF-kB‘s DNA binding domains. More importantly, ROS are 
capable of directly activating IkB kinase (IKK) which phosphorylates the C-terminal ankylin 
repeats of the IkBα proteins bound to NF-kB at serine residuals 32 and 36 (Hayden & Ghosh, 
2008). This leads to ubiquitination and degradation of the IkBα unmasking the DNA binding 
sites subsequently causing translocation of the NF-kB to the nucleus where it binds to kB 
sites and activates gene transcription involved in cell processes such as pro-inflammatory 
cytokines inflammation, thereby promoting oxidative stress (Bonizzi & Karin, 2004). Since 
NF-kB is a critical player in the regulation of the immune response to infection, its activation 
leads to proliferation of pro-inflammatory cytokines, provoking a vicious cycle of oxidative 
stress and inflammation. ROS, TNF-α, LPS and IL-1β are known to activate NF-kB, which is 
also a prerequisite for HIV replication (Brach et al., 1992). 
A previous study has indicated that chronic activation of TNF-α signalling pathway promotes 
transcription of the virus, initiation of apoptosis and suppression of haematopoiesis, therefore 
playing an important role in HIV-1 pathogenesis (Matsuyama, et al., 1991). Matsuyama et al.  
identified c-Jun N-terminal Kinase (JNK) as the effector molecule in the H2O2 induced cell 
death downstream of receptor interacting protein (RIP) and tumour necrosis factor receptor 
associated factor-2 (TRAF2) (Matsuyama et al., 2005). They proposed a pathway involving 
RIP, TRAF2 and JNK1 as novel signalling pathway regulating oxidative stress or ROS-
induced cell death. Depending on the various signalling pathways activated and target, ROS 
can have a variety of damaging effects which are discussed in the following section. 





Figure 2:9: Oxidative stress induced signalling pathways. The figure shows the 
different mitogen activated protein kinases (MAPK) activated by oxidative stress. 
Adapted from Kyaw et al., 2004. 
2.5.2 Oxidative damage in HIV 
As previously mentioned, excessive ROS leads to oxidative stress, which causes damage to 
biomolecules such as DNA, carbohydrates, proteins and uric acids (Devasagayam et al., 
2004). This oxidative damage is marked especially in lipids which constitute the cell 
membrane. More specifically, ROS can react directly with proteins, oxidising peptide bonds 
or side chains of amino acids to form products of carbonyl groups (1o oxidation modification) 
or can react with lipids to form products that reacts with proteins (2o oxidation modification), 
amino acids or peptide bonds for example covalent modification of proteins hydroxyl-nonenal 
(HNE), which is a very reactive unsaturated aldehyde produces lipid peroxidation 
(Devasagayam et al., 2003). The carbonyl groups produced can be estimated in the 
laboratory by carbonyl assays such as enzyme-linked immunesorbent assay (ELISA), 
fluorometry and immunoblot assays. DNA oxidative modifications and damage involves 
oxidation of specific bases, which might induce mutations, deletions, strand breaks, DNA 
cross-linkages, modification of base pairs microsatellite instability, chromosomal aberrations, 
altered gene expression and cytotoxicity or neoplastic growth (Devasagayam et al., 2004), all 




of which have been implicated in various pathological conditions (Khansari et al., 2009; Gil et 
al., 2013. Hydroxyl radicals attack on DNA base can produce several different primary 
products of oxidation such as 8-OH-2‘-deoxyguanosine (8-OH-dG), which is the most 
common marker for oxidative DNA damage in living systems (Evans et al., 2004) and 8-OH-
adenine (8-OH-Ade) among others. 
Several methods for analysis of oxidative DNA damage analysis such as high performance 
liquid chromatography (HPLC), gas chromatography mass spectrophotometry (GC-MS), 
ELISA and radioactive immune assay (RIA), immunodetection, comet assay are available. 
Lipid peroxidation, a marker of oxidative damage, involves attack by ROS on 
polyunsaturated fatty acids (PUFAs) generating very complex group of oxidation products. 
The process starts when an electron is removed from lipids by free radicals initiating a chain 
reaction which generates more free radicals (Devasagayam et al., 2003; Devasagayam et 
al., 2004). As a result, oxidative stress in living systems can be estimated by measuring ROS 
directly or the degree of protein, DNA oxidation as mentioned previously or by measuring 
products of lipid peroxidation in the systems (Laguerre et al., 2007). However, lipid 
peroxidation remains the most convenient marker of oxidative stress in living systems. 
The estimation of the lipid peroxidation process in general is not easy as it is an intricate 
process that occurs in several stages (Nalsen, 2006). Specifically, both MDA and conjugated 
dienes, which are by-products of lipid oxidation reactions, can be estimated in plasma, serum 
or RBC‘s lysates. Lipid peroxidation has been traditionally estimated by the increase in 
TBARS which mirrors the production of MDA, an oxidation product of lipid peroxidation and 
conjugated dienes. Conjugated dienes on the other hand are PUFAs produced as by-
products in the process of lipid peroxidation reaction. Plasma TBARS assay is based on the 
reaction of thiobarbituric acid (TBA) with malondialdehyde in the plasma and the absorbance 
of the MDA-TBA adducts is read at 530 nm (Khoschsorur et al., 2009). During oxidation of 
PUFA side chain, the double bonds are converted into conjugated double bonds resulting in 
conjugated dienes which absorb UV light at 234 nm. The concentration of dienes can 
therefore be calculated using an extinction coefficient. However, due to the unspecificity of 
the TBARS assay, it is advisable that at least two different assays for lipid peroxidation 
should be applied for a reliable estimation (Hwang & Kim, 2007).  
Several studies have reported increased lipid peroxidation in HIV infection (Pauspathi et al., 
2009; Suresh et al., 2009; Awodele et al., 2012). In their investigation of levels of oxidative 
stress parameters in HIV, Awodele et al. reported a significantly higher MDA levels in naïve 
patients when compared to HIV patients on HAART (Awodele et al., 2012). However, in their 
study (REACH cohort), Stephensen et al. reported no association of HIV infection with 




oxidative damage in adolescents between 14 - 23 years, indicating that young age and stage 
of disease were determinants of oxidative damage in HIV (Stephensen et al., 2005). 
2.5.3 Oxidative stress and apoptosis in HIV  
It is a well-known fact that HIV patients are under chronic oxidative stress due to either over 
utilization of antioxidant defence system or reduced intake of antioxidants (Pace & Leaf, 
1995; Kotler, 1998). That ROS can cause harm to the cells and tissues is also known and 
when the damage is extensive, it is to the advantage of the tissues to get rid of the cell to 
protect the surrounding cells. Consequently, ROS are capable of triggering both apoptotic 
and necrotic cell death depending on the severity of the oxidative stress (Saito et al., 2006). 
Oxidative stress is thought to be a co-factor for the induction of apoptosis in neutrophils and 
T lymphocytes during HIV/AIDS infection (Pitrak et al., 1996; Dobmeyer et al., 1997; Gil et 
al., 2013). Importantly, studies suggest that a reduction in CD4+ T-lymphocyte subsets 
during HIV might be due to apoptosis (Gougeon & Montagnier, 1993). Although apoptosis or 
programmed cell death is a normal physiological process involved in tissue homeostasis, it is 
increased during oxidative stress (Kotler, 1998). Several factors are known to induce 
apoptosis. These factors include; receptor-mediated signals, viral proteins, withdrawal of 
growth factors, direct viral toxicity, anti-tumour drugs and under certain conditions for 
example aberrant immune activation or oxidative stress damage to DNA (Appay & Sauce 
2008; Cummins & Badley, 2010; Hunt, 2010). Other factors thought to stimulate apoptosis in 
CD4+ T-cells include viral proteins (gp120) (Westerndorp et al., 1995), improper secretion of 
inflammatory cytokines by activated macrophages (TNF-α) (Wanchu et al., 2009; Morris et 
al., 2012) and toxins produced by opportunistic microorganisms (Repetto et al., 1996). 
According to Hockenbery et al., an overload of H2O2 during oxidative stress in conjunction 
with deficiencies in catalase and glutathione peroxidase possibly leads to overproduction of 
hydroxyl radicals and lipid peroxides and consequently induces apoptosis (Hockenbery et al., 
1993). In view of that, the addition of TNF and H2O2 to HIV-infected cells in vitro increased 
cell death, whereas addition of antioxidants decreased apoptosis in the cells (Malorni et al., 
1993; Sandstrom et al., 1993). Since most of the agents that induce apoptosis are either 
oxidants or activators of cellular oxidative metabolism, the generation of ROS consequently 
could induce apoptosis. The pathology of ROS is linked to oxidation of nucleic acids and 
chromosome breaks, when excessive of which promotes apoptosis (Greenspan & Aruoma, 
1994; Devasagayama et al., 2004; Gil et al., 2013). Furthermore, vulnerability of lymphocytes 
to ROS-induced apoptosis is increased in HIV infection from early stages of the disease 
(Bundres et al., 1993; Favier et al., 1994; Jarstrand & Akerlund, 1994; Kotler, 1998; Block et 
al., 2002; Pugliese et al., 2005; Roberts et al., 2010). Further research needs to be done to 
study why lymphocytes from HIV-infected individuals exhibit an enhanced vulnerability to 




oxidative stress. It has been shown that reactive oxygen radical scavengers, such as GSH, 
N-acetylcysteine (NAC), and catalase could prevent the initiation of apoptosis, while SOD, 
which degrades superoxide radicals to H2O2 decrease apoptosis significantly in a dose-
dependent way (Dobmeyer et al., 1997). As stated previously, caspases, important 
participants in apoptosis are cysteine-dependent and glutathione redox status sensitive 
enzymes (Staal et al., 1992; Kotler 1998; Circu & Aw, 2010). Interestingly, cysteine starvation 
of caspases has been shown to induce apoptosis (Armstrong et al., 2004). In addition, NAC, 
a well-recognized thiol antioxidant, which is converted to glutathione after uptake, as well as 
glutathione, has been reported to completely block activation-induced death and associated 
DNA fragmentation in T-cell hybridomas, therefore implicating redox regulation in the 
processes (Sandstrom et al., 1994; Akerlund et al., 1995; Morris et al., 2013).  
However, the significance of modulating oxidative stress on the clinical progression of HIV 
disease remains to be established, although trials to evaluate the clinical importance of 
oxidative stress in HIV are in advanced stages (Pace & Leaf, 1995; Wanchu et al., 2009; Gil 
et al., 2013). Results from recent clinical trials have indicated beneficial effects of antioxidant 
vitamins supplementation such as suppression of viral load (Hurwitz et al., 2007), improved 
mitochondrial function (Milazzo et al., 2010), CD4+ T-lymphocyte counts (Yousefi et al., 
2011) and suppression of progression of HIV (Morris et al., 2013). In a recent study, Morris et 
al. reported that NAC and liposomal formulation of glutathione (lGSH) supplementation 
improves macrophage functions in HIV (Morris et al., 2013). 
2.5.4 Oxidative stress, immune activation and antioxidant depletion in HIV 
The significant depletion of memory CD4+ T-cells lining the GIT mucosa in early HIV 
infection results in breakdown of the mucosa and on-going translocation of microbial 
products such as LPS across the epithelial surface (Brenchley et al., 2004; Brenchley et al., 
2006). As a result, LPS induces activation of innate immune cells such as monocytes and 
dendritic cells resulting in increased oxidative stress; depletion of antioxidant defence 
mechanisms and an increased susceptibility to apoptosis. Importantly, CD4+ T-lymphocytes 
express toll like-receptor-4 (TLR4), which is a receptor for LPS. Specifically, TLR4 activates 
various signalling pathways such as mitogen-activated protein kinases (MAPK), p38 and 
JNK, which induce activation of transcription factor NF-kB with subsequent production of pro-
inflammatory cytokines, chemokines, antimicrobial peptides and other defence molecules 
such as ROS (Kabelitz, 2007). As mentioned previously, the pro-inflammatory cytokines 
produced are capable of activating innate immune cells to produce more ROS. 
Subsequently, ROS and pro-inflammatory cytokines produced induce activation of both the 
extrinsic and intrinsic pathways of apoptosis. With the generation of excessive ROS and 
cytokines, adaptive immune system becomes activated, antioxidant defences such 




glutathione gets depleted as they try to scavenge for the free radicals, thereby initiating a 
vicious cycle of oxidative stress and immune activation (Morris et al., 2013). 
The role of in vitro stimulation with LPS on T-cell activation in HIV has been explored 
previously. However, majority of published studies have used CD38 and HLA-DR as the 
activation biomarkers and were conducted on HIV-infected patients who were on 
antiretroviral treatment (Tincati et al., 2010). A previous study by Bellezzo et al. reported 
activation of NF-kB in kupffer cells, which was inhibited by NAC and α-tocopherol (α-TOC). In 
this study NAC and α-TOC suppressed LPS-induced TNF-α mRNA levels and secretion 
(Bellezzo et al., 1998). Only a few studies on CD25 as an activation marker have been 
published despite CD25 being a well-established activation biomarker on activated T and B-
cells. 
Recently, the use of HAART has led to decline in viral load, qualitative and quantitative 
improvement in immune functions of HIV patients and constant progress in reducing 
morbidity and mortality (Corbeau & Reynes, 2011; Plaeger et al., 2013). However, since the 
ART therapies do not eliminate HIV completely, the problem of insufficient immune 
reconstitution in some patients persists (Coaccioli et al., 2010; Corbeau & Reynes, 2011). 
Unfortunately, hepatotoxicity and mitochondrial toxicity in patients on HAART has been 
reported recently meaning that the outcomes of treatment will largely depend on immune 
system‘s ability to recover and control residual virus (Gil et al., 2012). In spite of sufficient 
viral suppression, chronic inflammation and immune activation persist in HIV-infected 
patients on HAART (Plaeger et al., 2012), which independently predicts faster disease 
progression to non-AIDS related morbidity and mortality (Nixon & Landay, 2010). Therefore, 
reducing immune activation, inflammation and oxidative stress with interventions such as 
nutritional and antioxidant interventions becomes important (Hurwitz et al., 2007; Aquaro et 
al., 2008; Edeas et al., 2010; Gil et al., 2013). In their study to characterize oxidative stress in 
different clinical conditions, Gil et al. showed a significant beneficial change in antioxidant 
status (↑GSH, ↓MDA, ↓CD95 receptor) by nutritional and antioxidant supplementation with 
Vimang in HIV-infected Cuban patients (Gil et al., 2013). 
HIV infection has been shown to affect levels of antioxidant enzymes such as glutathione 
peroxidase (Stephensen, 2007). Furthermore, HIV Tat gene has been shown to induce H2O2 
signaling resulting in enhanced T-cell activation and death signal expression (Campbell, 
2005). Therefore, it is likely that both the depletion of endogenous antioxidants such as 
glutathione and the increased production of H2O2 as a result of chronic inflammatory 
processes, contribute to the deaths of CD4+ T-lymphocytes in HIV infection (Kotler, 1998; Gil 
et al., 2013).  




However, it is a well-known fact that factors such as temperature, duration and concentration 
have a bearing on results of these studies, thereby necessitating optimization in order to 
have reliable results. 
2.6 The effects of temperature, time and concentration on the activity of LPS and 
antioxidants in immune activation and oxidative stress 
Previous studies involving LPS-induced activation of cells have utilised varying 
concentrations of LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and vitamin C (25 - 50 nM), 
therefore there is a need for optimization (Dobmeyer et al., 1996; Shang et al., 2003; 
Yamanda et al., 2006). Different markers such as Annexin V/7-AAD, CD4, CD25 and CD69 
monoclonal antibodies have been used previously as convenient markers of early and late 
apoptosis and immune activation. Therefore, it is important to optimize the in vitro effects of 
temperature and concentration and concentrations of LPS and selected antioxidants on LPS-
induced immune activation in asymptomatic HIV infection. 
LPS is a polysaccharide, cell wall component expressed by gram negative bacteria, which is 
a strong immunostimulatory molecule associated with T-cell and monocyte activation 
(Brenchley et al., 2006). Annexins are a group of calcium-dependent phospholipid binding 
proteins occurring abundantly in eukaryotic cells. Annexin V is Ca+ dependent, phospholipid 
binding proteins, which is capable of specifically binding to PS strongly even when 
conjugated with fluorescein isothiocyanate (FITC) (Raynal & Pollard, 1994; Vermes et al., 
1995). This phenomenon has been applied in cell analysis. Annexin V-FITC and 7-AAD are 
used in combination to detect early apoptosis (Koopman et al., 1994). The principle of this 
assay is based on the ability of Annexin V to bind to PS and on the specificity of 7-AAD to 
bind DNA guanine-cytosine base pair (Zelenin et al., 1984). Early detection of apoptosis was 
based on morphological changes of the cell like cell shrinkage, nuclear condensation and 
pyknosis, which were complimented with biochemical changes such cleavage of the DNA 
between the nucleosomes, resulting in appearance of DNA bands on agarose gels. 
However, it was discovered that not all cells undergoing apoptosis cleave their DNA strands 
between nucleosomes and that those that does, do so only at latter stages in the apoptotic 
pathway (Israels & Israels, 2002). Hence other parameters had to be used to detect early 
stages of apoptosis.  
One of these parameters is the appearance of PS on the surface of the cells. During the 
early phase of apoptosis, although the integrity of the cell membrane is maintained, the cells 
loose the asymmetry of their membrane phospholipids thereby exposing PS at the surface of 
the cell (Martin et al., 1995). PS is a negatively charged phospholipid which is usually located 
in the inner leaflets of the plasma membrane. Importantly, the exposure of the PS at the 
surface of the cell forms one of the earliest and specific signals for recognition and removal 




of apoptotic cells by macrophages via PS receptor (Chaurio et al., 2009; Kim et al., 2005). 
Annexin V-FITC or PE is used to quantitatively determine the percentage of cell within a 
population that are actively undergoing apoptosis. The interaction of Annexin V and PS is 
calcium-dependent, thus it is critical to avoid buffers containing EDTA or other calcium 
chelators during Annexin V staining (Raynal & Pollard, 1994; Vermes et al., 1995). 
Since cell membrane integrity is lost as the apoptosis process progresses, distinction 
between early apoptotic and late apoptotic or necrotic cells is possible using a DNA specific 
dye like 7-AAD. The baseline levels of apoptosis and necrosis varies widely within a 
population and therefore even in the absence of induced apoptosis, most cell populations will 
show a little percentage of cells that are positive for apoptosis. It is recommended therefore 
that unstained or untreated cells population be included to define the baseline levels of 
apoptotic cells and dead cells (Vermes et al., 1995; Koopman et al., 1994).  
During LPS-induced stimulation, activated monocytes respond to LPS by secreting 
inflammatory cytokines such as IL-1, 6 & TNF-α which leads to increased ROS production. 
Furthermore, LPS is known to activate various signalling pathways including the ERK ERK, 
P38, and SAP/JNK, in addition to PI3 Kinase and IKK/NF-κB pathways in peripheral blood 
via the Toll-like receptor-4 (TLR4) complexes (Chow et al., 2005; Shankey et al., 2006; 
Hedley et al., 2008). Importantly, macrophages/monocytes, neutrophils as well as CD4+ T-
cells express TLR4 (Kabelitz, 2007), the principle signalling component of the LPS receptor 
complex (CD14, LBP & TLR4) on their surfaces, thus can be activated directly by LPS or 
indirectly by pro-inflammatory cytokines from activated monocytes, neutrophils or ROS (Xu et 
al., 2005; Caramalho et al., 2003). Flow cytometry can be used to monitor these signalling 
pathways activation. The same approach can be used to study or monitor the impact or 
activity of targeted inhibitors or of specific signalling pathways inhibitors. Using fluorescently 
labelled monoclonal antibodies to assess protein and antigen expression, cellular patterns 
and activation states can be identified (Alvarez et al., 2009).  
Studies on humans infected with HIV indicated that most of the depletion of the CD4+T-cells 
characterising HIV infection occurs in the mucosal tissues during acute phase of the infection 
either as direct targets of the cytopathic effects of the virus or indirectly by immune activation 
induced-apoptosis (Veazey et al., 2003; Brenchley et al., 2004; Haynes, 2006). The optimum 
concentrations of LPS on in vitro activation and apoptosis of immune cells in whole blood 
need to be established. As mentioned previously, studies involving LPS-induced activation of 
cells have utilised varying concentrations of LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and 
vitamin C (25 - 50 nM) therefore the need for optimization (Dobmeyer et al., 1996; Shang et 
al., 2003; Yamanda et al., 2006). Kim et al. in their study on analysis of cellular senescence 




induced by LPS, demonstrated a significant (p <0.005) decrease of cellular viability at 15 
µg/ml or greater concentration of LPS (Kim et al., 2012). 
Antioxidants such as NAC and vitamin C have been shown to inhibit cytotoxicity; free 
radicals-induced DNA damage, ROS generation, immune activation and apoptosis (Alul et 
al., 2003). Therefore, optimizing a functional assay for LPS induced activation and 
amelioration of this activation by antioxidants is important. However, antioxidants such as 
vitamin C at higher concentrations are pro-oxidants and therefore toxic to cells or can cause 
activation of the cells (Halliwell & Gutteridge, 1989; Godin & Wahaieb, 1988). Therefore, 
antioxidant concentrations optimum for inhibition of the LPS-induced cell activation and 
apoptosis should be established before the start of analysis. Importantly, incubation of cells 
with 0.2 mg/ml of vitamin C for 24 hours was shown to cause a 39% increase in apoptotic 
cells, suggesting toxicity of vitamin C (Bergman et al., 2004). Therefore, the importance of 
optimizing the concentrations of NAC and vitamin C prior use cannot be over emphasized. 
By using fluorescently labelled monoclonal antibodies to assess protein and antigen 
expression, cellular patterns and activation states can be identified (Alvarez et al., 2009). 
Some of the monoclonal antibodies includes; CD45, CD 25, CD69, CD4, Annexin V & 7-AAD 
which can be used in LPS stimulation and antioxidants optimization. CD45 also known as 
leukocyte common antigen (LCA) is a member of the protein tyrosine phosphate family 
expressed on all hematopoietic cells except mature erythrocytes and platelets (Braford, 
1994). Different isoforms of CD45 arising from splicing of variable splicing of exon 4, 5, and 
which are specific to the activation and maturation state of the cells and cell type exists (Virts 
et al., 1997). CD45 plays an important role in T-cell receptor (TCR) and B-cell receptor 
(BCR) signal transduction. CD4 monoclonal antibody is a single-chain transmembrane 
glycoprotein expressed on T-helper lymphocytes. It is a member of the immunoglobin g (Ig) 
superfamily, present on most thymocytes, where it is co-expressed with CD8 (Littman, 1987). 
CD4 is also expressed on all monocytes/macrophages and dendritic cells although dimly. 
CD4 acts a co-receptor with the TCR during T-cell activation and thymic differentiation by 
binding MHC class II. More importantly, CD4 is the main receptor for HIV-1 envelops protein 
gp-120 (Hannet, 1992). 
CD69 is a 60 kDa cell surface glycoprotein also known as activation inducer molecule. CD69 
antigen is one of the earliest activation markers to be expressed and is found on activated T, 
B-lymphocytes and platelets, but absent on resting lymphocytes (Testi, 1994; Sanchez-
Madrid, 1995). CD69 is expressed on activated macrophages, NK cells and other cells such 
as neutrophils, eosinophils and platelets (Testi, 1994). The use CD69 fluorochrome 
conjugated monoclonal antibody has allowed the phenotyping, characterization, and 
enumeration of activated cells in HIV/AIDS and other immune system disorders using flow 




cytometry (Maino et al., 1995). CD 25 antigen is a 55 kDa single chain glycoprotein which in 
association with CD122 and CD 132 is the receptor for IL-2. It is found on activated T and B-
cells, on activated monocytes, macrophages and T-cell clones (Anderson et al., 1995). It is 
also found on CD4 T-regulatory cells. It is a late marker of activation. The use of CD45, CD4, 
CD25and CD69 fluorochrome conjugated monoclonal antibody has allowed the maximizing 
of gate purity and lymphocyte recovery, thus immunophenotyping, characterization, and 
enumeration of lymphocytes in HIV/AIDS and other immune system disorders can be done 
using flow cytometry (Aandahl et al., 2004; WHO, 2007).  
7-AAD emits light in the far-red of the spectrum and can be separated from phycoerythrine 
(PE) or FITC or other tandem dyes, thus monoclonal antibodies conjugated with these 
fluorochromes can be used to identify different cell types simultaneously (Rabinovitch, 1986). 
However, cells lose their viability if left in the presence of 7-AAD dye for too long; therefore it 
is recommended that the incubation with Annexin V and 7-AAD be carried out on ice to 
sustain cells viability (Keeney, 1999). 
2.7 Biomarkers of antioxidant status and lipid peroxidation 
Baseline levels of TAS, markers of lipid peroxidation and redox cellular status of plasma 
have previously been used to indicate oxidative stress in HIV infection (Pasupathi et al., 
2009; Suresh et al., 2009). The TAS determination in human blood plasma is necessary 
when investigating the relationship between diet, oxidative stress and human disease and 
when estimating the potential to resist oxidative stress (Rice-Evans & Miller, 1994). It 
considers the cumulative effect of all antioxidants present in the blood and body fluids and 
can be used as an early biomarker of oxidative stress in HIV-infected patients (Suresh et al., 
2009). The three commonly used assays for TAS are; ORAC, trolox equivalent antioxidant 
capacity (TEAC/ABTS) and ferric reducing antioxidant power (FRAP) assays. The principle 
of all these assays is to produce free radicals at a known rate and then study the ability of a 
sample to hinder this radical production by a certain end point (Cao et al., 1995; Cao & Prior, 
1998; Cao et al., 1998). ORAC is based on the fact that the fluorescence of an oxidizable 
substrate e.g. fluorescein changes with respect to time upon damage caused by a peroxyl or 
hydroxyl attack. This assay involves a pro-oxidant produced by a generator such as 2,2‘-
azobis (2-amidinopropane) hydrochloride (AAPH) and an oxidizable substrate capable of 
fluorescence. The free radical induces oxidative damage which is inhibited in the presence of 
an antioxidant (Huang et al., 2005). This inhibition is measured (in terms of fluorescence) 
and related to the antioxidant capacity of the antioxidant. FRAP assay is based on electron 
transfer reactions where antioxidants are used as reductants in a redox-linked colorimetric 
method. The change in absorbance is directly proportional to the concentration of 
antioxidants. One FRAP unit has been randomly defined as the reduction of 1 mole of Fe (III) 




to Fe (II) by Benzie & Strain (Benzie & Strain, 1996). The FRAP assay is fast, reproducible 
with single antioxidants in pure solutions and with mixtures in aqueous solutions. However, in 
FRAP there are no free radicals. It is simply a redox reaction to measure the ability of 
antioxidants in a sample to reduce ferric iron (III) to ferrous iron (II). Hence, FRAP is not a 
direct measure of the antioxidant capacity of a potential antioxidant.  At low pH, reduction of 
a ferric-tripyridyltriazine (FeIII-TPTZ) complex to the ferrous form, which has an intense blue 
colour, can be monitored by measuring the absorption at 593 nm (Benzie & Strain, 1996). 
Although ORAC and FRAP are fast, reproducible and reliable assays they have their own 
limitations which necessitates caution when interpreting results; they do not include 
measurements of blood albumin levels and metal binding proteins like transferrin and 
lactoferrin. 
As mentioned previously, oxidative stress in living systems can be estimated by measuring 
the degree of lipid peroxidation in the systems (Laguerre et al., 2007). Lipid peroxidation has 
been traditionally estimated by the increase in TBARS which mirrors the production of MDA, 
an oxidation product of lipid peroxidation and CDs, polyunsaturated fatty acids produced as 
by-products in the process of lipid peroxidation reaction. Plasma TBARS assay is based on 
the reaction of thiobarbituric acid (TBA) with malondialdehyde in the plasma and the 
absorbance of the MDA-TBA adducts is read at 530 nm (Khoschsorur et al., 2009). During 
oxidation of polyunsaturated fatty acid (PUFA) side chain, the double bonds are converted 
into conjugated double bonds resulting in conjugated dienes which absorb UV light at 234 
nm (Recknagel & Glende, 1984). The concentration of dienes can thus be calculated using 
an extinction coefficient. 
2.8 Antioxidants, oxidative stress and HIV infection 
Whereas several studies have indicated a weakened antioxidant defence system in 
HIV/AIDS infection (Allard et al., 1998), however, the question of whether antioxidants have 
potential therapeutic benefits if they are capable of inhibiting oxidative stress-induced 
apoptosis of CD4+ T-cells and disease progression, still remains (Wanchu et al., 2009). 
Importantly, the antioxidant defence system depends on the integrity of an enzymatic system 
that needs sufficient intake of trace minerals including selenium, copper, zinc and 
manganese and adequate amounts of vitamin A, C, E and β-carotene in the cytoplasm and 
lipid membrane of the cells. Previous studies have indicated that HIV/AIDS patients may 
have deficiencies in some of these trace minerals and vitamins such as selenium and vitamin 
A (Cirelli et al., 1991; Simba et al., 1993; Allard et al., 1998; Allard et al., 2008). Allard et al 
showed an increased oxidative stress in HIV-positive patients when compared to 
seronegative controls and decreased plasma concentrations of various antioxidant vitamins 
and selenium (Allard et al., 2008). Whether antioxidant supplementation will have any effect 




on oxidative stress, viral replication and disease progression remains to be established. 
Some investigators have suggested that the best way to prevent immune depression in HIV 
infection is to reduce oxidative stress, which is key at the earliest stage (Baruchel & 
Wainberg, 1992; Pace & Leaf, 1995) in particular at stage II where free radical production is 
highest (Wanchu, et al., 2009). More specifically, a role of antioxidants such as NAC, vitamin 
C in HIV therapies has been proposed (Harakeh & Jariwalla, 1995; Garland & Fawzi, 1999; 
Aquaro et al., 2008; Suresh et al., 2009; Edeas et al., 2010) and in addition, antioxidants 
might slow down the rate of apoptosis which has been implicated in HIV/AIDS progression 
(Gougen & Montagnier, 1993; Akerlund et al., 1996; Herzenberg et al., 1996; Marmor et al., 
1997). The ability of antioxidant supplements to reduce DNA damage and disease 
progression in HIV infection has been reported (Akerlund et al., 1996; Jaruga et al., 2002)  
2.8.1 Vitamin C 
Decreased levels of serum vitamins and minerals have been linked with a higher risk of 
disease progression and mortality in HIV infection (Allard et al., 1998; Gil et al., 2013). 
Furthermore, supplementation with micronutrients such as vitamin C has been shown to 
delay HIV progression and reduce mortality in HIV-infected individuals not receiving HAART 
(Fawzi et al., 2004; Drain et al., 2007). 
Vitamin C is a six-carbon lactone synthesised in the liver of majority of mammalian species 
except humans, non-human primates and guinea pigs (Nishikimi & Yagi, 1996). It is a water-
soluble, chain-breaking antioxidant which occurs primarily as a monovalent anion at 
physiological pH. The ability of vitamin C to donate electrons confers strong antioxidant 
properties to it. Its strong antioxidant effects have been reported in vitro in numerous studies 
(Packer & Colman, 1999; Padayatty et al., 2003). More importantly, the ability of vitamin C 
(ascorbate) to donate one electron and form semi-dehydroascorbate, which is an ascorbyl 
radical, of little reactivity and to donate a second electron, resulting in the formation of 
dehydroascorbate confers its strong antioxidant activity (Padayatty et al., 2003). Glutathione 
through chemical reduction and via glutathione-dependent enzymes is directly involved in the 
recycling of ascorbate. Since humans cannot synthesise vitamin C, which is essential for iron 
absorption, synthesis of bile, collagen and maintenance of skin elasticity due to lack of L-
gulonolactone oxidase as they lack, they must obtain it from if from dietary intakes (Packer 
&Colman, 1999; Padayatty et al., 2003; Pavlovic & Sarac, 2010). The chemical structure of 
vitamin C is shown in Figure 2:10. 












Figure 2:10: Chemical structure of vitamin C (Astley, 2003). 
Interestingly, vitamin C‘s ability to regenerate vitamin E in the cell membranes enables it to 
synergistically participate with vitamin E in protecting cells from oxidative stress (Packer & 
Colman, 1999). As a consequence, vitamin C removes the tocopherol radical formed by 
vitamin E activity within the membrane and vitamin C recycles the tocopherol radical 
produced from the lipid radical back to tocopherol (Padayatty et al., 2003). 
Ascorbate also participates in the reduction of Fe3+ (III) or Cu2+ (II) to Fe2+ (II) or Cu+ (I) and 
the ascorbyl radical during fenton reaction with the Fe2+ or Cu+ produced capable of 
catalysing the production of H2O2, eventually generating the highly reactive hydroxyl radicals. 
This reaction has been associated with the pro-oxidant activity of vitamin C and as a 
consequence, high doses and long-term mega doses of vitamin C may be toxic as they can 
cause oxidation in a living system, there great care and consideration should be taken when 
designing doses or experiments (Carr & Frei, 1999; Lee et al., 2001). 
In vitro suppression of virus production and cell fusion in HIV-infected T-lymphocytes cell 
(Harakeh et al., 1990), inhibition of antigen-induced and spontaneous T-cell apoptosis 
(Pavlovic et al., 2005), Fas-induced monocyte apoptosis (Perez-Cruz et al., 2003), increased 
activity of natural killer cells (Vojdani et al., 2000) and inhibition of reactivation in TNF-α 
stimulated cells by vitamin C have been reported (Harakeh et al., 1995). In a previous study, 
clinical improvement was reported in AIDS patients who willingly consumed high doses of 
ascorbic acid (Cathcart, 1984). Since vitamin C is an essential water soluble antioxidant, as it 
can scavenge for superoxide radical, singlet oxygen, H2O2 and hydroxyl radical directly 
(Packer & Colman, 1999), it has also been shown to be a potent inhibitor of apoptosis, albeit 
in erythrocytes (Mahmud et al., 2010). It has been reported that supplementation of vitamin E 
and C in HIV-infected persons reduces oxidative stress and could reduce viral load (Allard et 
al., 1998).  
2.8.2 N-acetyl cysteine (NAC) 
NAC is a cysteine analogue that replenishes intracellular GSH and glutathione peroxidase. 
NAC is a well-recognized thiol antioxidant, which is converted to glutathione after uptake 
(Sandstrom et al., 1994). This antioxidant that scavenges peroxides has been shown to 
inhibit apoptosis (Hockenbery et al., 1993).and protect alveolar cells from H2O2 induced 
apoptosis by scavenging ROS and suppressing c-Jun- N-terminal kinase (Fang et al., 2010). 




More specific, NAC and glutathione have been shown to completely block activation-induced 
death and associated DNA fragmentation in T-cell hybridomas, therefore implicating redox 
regulation in the processes (Sandstrom et al., 1994).  
Although NAC acts directly as a free radical scavenger by reducing hypochlorus acid 
produced by neutrophils to kill target pathogens and cells, however, this direct antioxidant 
activity of NAC could inhibit the natural mechanisms of neutrophils cytolysis. Cell studies 
however, have indicated that NAC essentially boosts intracellular killing of bacteria by 
protecting the neutrophils and macrophages from free radical generated during phagocytosis 
(Oddera et al., 1994). 
2.8.3 Vitamin E and other antioxidants 
Vitamin E, a lipid soluble, chain breaking antioxidant, is important for the appropriate 
functioning of the immune system, as it increases humoral and cell mediated responses, 
antibody production, phagocytic response and resistance to viral and infectious diseases 
(Allard et al., 1998, Watson, 1994). Vitamin E, broadly classified as tocopherols and 
tocotrienols is the major chain breaking, lipid soluble antioxidant present in body tissues. 
More importantly, it provides the first line of defence to cell membranes against oxidative 
stress by trapping peroxyl radicals at early stages of free radical attack (Lien et al., 1999). 
Although vitamin E (α-tocopherol) and vitamin C react synergistically, vitamin E is considered 
more lipophilic and the more potent antioxidant with respect to lipid peroxidation and 
penetration to specific sites in bio membranes. Oxidative stress in HIV increases utilization of 
vitamins, which leads to deficiency, leading to further weaken of the immune system 
(Chandra, 1997). Supplementation with vitamin E and C was shown to reduce oxidative 
stress and produced a trend towards a reduction in viral load in HIV-infected persons (Allard 
et al., 1998). 
As previously discussed in section 2.4.1, other exogenous antioxidants, including vitamins 
such as vitamin A (retinol), vitamin C (ascorbic acid), carotenoids and polyphenols (Papas, 
1999; Podsedec, 2007; Valko et al., 2007) exist. 
2.8.4 Antioxidants: potential for ameliorating immune activation and apoptosis? 
Several antioxidants including NAC, glutathione and alpha-lipoic acid have been shown to 
play a significant role in the inhibition of apoptosis and viral activation as well as replication in 
HIV infection (Hockenberry et al., 1993; Gougen & Montagnier, 1993). The dispensation of 
the ARV zidovudine in combination with antioxidants has been reported to increase its 
therapeutic capability (Romero-Alvira & Roch, 1998). Although the contemporary use of 
HAART has greatly reduced morbidity and mortality of HIV infection (UNAIDS, 2011; Gil et 
al., 2013), increased toxicity, complications and considerable failure to reconstitute immune 
system (De Clercq, 2009; Corbeau & Reynes, 2011) have necessitated a more cautious re-




evaluation of HIV therapies and examining of other creative alternative interventions (Aquaro 
et al., 2008; Edeas et al., 2010; Gil et al., 2013). Furthermore, the initial objective of HIV 
treatment was to manage opportunistic infections and keep the individual alive, which later 
shifted to suppressing HIV replication and managing drug side effects and complications that 
may arise (De Clercq, 2009; Gil et al., 2013; UNAIDS, 2011). However, today‘s emphasis is 
on improving overall health and enabling people with HIV to live long.  
Immune activation and inflammation-induced oxidative stress is thought to contribute 
significantly to the apoptosis and subsequent depletion of CD4+ T-cells. Therefore, strategies 
targeting amelioration of inflammation-induced oxidative stress driven apoptosis should be 
explored as therapeutically viable strategies. Antioxidants, anti-inflammatories, in 
combination with HAART provide potential viable therapeutic strategies. Highleyman, (2010) 
has proposed three ways in which this can be approached: (i) reducing T-cell activation, (ii) 
altering production and activity of cytokines and inflammatory mediators such ROS and (iii) 
changing underlying risk factors through lifestyle modifications. 
Although free radicals have been implicated as a major cause of oxidative damage in living 
tissues, it is important to note that they are not always harmful. They also perform important 
biological functions like normal phagocytosis and apoptosis, signal transduction, gene 
transcription among others. Thus, extra care should be taken when dealing with antioxidants 
to alleviate oxidative stress. A proper redox balance must always be maintained in order not 
to disrupt the normal body functioning. The antioxidant status and redox status of the 
individual must always be considered before any antioxidant intervention or supplementation 
can be recommended. The strategy recommended in this review is to treat oxidative stress at 
the earliest possibility by measuring oxidative stress markers in the blood and tailoring 
treatment based on these tests. 
The link between oxidative stress, inflammation and immune activation and their roles and 
impacts on immunohaematopoietic cells has been explored in this literature review. The 
potential of antioxidants to ameliorate inflammation-induced oxidative stress and its 
implications such as apoptosis of CD4+ T-lymphocytes, in HIV has also been highlighted. 
Glutathione, NAC, vitamin C and E as potential ameliorating interventions has been part of 
the focus of this review, since they are the most potent naturally occurring antioxidants in the 
cell membranes that protect the cells from oxidative stress induced-damage. 
ROS participates in chronic inflammation, HIV replication and the apoptosis seen in HIV 
infections. The estimated duration from infection with HIV to development of AIDS is 8-10 
years, however, it can be as few as 2 to 3 years, but overall it varies from individual to 
individual depending on various factors such as host‘s immune system and dietary factors 
(Appay & Sauce, 2009; Hunt, 2010). Due to the large numbers of people already infected 




with HIV requiring ARV treatment and the fact that only a few of them are receiving such 
treatments due to various constraints, other means of delaying progression to full blown 
AIDS will have important implications in the management of the disease. For this reason, 
reducing the impact of oxidative stress in immune cells might present an additional strategy 
for slowing down HIV progression and prognosis and thus increase the survival rate of 
infected persons. The importance of finding ways to reduce oxidative stress at the earliest 
stage in the infected immune-hematopoietic cells becomes paramount. The general question 
is whether reduced oxidative stress in immunohaematopoietic cells with a resultant reduced 
apoptosis will delay the progression from HIV infection to AIDS? 
The discovery of a cure for HIV/AIDS has remained elusive and is still a serious challenge for 
scientists. As scientists continue to seek cure for HIV, we must continue relentlessly to find 
cost effective ways of prolonging the lives of the already infected. Out of the many people 
infected with HIV only a small proportion can access ARV treatment due to cost and logistical 
constraints and despite viral suppression, chronic inflammation still persists. The mechanism 
by which the chronic inflammation persists and continues to promote pathology remains 
unclear (Plaeger et al., 2012). Therefore, other interventions to reduce inflammation, 
oxidative stress and immune activation in infected individuals which is a key factor in 
progression of the infection from HIV to AIDS and to death would be important in 
supplementing stakeholders‘ effort of managing the disease.  
2.9 Significance of literature review 
In general the immune system of HIV-infected individuals encounters many challenges; it has 
to cope with a massive CD4+T-cells depletion through apoptosis or direct infection and 
contain HIV replication and associated pathogens which more often than not is 
overwhelming. It has also been indicated in this review that HIV-infected individuals are 
under chronic oxidative stress. An insight into the inflammatory and oxidative stress status of 
HIV-infected individuals will enable long term profiling of each patient with a view of 
individualized therapy. This approach may have a direct impact on patient care in resource 
limited settings like sub-Saharan Africa.  
The basic objectives of this literature review was to highlight the previous studies on 
inflammation, immune activation and oxidative stress and its role in progression and 
pathogenesis of HIV infection, to highlight the relationship between inflammation, oxidative 
stress and apoptosis and its impact on CD4+ T-lymphocytes in HIV infection. Potential ways 
to ameliorate oxidative stress using selected micronutrients which could delay the 
progression and thereby increase survival rate of infected persons have also been 
discussed. In this review, the interrelationship between oxidative stress, inflammation and 
apoptosis and their possible role and impact on apoptosis and depletion of the CD4+ T-




lymphocytes was analysed. A brief overview of some of the immunohaematopoietic cells 
targeted by HIV has also been discussed. 
The above objectives were based on the following hypotheses; chronic inflammation and a 
dysfunctional enzymatic antioxidant defense system (SOD, CAT & GPx) will lead to an 
overall increase in H2O2 levels which have been implicated in the death of cells from HIV-
infected individuals; specific antioxidant intervention will ameliorate HIV inflammation- 
induced oxidative stress and thereby limit the death of the cells from HIV-infected individuals 
which may represent a valuable adjunct in the management of patients with chronic HIV 
infection. 
By addressing one of the underlying mechanisms by which dietary antioxidants (in 
combination) can modulate inflammation-induced oxidative stress, in specific immune cells 
(CD4+ T-cells) from HIV-infected individuals, results from this study will contribute to our 
current knowledge in the field of HIV management. 
2.9.1 Research gaps 
Confirmation from various studies has indicated that HIV-infected patients are under chronic 
oxidative stress and that oxidative stress plays a key role in HIV pathogenesis (Pace & Leaf, 
1995; Pasupathi et al., 2009; Suresh et al., 2009; Wanchu et al., 2009; Awodele et al., 2012; 
Morris et al., 2012). Numerous studies on oxidative stress and HIV have been undertaken 
and all have consistently implicated alterations in the antioxidant defence system and 
increased ROS production during infection in the disease progression (Allard et al., 1998; Gil 
et al., 2003; Pasupathi et al., 2009; Suresh et al., 2009; Coaccioli et al., 2010). These studies 
have also concluded that micronutrients such as antioxidants, could offer a cost effective 
supplementary therapy to HIV patients to prolong and improve survival rate. However, 
despite the numerous studies done on HIV and oxidative stress, several gaps in these 
studies exist that warrants further research.  
Several aspects still need to be addressed and include; 
1) Immunomodulatory effects of antioxidants and clarification of the role of antioxidants on 
oxidative stress and apoptosis in HIV infection; 
2) The relationship between HIV-induced inflammation and respiratory burst/oxidative stress 
3) The role of antioxidant enzymes such as; superoxide dismutase, catalase and glutathione 
peroxidase in apoptosis; for example: do increased SOD activity and reduced GPx activity 
enhance apoptosis? 
4) Why lymphocytes of HIV-infected people show increased susceptibility to oxidative stress 
- the role of micronutrient/antioxidant deficiency; decreased SOD activity, H2O2 or 
dysfunctional antioxidant defence system. 




This review has addressed some of the above research gaps such as determining the impact 
of inflammatory induced oxidative stress on the apoptosis of CD4+ T-lymphocytes in HIV 
infection and further, investigation of potential ameliorating interventions and future 
directions. Due to a limitation of small sample size, this study has only tried to provide an 
insight into the research gaps highlighted above but has not closed them. 
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Abstract 
HIV infection is associated with on-going and aberrant activation of both the innate and adaptive 
immune systems. The enrolment and activation of neutrophils at the site of infection in order to 
eliminate pathogens is a key aspect of innate immunity. Activated neutrophils and macrophages 
produce H2O2 and other oxidants during the respiratory burst as a result of increased oxygen 
use and ATP production. This further promotes tissue injury and inflammation. Enhanced 
respiratory/oxidative burst may produce excessive ROS resulting in oxidative stress as a by-
product of inflammation, which is thought to contribute to the depletion of the CD4+T-
lymphocytes in HIV infection. 
The aim of this preliminary study was to determine the neutrophil respiratory burst response in 
asymptomatic HIV-infected individuals and compare it with uninfected controls. This was a 
preliminary study design whereby blood samples of 14 consenting, untreated HIV positive 
individuals and 12 HIV negative controls was analysed for respiratory burst. The neutrophil 
respiratory burst (phagoburst test) was analysed using flow cytometry. The results were 
correlated with CD4 count, viral load and other markers of immune system activation and 
inflammation in these individuals and control samples. 
Neutrophils from HIV-infected individuals at rest and in response to low stimulating agent, 
bacterial N-formyl peptides (fMLP), showed significantly (P = 0.041) higher levels of burst 
response than in the uninfected controls. No differences were detected with the more potent 
stimulating agents, phorbol myristate acetate (PMA) and E. coli. The CD38/8 was significantly (P 
= 0.0069) different between this two groups as was the CD4 count (P<0.001). In summary, 




neutrophils from HIV-infected individuals at rest showed a ―primed‖ response to low stimulating 
agent (fMLP), which was significantly different from control group. The HIV-infected group 
showed significantly higher immune activation levels (%CD38/8) compared to the controls. This 
may indicate that patients with untreated asymptomatic HIV infection have higher levels of 
oxidative stress in vivo. Therefore, respiratory burst might be an important contributing factor in 
inflammation-associated oxidative stress in HIV infection and increased depletion of CD4+ T-
lymphocytes in the asymptomatic stage of HIV infection. 
Keywords; Neutrophils, respiratory burst, HIV, reactive oxygen species, neutrophil activation, 
apoptosis, phagocytosis. 
3.1 Introduction 
A major characteristic of HIV infection is the continuous systemic immune activation and chronic 
inflammation resulting in weakened immune responses, pro-inflammatory cytokine production 
and uncontrolled viral replication in activated CD4+ T-cells (Haynes, 2006). The significant 
depletion of memory CD4+ T-cells lining the GIT mucosa in early HIV infection results in loss of 
mucosal integrity and on-going translocation of microbial products such as LPS across the 
epithelial surface (Brenchley et al., 2004). LPS induces activation of innate immune cells such as 
monocytes and dendritic cells resulting in increased oxidative stress; depletion of antioxidant 
defence mechanisms and an increased susceptibility to apoptosis (Brenchley et al., 2006; 
Cassol et al., 2010).  
Neutrophils continuously traverse blood vessels scrutinizing for bacterial infection and 
inflammation. When they encounter an infection they leave the circulation and migrate to the site 
of infection where they phagocytose and kill invading microbes by releasing packaged anti-
microbial systems (Prescot, 2002). The recruited phagocytes kill the invading pathogens by a 
combination of two mechanisms; the oxygen-independent and the oxygen-dependent response 
or respiratory burst (Prescott et al., 2002). The oxygen-independent mechanism is mediated by 
highly toxic cationic proteins and enzymes e.g. myeloperoxidase (MPO), defensins, lactoferrin, 
lysozyme, gelatinase, etc contained in azurophilic, gelatinase and specific granules (Segal, 
2005). The oxygen-dependent mechanism (the respiratory or oxidative burst) involves a 
sequential reduction of oxygen by an NADPH oxidase leading to the production of toxic oxygen 
metabolites such as H2O2, hydroxyl radicals and singlet oxygen (Parkin & Cohen, 2001). Once 
neutrophils ingest bacteria, oxygen consumption of neutrophils is enhanced 100-fold, most of 
which is converted to ROS in what is referred to as respiratory burst (Israel & Israel, 2002). 
Respiratory burst occurs via the membrane bound NADPH oxidase. The NADPH oxidase 
system is inactive, but is activated when the neutrophils are stimulated by chemokines, immune 




complexes, C5a, or N-formyl oligopeptides shed by microbes (Taylor et al., 1993; Cruse & 
Lewis, 2010). The process of recruitment, activation and respiratory burst of the neutrophils and 
macrophages at the sites of infection is well regulated, however, if prolonged, can lead to 
inflammation and damage to the surrounding tissues and cells. Previous studies of neutrophils 
from HIV-infected individuals have indicated increased baseline levels of superoxide especially 
before AIDS sets in (Elbim et al., 2001). Enhanced respiratory burst of neutrophils may produce 
excessive ROS in HIV infection, consequently causing oxidative stress, which is thought to 
contribute to the depletion of the CD4+ T-lymphocytes (Aquaro et al., 2008). 
Activated neutrophils and macrophages during inflammation and infection, are major source of 
H2O2 and other oxidants as a result of increased oxygen intake and ATP production. This 
promotes further tissue injury and more inflammation (Kotler, 1998; Prescot et al., 2002. 
Inflammation is an important non-specific protective response to harmful stimuli e.g. a pathogen, 
damaged cells or irritants (Prescott et al., 2002). However, an unregulated inflammatory process 
becomes harmful such as the one that occurs in HIV infection. Inflammatory cytokines such as 
tumour necrosis factor α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), are known to stimulate 
HIV transcription and replication and thus may be important factors in the progression of HIV to 
AIDS (Aquaro et al., 2008). Neutrophil respiratory burst response and its impact on CD4+ T-cell 
group of immune cells has not been described previously in the context of asymptomatic HIV 
infection. Therefore, this preliminary study determined neutrophil respiratory burst response in 
asymptomatic HIV-infected and compared with uninfected controls. The results were correlated 
with CD4 count, neutrophil count, viral load, and total antioxidant status. 
3.2 Material and methods 
Monobasic sodium phosphate (NaH2PO4.H2O) and dibasic sodium phosphate 
(Na2HPO4.12H2O), hydrochloric acid (HCl), sodium Phosphate, (NaH2PO4), per chloric acid 
(HCIO4), sodium di-hydrogen orthophosphate dehydrate (NaH2PO4.2H2O), di-sodium hydrogen 
orthophosphate dihydrate (Na2HPO4.2H2O), metaphoshoric acid (MPA), trichloric acetic acid, 
5,5‘ Dithiobis-(2-nitrobenzoic acid) were purchased from Merck Chemicals (South Africa). 
Fluorescein sodium salt (C20H10Na2O5), 2,2‘-azobis(2-methylpropionamidine) dihydrochloride 
(AAPH) and Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), were purchased 
from Sigma-Aldrich (South Africa). The phagoburst assay kit was purchased from Orpegen 
Pharma (Germany). The fluorescence was read on a Fluoroskan plate reader (Thermo Electron 
Corporation). The absorbance was read in a Multiskan plate reader (Thermo Electron 
Corporation, Germany). A FACSCalibur four colour flow cytometer (Becton Dickinson San Jose, 
USA), with one laser, Cell Quest Pro and FCS Express V3 softwares were used in this study. 




3.2.1 Study population & design 
In this preliminary study, twelve eligible untreated asymptomatic HIV positive individuals (4 
males and 8 female) and 14 negative controls (6 males 8 females), average age 31 years (range 
21-51) were sourced from the well-established clinics attached to the Institute of Infectious 
Diseases, Desmond Tutu HIV centre. There was no significant age difference between the two 
groups. The average CD4 count for the HIV-infected group was 439 cells/mm3 while that of the 
uninfected control was significantly higher (P>0.001) at 929 cells/mm3. The patients‘ 
demographics are summarized in Table 3.1. Informed consent was obtained from each 
participant and each participant was assigned a random number. Confidentiality was maintained 
during the duration of the study. Inclusion criteria for the study participants were; 21 years or 
older, patients with chronic HIV infection and CD4 count > 200 not started on ARV‘s or any other 
chronic medication nor antioxidant supplementation, minerals and vitamins supplements, aspirin 
or any other drugs e.g. anti-inflammatory, with established antioxidant properties. Exclusion 
criteria include patients with TB or other co-infections and those receiving antiretroviral therapy, 
anti-TB treatment or other antibiotic treatment, use of any chronic/life sustaining medication, 
antioxidant supplementation, minerals and vitamins supplements, aspirin or any other drug e.g. 
anti-inflammatory, with established antioxidant properties. Ethics approval was obtained from 
both the clinical site: University of Cape Town: REC: REF: 417/2006 and University of 
Stellenbosch (laboratory site): N07/09/197. This preliminary sub-study was added as an 
addendum to the ethics approval received for the original project N07/09/197. 
3.2.2 Sample processing 
The blood samples were collected from the antecubital vein in the forearm in both 
(Ethylenediaminetetraacetic acid) EDTA and Heparin vacutainers. The blood samples were 
transported to the laboratory within two hours of collection. Plasma samples for the total 
antioxidant status assay were processed appropriately by centrifuging them at 1200 g at 4 oC for 
10 minutes, aliquoting 500 µl of plasma and storing at -80 oC till the day of analyses. All the 
antioxidant status samples were analysed in triplicates. EDTA blood samples were used for CD4 
count and viral load while plasma samples were used for analysis of antioxidant status. 
3.2.3 Laboratory investigation 
3.2.3.1 Markers of disease and immune activation 
CD4+ T-cell counts were determined by staining whole blood with BD MultiTESTTM CD3-
FITC/CD8-PE/CD45-PerCP/CD4-APC reagent in BD TruCOUNTTM tubes according to the 
manufacturer‘s instructions and analysed on a BD FACSCalibur™ flow cytometer (BD 




Biosciences, San Jose, CA). HIV-1 RNA quantifications were performed using 1.0 mL of plasma 
with use of the Nuclisens Easy Q HIV-1 v.1.2 kit (BioMerieux Inc., Boxtel, Netherlands). 
CD38 expression on CD8+ T-cells (CD38/8) was determined by flow cytometry. Whole blood 
samples were incubated with the monoclonal antibodies; CD8 Per-CP; CD38 APC; CD3 FITC 
(BD Biosciences, San Jose, CA) and analysed on a BD FACSCalibur instrument using BD Cell 
Quest Pro (Version 2) software. Lymphocytes were gated on forward vs. side scatter, CD3 and 
CD8 expression. 
3.2.3.2 Total antioxidant status assay 
The total antioxidant status measured as ORAC was determined using the modified fluorescein 
assay by Huang et al. which is based on the principle that the fluorescence of an oxidizable 
substrate e.g. fluorescein, changes with respect to time upon damage caused by a peroxyl or 
hydroxyl attack (Huang et al., 2005). ). In this assay, fluorescence was measured at 1 min 
intervals at an emission wavelength of 563 nm and excitation wavelength of 540 nm using a 
Fluoroskan plate reader (Thermo Electron Corporation Germany) until zero fluorescence 
occurred. The final assay mixture consisted of AAPH (peroxyl radical generator), sample (target 
of the free radical attack), trolox as the standard control and an oxidizable substrate capable of 
fluorescence. All the dilutions were prepared using phosphate buffer pH 7.0. In order to initiate 
the reaction, AAPH was added and the mixture incubated at 37 oC. Fluorescence was measured 
at 1 min intervals at an emission wavelength of 563 nm and excitation wavelength of 540 nm 
using a Fluoroskan plate reader (Thermo Electron Corporation Germany) until zero fluorescence 
occurred.  
3.2.3.3 Phagoburst assay 
The phagoburst assay was done according to Rothe et al. method, which is based on the 
oxidation of DHR 123 to R 123 by ROS, which is then measured using flow cytometer (Rothe et 
al., 1988). When stimulated, phagocytes produce ROS to destroy bacteria. The ROS produced 
can be monitored by addition of DHR 123 which in presence of ROS is converted to R 123. The 
percentage of the phagocytic cells expressing R 123 can then be measure using flow cytometer. 
The reaction was stopped by addition of lysing solution, which removes erythrocytes and results 
in a partial fixation of leukocytes. After one washing step with washing solution, DNA staining 
solution was added to exclude aggregation artefacts of bacteria or cells and to stain DNA. The 
percentage of cells having produced ROS was then analysed as well as their mean fluorescence 
intensity (enzymatic activity) using flow cytometry.  




The cells were analysed by flow cytometry using the blue-green excitation light (488 nm argon-
ion laser and FACSCalibur Cell Quest Pro software. During data acquisition a "live" gate was set 
in the red fluorescence histogram on those events which had at least the same DNA content as 
a human diploid cell (i.e. exclusion of bacteria or platelet aggregates having the same scatter 
light properties as leukocytes. The percentage of cells having produced ROS was analysed as 
well as their mean fluorescence intensity (amount of cleaved substrate, activity). For that 
purpose, the granulocytes were gated in the software program in the scatter diagram (Linear 
FSc. vs. Linear SSc.) as shown in figure 3.1 and its green fluorescence histogram (FL1) was 
analysed. A control sample was used to set a marker for fluorescence-1 (FL1) so that less than 
1 - 3% of the events were positive. The percentage of positive cells in the test samples could 
then be determined by counting the number of events above this marker position. The mean 
fluorescence correlated with oxidation quantity per individual leukocyte. 
 
Figure 3:1: Typical gating strategy (Source, ORPEGEN Pharma; Burst test Test Kit 
Instructions) 
3.3 Statistical analysis 
Data analysis was done in consultation with a stastician using various statistical techniques. 
Comparisons between groups (e.g. HIV+ vs. HIV-) were done using Mann-Whitney‘s non- 
parametric test. No assumptions were made. Spearman‘s rank correlation test was done. The 
results were reported as medians with interquartile ranges. A 5% or lower (P≤0.05) significance 
level was used to determine significant findings.  





3.4.1 Demographics of the study population 
The demographic characteristics of the study group are summarized in Table 3.1. The study 
group consisted of 12 HIV-infected individuals and 14 uninfected controls. The HIV-infected 
participants‘ mean age was 29.5 and 25 for the uninfected control group. There was no 
significance difference (P=0.09) in age between the two groups. The HIV-infected group had a 
well maintained CD4 count averaging 443; were clinically well and had a median viral load of 
6300. The uninfected control group had a significantly (P=0.002) higher CD4 count with an 
average of 905 and were also clinically well. 
Table 3:1: Demographic characteristics of both the HIV-infected and uninfected control 
participants. 
Parameter HIV+ (n=12) Controls (n=14) P value 
Male: Female  4:8 6:8  
Median age (yrs.) 29.5(27-45) 25(24-34) 0.09 
Range 21-56 21-51  
Median CD4 cells/mm 443(323-543) 905(624-1079) 0.0002** 
Median Viral load 
(copies/ml) 




All the values in columns are medians (interquartile range) of HIV-infected (n = 
12) and uninfected controls (n = 14). **Medians significant at P<0.05. 
 
3.4.2 Neutrophil respiratory burst in HIV-infected group and HIV negative group 
The results of the neutrophil respiratory burst of the HIV-infected and control groups are 
summarized in Table 3.2. The median % of resting neutrophils and after stimulation with a low 
stimulant fMLP was significantly (P = 0.001 & P = 0.002 respectively) different. The response to 
stronger stimulants PMA and E. coli of the two groups was not significantly different between the 
two groups. 
Table 3:2: Neutrophil respiratory burst in HIV-infected group and HIV negative group 




Mean PMA (%) Mean E.coli (%) 
HIV+  4.6(2.4-9.5) 13.7(5.7-17.5) 99.9 99.1 
Controls 2.6(2.0-3.5) 5.9(3.4-8.9) 99.9 98.8 
P - value 0.041** 0.046** 0.78a 0.714a 
The values are medians (interquartile ranges) percentages of neutrophils. ** Median significantly different 
at (P<0.05); 
a 
Not significant at P<0.05. 




3.4.3 The total white cell count, absolute neutrophil count, CD38/8 viral load and total 
antioxidant status 
Table 3.3 summarizes the results of other markers of disease and total antioxidant status 
measured as ORAC. As expected the CD4 count between the HIV-infected and control groups 
was significantly (P = 0.000) different. CD38/8 was significantly (P = 0.006) increased in HIV-
infected group. The differences in the other markers of disease and total antioxidant status were 
not significant. 






























P- value 0.155b 0.54b 0.0069*** 0.00014***  0.74b 
The values for cell counts are either median (interquartile range) for percentage cells count and mean ± 
S.D for absolute counts. *** Medians significantly different (P>0.05); 
b 
Medians not significantly different at 
P<0.05. 
 
A negative correlation (r = -0.6; P<0.05)) between fMLP stimulated neutrophils and CD4 count 
was noted. 
3.5 Discussion 
HIV infection is associated with on-going and aberrant activation of both the innate and adaptive 
immune systems. The central feature of innate immune response is the recruitment and 
activation of neutrophils at the site of infection, with subsequent generation of ROS (Elbim et al., 
2001). In this preliminary study, the neutrophil respiratory burst response in asymptomatic HIV 
infection was investigated as a possible indication of baseline levels of inflammation and in vitro 
response to immune stimulation. The aim was to determine whether the neutrophil respiratory 
burst response is enhanced in HIV infection and whether the resultant oxidative stress could be 
a contributing factor to the overall depletion of CD4+ T-lymphocytes associated with 
asymptomatic stages of the disease. Using the phagoburst test assay, the neutrophil respiratory 
burst was measured in HIV-infected individuals (n = 12) and compared with that of controls (n = 
14). Interestingly, no differences in the response were detected with the more potent stimulating 
agents PMA and E.coli, suggesting that at this stage of the infection, neutrophils are not yet 
exhausted and retain the capacity to respond to these strong stimuli. Importantly, this test 
demonstrated that neutrophils from HIV-infected individuals at rest and in response to low 




stimulating agent (fMLP), showed significantly (P = 0.041) higher levels of burst (13 ± 7) 
response than in the uninfected controls (3 ± 2); suggesting a ‗pre-activation‘ or priming by ROS 
or pro-inflammatory cytokines in vivo. The significantly higher expression of CD38/8 may 
indicate that patients with asymptomatic HIV infection have higher immune activation and higher 
levels of oxidative stress in vivo. This was also demonstrated by statistically higher baseline 
resting levels and a ‗primed‘ response to a low stimulating agent. The total antioxidant status 
(ORAC) showed no significant differences at this stage of the infection as shown in Table 3.3. 
The enhanced respiratory burst in unstimulated/resting and neutrophils stimulated with fMLP is 
suggestive of a pre-activation or priming of the cells by ROS or pro-inflammatory cytokines in 
vivo which could be from other cells such as activated macrophages or T-cells. Supporting 
evidence of possible pre-activation and priming of neutrophils by TNF comes from a study by 
Elbin et al. (1996). The authors showed that TNF, granulocyte macrophage colony stimulating 
factor (GM-CSF), interleukin 8 (IL-8) strongly prime a sub-population of neutrophils which 
strongly bound fMLP and produced large amounts of H2O2 in response to fMLP. Elbin et al. 
showed that in the process of priming, resting phagocytes acquire a state of pre-activation that 
enables them to produce a more powerful bactericidal response at the infection site (Elbin et al., 
1996). Tumour necrosis factor is therefore not only a pro-apoptotic cytokine but also a primer of 
neutrophils in a similar manner to that of IL-8, GM-CSF, IL-1 α & β (Elbim & Gougerot-Pocidalo, 
1996).  
Additional evidence of pre-activation, priming and increased respiratory burst comes from a 
study by Bandres et al. who showed an enhanced respiratory burst and phagocytosis by 
neutrophils and monocytes of men with stage 1 HIV infection (Bandres et al., 1998). However, 
the results from previous studies on respiratory burst have been contradictory. They range from 
decreased burst in monocytes (Dobmeyer et al., 1995; Michailidis et al., 2012), decreased 
oxidative burst in AIDS, which correlated with CD4 count (Elbim et al., 1996) to increased 
phagocytosis and oxidative burst (Bandres et al., 1993) to normal oxidative burst in HIV (Nottet 
et al., 1993). In this study there was normal respiratory burst in both HIV positive and negative 
controls patients, however, there was enhanced oxidative burst of resting and fMLP stimulated 
neutrophils in HIV positive patients than in negative controls suggesting a preactivation or 
priming by the inflammatory cytokines (TNF, IL-1, 8). This was in agreement with of our findings 
in our preliminary study.  
Previous study findings may have been contradictory due to the isolation of neutrophils from 
their whole blood environment (Elbim & Lizard, 2008). In line with this, Dobmeyer et al. in their 
study showed a significant decrease in respiratory burst response of asymptomatic HIV infection 




patients in contrast to those with AIDS and this correlated well with CD4 count (Dobmeyer et al., 
1995). In this study, we used whole blood in order to maintain the phagocytes in their normal 
environment as much as possible. The contradictions could also have arisen from the stage of 
the HIV infection investigated. Thus it was important to correlate the respiratory burst response 
findings with CD4 count. The staging of the disease is critical in the interpretation of the results. 
There seems to be either normal or increased respiratory burst in early or stage one of HIV 
infection (Dobmeyer et al., 1995; Michailidis et al., 2012). As the disease progresses there 
appears to be a decrease in respiratory burst as the ROS and inflammatory cytokines cause the 
dysfunction and increased apoptosis of the neutrophils (Elbim et al., 1996; Michailidis et al., 
2012).  
The results of our study not only confirms enhanced neutrophil respiratory burst in HIV infection 
but also reported a negative correlation (r = -0.6; P<0.05)) of fMLP stimulated neutrophils with 
CD4 count showing a possible link between the respiratory burst (at rest and fMLP), immune 
activation and apoptosis of the CD4+ T-lymphocytes in HIV infection. It has previously been 
reported that the cytochrome release from the mitochondrial is associated with exhaustion of 
glutathione and that Bcl-2 driven blockage of cytochrome C release hinders depletion of 
glutathione concentration, thus modifying the redox environment towards a reducing one which 
is unfavorable for apoptosis (Circu et al., 2008: Circu & Aw, 2010). 
In order to determine the levels of immune activation, we investigated the expression of CD38/8, 
a marker of activation on CD8+ T-lymphocytes. A significant (P = 0.0018) difference in 
expression of the activation marker between the two groups (HIV positive individuals and 
uninfected controls) was noted. The significantly higher expression of CD38/8 may indicate that 
patients with asymptomatic HIV infection have higher immune activation and higher levels of 
oxidative stress in vivo. 
Thus far, only a few studies on respiratory burst response have been performed on neutrophils 
in HIV infection. Most of the previous studies were performed on monocytes (Spear et al., 1990; 
Dobmeyer et al., 1995; Elbim et al., 1996). A limitation of our study was that the phagoburst 
assay only measures the neutrophils respiratory burst. It does not measure other cells such as 
activated macrophages and the ‗NOX‘ family members which are also known to have NADPH 
oxidase system thus capable of respiratory burst response. Another limitation of this study was 
its preliminary nature which provides ‗snap-shot‘ insight into neutrophil respiratory burst 
response towards various stimulants at the time of patient sampling. Follow-up studies may be 
of value. In addition, although the neutrophil respiratory burst assay is not specific for HIV 
infection only; it was of value here in demonstrating the significant differences in HIV at this 




stage compared with the uninfected group. Other potentially confounding factors were that 
specific tests for diagnosing underlying subclinical infections were not performed and smoking 
and alcohol habits were not documented. 
3.6 Conclusions 
In summary, neutrophils from HIV-infected individuals showed a ―primed‖ response at rest and to 
low stimulating agent (fMLP), which was statistically different from controls. This may indicate 
that patients with asymptomatic HIV infection have higher levels of oxidative stress in vivo. Thus 
the respiratory burst may be an important contributing factor in inflammation-associated 
oxidative stress in HIV infection and increased depletion of CD4+ T-lymphocytes in the 
asymptomatic stages of HIV infection. 
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Abstract 
Chronic inflammation and immune activation are hallmarks of HIV infection, resulting in 
chronic oxidative stress with over-utilization of antioxidant defences, which may contribute to 
the loss of immune cells and faster disease progression. Low levels of antioxidants in HIV 
positive individuals have been associated with frequent opportunistic infections and 
increased mortality risk. The purpose of this study was to determine the baseline total 
antioxidant status, oxidative stress biomarkers, antioxidant enzymes and glutathione redox 




status in untreated HIV positive South African participants and compare them with uninfected 
control group. 
In a cross-sectional study, blood samples of 20 untreated HIV positive individuals and 20 
controls were analysed for the total antioxidant status (ferric reducing antioxidant potential, 
oxygen radical absorbance capacity & trolox equivalent antioxidant capacity), lipid 
peroxidation [(MDA, measured as TBARS) & CDs] glutathione redox status (GSH:GSSG 
ratio) and activity of antioxidant enzymes [SOD, CAT & GPx] in red blood cells. The results 
were also correlated with CD4 counts, viral loads and markers of inflammation in these 
groups.  
There was a significant increase in catalase activity (0.36 (0.28-1.3) vs. 0.25 (0.21-0.29) 
µg/mg/min: P = 0.0028), and lipid peroxidation markers (CDs – 195.6 (144.1-238.0) vs. 137 
(131.9-151.3) µm/L: P = 0.0164) and a decrease in the antioxidant status (TEAC – 4853 
(2391-7121) vs. 7512 (7231–7711) µmole TE/L: P = 0.0022) in HIV positive individuals. 
There was a positive correlation between (r = 0.79; P<0.01) the antioxidant status and CD4 
counts and negative correlation (r = -0.8; P = 0.008) between redox status and MDA levels. 
Increased oxidative stress with corresponding decrease in antioxidant capacity in untreated 
HIV positive individuals with lower CD4 count has implications for untreated patients with 
relatively well-maintained CD4 counts and who are already showing the effects of oxidative 
stress.  
Keywords: Oxidative stress, total antioxidant status, antioxidant enzymes, glutathione redox 
status, lipid peroxidation. 
4.1 Introduction 
A major characteristic of HIV infection is chronic inflammation and immune activation, which 
may result in chronic oxidative stress with over-utilization of the endogenous antioxidant 
defences. This may contribute to the loss of immune cells and disease progression. Low 
levels of antioxidants in HIV-infected individuals have been associated with frequent 
opportunistic infections, faster disease progression and an increased risk of mortality 
[1,2,3,4]. A dysfunctional antioxidant defense system which includes a decreased TAS and 
decreased levels and activities of vitamin C, E, carotenoids, SOD, GPx, CAT and elevated 
markers of lipid peroxidation such as MDA/TBARS and conjugated dienes, have all been 
reported in HIV-infected individuals [5;6;7]. 
Previous studies have proposed a role of oxidative stress in the stimulation of HIV replication 
and the progression of HIV infection to AIDS [8,9]. Importantly, the total antioxidant capacity 
(TAC) has been proposed as an early novel biomarker of oxidative stress in HIV infection 
and may be utilized as a monitoring tool of tissue damage by free radicals. TAC therefore, 
may be useful to monitor and optimize antioxidant therapy in HIV infection [5,6,7]. A 




significant decrease in activity of erythrocyte antioxidant enzyme activity has been observed 
in AIDS patients when compared to HIV-infected and healthy subjects [6]. The central role 
glutathione, a tripeptide of glycine, glutamate and cysteine, plays in cellular redox 
homeostasis and the subsequent importance of this redox balance in cell apoptosis, is well 
established in various cell types. This makes glutathione redox status a reliable marker of 
oxidative stress. Importantly, caspases, key players in apoptosis are cysteine-dependent and 
glutathione redox status sensitive enzymes [10,11,12]. Staal et al. (1992) observed 
significantly lower GSH levels in CD4+ and CD8+ T cells from HIV-infected individuals 
compared with uninfected control individual, the greatest decrease occurring in the later 
stages of the infection. These results suggest that intracellular GSH levels could be an 
important aspect in HIV infection and progression to AIDS [10]. 
The baseline levels of markers of total antioxidant status, markers of lipid peroxidation and 
glutathione redox status of plasma and blood samples, have previously been used as 
indicators of oxidative stress in HIV infection, but not in the context of asymptomatic 
infection. In this study, we investigated how the baseline antioxidant status and oxidative 
stress markers relate to markers of disease and inflammation in untreated HIV infection. 
Therefore, the baseline total antioxidant status, oxidative stress biomarkers, activity of 
antioxidant enzymes and the glutathione redox status in asymptomatic untreated HIV-
infected individuals in comparison to uninfected controls were determined and correlated with 
other markers of the disease. To our knowledge, this is the first study to report on these 
parameters in the context of asymptomatic untreated HIV infection in South African 
participants. Using a battery of assays, that included, FRAP, ORAC & trolox equivalent 
antioxidant capacity (TEAC), the total antioxidant status was determined, while MDA/TBARS 
using HPLC methodology and conjugated dienes were used as markers of lipid peroxidation. 
4.2 Materials and Methods 
4.2.1 Reagents 
Monobasic sodium phosphate (NaH2PO4.H2O) and dibasic sodium phosphate 
(Na2HPO4.12H2O), hydrochloric acid (HCl), sodium phosphate, (NaH2PO4), perchloric acid 
(HCIO4), hydrogen peroxide, chloroform, methanol, cyclohexane, sodium di-hydrogen 
orthophosphate dehydrate (NaH2PO4.2H2O), di-sodium hydrogen orthophosphate dihydrate 
(Na2HPO4.2H2O), metaphoshoric acid (MPA), trichloric acetic acid, 5,5‘ dithiobis-(2-
nitrobenzoic acid) were purchased from Merck Chemicals (South Africa). Fluorescein sodium 
salt (C20H10Na2O5), 2,2‘-azobis(2-methylpropionamidine) dihydrochloride (AAPH) and trolox 
(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), L-ascorbic acid and iron (III) 
chloride salt, GSH, GR, NADPH solution and sodium azide solution, nicotinamide adenine 
dinucleotide phosphate (NADPH), 2,4,6-Tri [2-pyridyl]-s-triazine (TPTZ),1-methyl-2-vinyl-




pyridinium trifluoromethane sulfonate (M2VP), 6-hydroxydopamine (6-HD) and GSSG were 
purchased from Sigma-Aldrich (South Africa).  
The BCA reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in sodium hydroxide) and BCA reagent B (4% cupric acid), and albumin standard 
(bovine serum albumin, 2.0 mg/ml in 0.9% saline and 0.05% sodium azide) working stock 
solution were purchased from Thermo scientific (South Africa). The fluorescence was read 
on a Fluoroskan plate reader (Thermo Electron Corporation, Germany). The absorbance was 
read in a Multiskan plate reader (Thermo Electron Corporation, Germany). 
4.2.2 Study population and design 
In this cross-sectional study, twenty untreated HIV positive individuals (6 males; median age 
32 (27-42); 14 females, mean age 29 (27-34) and 20 controls (7 males mean age 28 (26-30); 
13 females mean age 27 (24-38) were sourced from the same HIV testing and prevention 
primary health clinic in Crossroads, Cape Town (South Africa). In this phase of the study, 
only 20 HIV positive participants and 20 uninfected controls were used as this was part of 
larger study investigating the impact of inflammation-induced oxidative stress in 
asymptomatic untreated HIV infection. There was no significant difference in age between 
the two groups. The patients‘ demographics are summarised in Table 3.1. The HIV positive 
group had a significantly (P = 0.0003) lower CD4 count compared to the control group. 
Eleven of the HIV positive participants had CD4>500, while 9 had CD4<500 but greater than 
200. Informed consent was received from all the participating subjects. Inclusion criteria for 
the study participants were 21 years or older, individuals with HIV infection and CD4 counts 
>200 and not taking anti-retrovirals (ARV‘s) or any other chronic medication or antioxidant 
supplements. Exclusion criteria included patients with tuberculosis (TB) or other co-infections 
and those receiving antiretroviral therapy, anti-TB treatment or other antibiotic treatment, 
antioxidant supplementation, minerals and vitamins supplements, aspirin or any other drug 
e.g. anti-inflammatory, with established antioxidant properties. Ethics approval was obtained 
from both the clinical site: University of Cape Town: REC: REF: 417/2006 and laboratory site, 
University of Stellenbosch: N07/09/197.This sub study was added as an addendum to the 
ethics approval received for the original project N07/09/197 and performed in accordance to 
Helsinki Declaration of 1975, as revised in 2000. 
4.2.3 Sample processing 
The blood samples were collected in the morning from non-fasting participants from the 
antecubital vein in the forearm in (ethylenediaminetetraacetic acid) EDTA, sodium citrate and 
Heparin vacutainers and transported to the laboratory on ice. Plasma samples for the total 
antioxidant status assays were processed appropriately by centrifuging them at 1200 g at 4 
oC for 10 min, aliquoting 500 µl of plasma and storing them at -80 oC till the day of analyses. 




The samples for the GSSG analysis were prepared by mixing 100 µl of whole blood with 10 
µl of M2VP to derivatize GSH and stored at -80 oC. Erythrocyte lysates were prepared by 
centrifuging EDTA whole blood (as described above), removing the white buffy layer 
(leukocytes) and washing the RBC‘s 3 times in phosphate buffer (PBS). The red blood cells 
were lysed in 4 times their volume ice cold distilled water and then centrifuged at 1200 g for 
15 min at 4 oC. The supernatant (erythrocyte lysate) was collected and frozen at -80 oC until 
analysed. EDTA blood samples were used for CD counts and viral loads, while serum 
samples from the sodium citrate tubes, were used for analysis of inflammatory markers 
(fibrinogen and D-dimers). The study was carried out from 12th of September 2011 to 20th of 
December 2011. Recruitment of participants took 11/2 month (12th of September to 25th of 
October). About 10 ml and 5 ml of blood were taken into heparin, EDTA or citrate tubes 
respectively. 
4.2.4 CD 4 counts, viral loads, fibrinogen and D-Dimers 
Heparin blood samples (50 µl) were mixed with 20 µl of the multitest reagent of antibody mix 
and incubated for 15 min in the dark at room temperature. Red blood cells were lysed with 
450 fluorescent activated cell sorters (FACS) lysing solution from Beckton Dickinson. The 
cells were washed once in PBS (1300 g), resuspended and analysed by flow cytometry 
(FACSCalibur B.D Biosciences., San Jose, CA, USA). 
EDTA blood was used for quantification of viral load. The plasma viral load was determined 
by the amplification of viral RNA on duplicate samples using PCR and detecting the real time 
molecular beacons according to assay kit‘s manufacturers (BioMerieux Inc., Boxtel, 
Netherlands) specification. 
Fibrinogen, a marker of inflammation, was analysed using the Hemos IL- Fibrinogen C 
method using ACL TOP (Beckman Coulter, Inc., USA) that utilises excess of thrombin to 
convert fibrinogen to fibrin in diluted plasma. Sodium citrated blood was centrifuged at 2000 
g for 15 min and plasma aliquoted. Plasma was mixed with fibrinogen reagent and 
absorbance read at 405 nm. 
D-dimer, a marker of fibrinogen breakdown and clot formation, thus an indirect marker of 
inflammation, was estimated by spectrophotometry using the IL-D-dimer method, which is an 
automated immunoassay for quantitative determination of D-dimers in plasma. Plasma from 
sodium citrate blood samples, was mixed with latex reagent and buffer all supplied by 
Beckman Coulter (SA) and agglutination, measured as decrease in absorbance was read at 
405 nm using ACL TOP from Beckman Coulter Inc.,(USA). 




4.2.5 Measurement of total antioxidant status (TAS), antioxidant enzymes and lipid 
peroxidation 
To measure the plasma TAS ORAC, FRAP and TEAC assays were used. ORAC was 
determined using the method described by Ou et al. (2001) [13]. In this assay, fluorescence 
was measured at 1 min intervals at an emission wavelength of 563 nm and excitation 
wavelength of 540 nm using a fluoroskan plate reader (Thermo Electron Corporation 
Germany) until zero fluorescence occurred. FRAP was determined using the assay method 
of Benzie & Strain (1996) [14]. The reaction mixture was incubated at 37 oC for 30 min and 
absorbance read using a multiskan plate reader (Thermo Electron Corporation, Germany). 
TEAC was determined using Re et al. (1999) method [15]. The reaction mixture was left at 
room temperature for 30 min before taking a reading after which, the absorbance was read in 
a multiskan plate reader (Thermo Electron Corporation). The activity of CAT and SOD in 
RBC lysates was analysed using the modified method of Ellerby & Bredesen (2000) [16]. 
Glutathione peroxidase activity was analysed using the method of Flohe & Gunzler which 
measures GPx activity indirectly [17]. All the RBC‘s antioxidant enzyme activities were 
expressed per milligram of proteins per millilitre of the sample. Therefore, total proteins of the 
RBC lysates were determined using the BCA assay method. Lipid peroxidation was 
measured as CDs and TBARS/MDA. The level of plasma conjugated dienes was estimated 
according to the method of Recknagel & Glende (1984) [18]. Plasma TBARS were measured 
using Khoschsorur (2000) method [19]. Agilent technology 1200 series HPLC (Germany) 
system was used in the analysis of plasma TBARS. The glutathione redox analysis was done 
according to of Asensi et al. (1999) method [20]. 
4.3 Statistical analysis 
The data was analysed using the Graphpad Prism version 5 statistical analysis software. 
Analysis of variance (ANOVA) was used to determine whether the means of the two groups 
(HIV positive and control groups) differed significantly. Comparisons between the groups 
(HIV positive and control groups) were done. Mann Whitney non-parametric test and 
spearman‘s correlation were applied. Results were reported as medians with interquartile 
range. A 5% or lower significance level was used to judge significant findings (P≤0.05).  
4.4 Results 
4.4.1 Demographics of study population 
The participants‘ demographic characteristics are summarized in Table 4.1. The group 
included 20 HIV positive individuals; (6 males; mean age 32 (27-42); 14 females, mean age 
29 (27-34) and 20 controls (7 males mean age 28 (26-30); 13 females mean age 27 (24-38). 
Using unpaired t-test, there was no significant difference in age between the two groups (P = 
0.187). The HIV positive group had a well maintained CD4 count averaging 458 (median 427 
(310-734) and clinically well with a median viral load of 43959 median 2240 (628.5 - 40998). 




The control group had a high CD4 count with an average of 861 and also clinically well. The 
CD4 count of the two groups was significantly (P = 0.0001) different, the other parameters 
were not. Thirteen of the HIV-infected participants had CD4 > 350, while 7 had CD4 < 350 
but greater than 200. 




Table 4:1: Demographics characteristics of both the HIV positive and controls. 
Parameter HIV positive group 
(n=20) 
Controls (n=20) P -values 
Male: Female (%) 6:14 7:13  
Median age (yrs.) 30(27-35) 28(24-32) 0.187 
Range 22-47 21-58  
Median CD4 cells/mm3  427(310-734) 810(700-997) 0.0003*** 
Median Viral load 
(copies/ml) 




All the values in columns are median (interquartile ranges) of HIV positive (n = 20) and controls (n = 
20).*** CD4 counts were significantly different at P = 0.05. 
4.4.2 Plasma total antioxidant status and levels of lipid peroxidation products 
The total antioxidant status and lipid peroxidation products of the forty study participants are shown 
in Table 4.2. There was a significant (P<0.005) difference in TAS as measured by TEAC assay 
between the two groups. The ORAC and FRAP showed no significant differences. However there 
was a statistically significant difference in TEAC between the groups. Plasma conjugated dienes 
concentration were significantly (P<0.05) higher in HIV positive individuals when compared with 
control individuals. 




Table 4:2: Plasma total antioxidant status of study participants measured as FRAP, ORAC and TEAC and lipid peroxidation markers (MDA & 
CDs). 
 Total antioxidant status Lipid peroxidation markers 
 FRAP (µmole/L) ORAC (µmol TE/L) TEAC (µmole TE/L) MDA (µmol/L) CD (µm/L 





















All values in columns are medians (interquartile ranges) (all samples analysed in triplicates and repeated. Plasma total antioxidant measured as 
TEAC was significantly higher; ** at P = 0.05 in HIV positive group when compared with controls. CDs were significantly different between the 
groups. 
 
4.4.3 Red blood cell (RBC) antioxidant enzymes and Erythrocyte redox status 
Table 4.3 show the RBC antioxidant enzyme activities and glutathione redox status as indicated by GSH:GSSG ratio of the study population. 
Catalase activity was significantly (P = 0.003) increased in HIV positive individuals when compared to the controls, while no significant 
differences were shown for SOD and GPx. 










Table 4:3: RBC enzyme activity and glutathione redox status of the participants 
 RBC enzyme activity Glutathione redox status  




GSHt (µM) GSSG (µM) Ratio 
HIV positive 0.36(0.28-1.3) 1.0(0.79-1.2) 0.06(0.05-0.07) 1128(944.1-1241) 135.1(68.0-162.6) 7.9(7.2-20.3) 
Controls 0.25(0.21-0.29) 0.75(0.44-1.31) 0.07(0.05-0.16) 1206(1080-1388) 104.8(62.6-126.2) 11.8(9.9-17.7) 
P-values 0.0028** 0.117 0.1520 0.093* 0.22 0.014** 
**Medians significantly different at P< 0.005 between the two groups. Catalase activity was significantly (P =0.0028) between the two groups the total 
glutathione (GSH) GSSG and glutathione redox ratio are shown in Table3. * The total glutathione and GSSG in HIV-positive group although lower than the 
control group, the difference was not significant. However, the redox ratio was significantly (P = 0.014) different. 
 
.
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4.4.4 Other markers of disease in HIV infection 
Table 4.4 shows the values of other markers of inflammation, viral load and CD4 counts of 
these groups. When compared with the controls, as expected, the HIV positive individuals 
had significantly (P<0.05) lower CD4 counts. D-dimers, an indirect (marker of fibrinogen 
breakdown and clot formation) and marker of inflammation was significantly (P<0.05) higher 
in the HIV positive individuals than in controls.  
Table 4:4: Other markers of disease in HIV infection 





















810(700-997) N/A N/A 
P- value 0.0306** 
 
0.0003***   
The table shows the D-dimers CD4 count and viral load in this cohort expressed as medians 
(interquartile range): ** indicates that the medians were significantly different at P<0.05. *** CD4 count 
was significantly different (P<0.001). 
 
A negative correlation (r = -0.63; P<0.05) between SOD and redox ratio was noted in the 
untreated HIV positive group. There was a high negative correlation (r = -0.8; P = 0.008) 
between the glutathione ratio and MDA. The viral load was inversely correlated (r = - 0.58; P 
= 0.03) with redox status. There was a negative correlation between D-dimers and catalase 
(r = -0.701; P<0.05); a positive correlation between total antioxidant status and CD4‘s (r = 
0.79; P<0.01), GPx and viral load (r = 0.73; P<0.05), SOD and fibrinogen (r = -0.68; P<0.05), 
and SOD and redox status (r = -0.63; P<0.05). 
4.5 Discussion 
HIV infection is characterized by chronic inflammation and persistent immune activation, 
which could lead to chronic oxidative stress and deficiencies in antioxidant defenses. In this 
study, we determined the baseline total antioxidant status, oxidative stress biomarkers, 
antioxidant enzyme activities and glutathione redox status in asymptomatic untreated HIV 
positive individuals and compared with those of controls.  
Results from this study showed increased catalase activity, increased levels of lipid 
peroxidation products (MDA & CDs) and decreased total antioxidant status (TEAC) in the 
untreated HIV positive individuals when compared to the control group. The increase in 
catalase activity in this phase of HIV infection could be in response to heightened levels of 
oxidative stress as evidenced by the increased levels of lipid peroxidation markers as shown 
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in this study. Catalase eliminates H2O2 in the cells; while the antioxidant capacity of GSH 
protects the cells from oxidative stress [21,22,23]. Catalase is a ubiquitous antioxidant 
enzyme that occurs in high levels in human red blood cells. It is a convenient marker of 
oxidative stress in living systems [24, 25]. It protects the cells from H2O2 generated within 
them and therefore plays a vital role in acquiring tolerance to oxidative stress in the adaptive 
response of cells [26]. Thus, the increased catalase activity in the HIV positive individuals 
could be indicative of increased oxidative stress in those individuals. Previous studies have 
shown a significantly decreased catalase activity in AIDS as compared to HIV infection and 
healthy individuals supporting our finding of increased catalase activity in asymptomatic 
untreated HIV-infected individuals [27]. The increase in catalase in asymptomatic HIV 
infection could be attributed to an increased synthesis of these enzymes precursors as a 
response to increased oxidative stress. 
In this study a significant (P = 0.002) decrease in total antioxidant status (TEAC) was 
observed. There was no significant differences in TAS measured as FRAP and ORAC. 
FRAP assay is based on ability of antioxidants to reduce Fe (III) to Fe (II), thus unspecific 
and not a direct measure of antioxidant capacity [14]. FRAP assay cannot measure 
antioxidant capacity of certain antioxidants because the iron (II) does not react with SH 
(sulphur and hydrogen) group containing antioxidants (e.g. lipoic acid and GSH) [28]. 
Although ORAC is a simple, sensitive and reliable assay, sometimes its use is disappointing 
due to lack of discrimination among health and diseased individuals. The assay is influenced 
by proteins of biological fluids; furthermore, high levels of bilirubin and uric acid are major 
contributors of increased serum and plasma ORAC values. Similar or ORAC values not 
significantly different in normal individuals and in diabetes, cancer and HIV positive 
individuals have been reported [28]. These shortcomings of FRAP and ORAC assay could 
explain lack of significant differences in our study.  
Lipid peroxidation markers (MDA/TBARS and CDs) measure oxidative damage by ROS, and 
increased levels in the untreated HIV positive individuals would indicate increased levels of 
oxidative stress in these individuals. Chronic inflammation and persistent immune activation 
in HIV infection, induces chronic oxidative stress, which may result in over-utilization of the 
antioxidant defences, as previously mentioned. This explains our finding of lower total 
antioxidant status (measured as TEAC) in the untreated HIV positive individuals than in the 
controls group. In this study we investigated the baseline levels of lipid peroxidation products 
(MDA measured as TBARS and CDs. Increased oxidative stress in HIV infection is 
supported by our finding of significantly higher levels of MDA/TBARS (P = 0.053), catalase (P 
= 0.0028) and conjugated dienes (P = 0.016) and lower total antioxidant status (TEAC) in 
HIV positive individuals when compared to controls. Due to the non-specificity of the TBARS 
assay, two different assays for lipid peroxidation were used for a more reliable estimation 
and both indicated increased lipid peroxidation in the current study. 
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The ratio of GSH in relation to GSSG (redox status) is a reliable marker of oxidative stress in 
living systems [22,27]. Usually GSH:GSSG ratio is approximately 90% to 10% in humans 
and a change in the ratio or a decrease in GSH/increase in GSSG, indicates oxidative stress. 
In this study, the lower total glutathione (tGSH) and GSH:GSSG ratio in HIV positive 
individuals compared to the controls indicated an increased oxidative stress. Another 
important finding in this study was the high negative correlation (r = -0.8; P = 0.008) between 
the glutathione ratio and MDA. Therefore, the higher the levels of lipid peroxidation, the lower 
the GSH redox potential. This has important implications considering that this group is not 
yet on any ARV treatment, and seemingly clinically well with reasonably well-maintained CD4 
counts, but are already showing adverse effects of oxidative stress as indicated by higher 
levels of lipid peroxidation and decreased GSH redox status. Glutathione being a major 
intercellular free radical scavenger is thought to inhibit activation of NF-kB which is involved 
in the transcription of HIV-1. Depletion of glutathione leads to a glutathione redox imbalance. 
Consequently, the arising oxidative stress may lead to activation of NF-kB, increased HIV 
transcription and replication [9,27]. This further promotes increased oxidative stress as 
indicated by increased levels of lipid peroxidation products (MDA and CDs). Several studies 
have indicated significantly lower GSH levels in CD4+ and CD8+ T-cells from HIV positive 
individuals, with the greatest decrease occurring in the later stages of the infection [10,29]. 
These results suggest that intracellular GSH levels could be a key aspect in HIV infection 
and progression to AIDS. Interestingly, viral load was inversely correlated (r = - 0.58; P = 
0.03) with redox status, suggesting the higher the viral load the lower the redox potential in 
these patients. 
SOD is an important antioxidant enzyme as it protects the cells from the oxidative stress-
related damage of superoxide radicals. In the current study, there were no significant 
differences between the two groups investigated, although the median SOD activities were 
higher in untreated HIV positive individuals than in the control group. The lack of significant 
differences in SOD activity between the two groups in indicates an intact antioxidant 
enzymes defence mechanism in this relatively asymptomatic phase of HIV infection. SOD 
requires the presence of GSH to be effective. Hence, in the current study, there was a 
negative correlation between SOD and GSH:GSSG ratio. Another important antioxidant 
enzyme, GPx also protects the cells from oxidative damage by catalysing the removal of 
hydroperoxides at the expense of glutathione. Although lower GPx median values in HIV 
positive individuals were shown in the current study, it was not significant, again indicating an 
intact antioxidant enzymes defence mechanism in this relatively asymptomatic phase of HIV 
infection. A dysfunctional antioxidant enzyme defence appears to occur only at later stages 
of the HIV infection. 
In their study of activity of blood antioxidant enzymes in HIV infection, Kostyushov, et al. 
found a much more pronounced increase in lipid peroxidation (MDA) and a decrease in total 
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antioxidant status and activity of blood serum antioxidant enzymes (SOD, CAT and GPx) in 
patients with manifested forms of AIDS [30]. The stage of HIV infection is also important, 
thus the more advanced the infection, the more the increase in lipid peroxidation the more 
the decrease in total antioxidants (TEAC) and antioxidant enzymes such as GPx and SOD. 
Our finding of increased catalase activity, increased levels of lipid peroxidation products 
(MDA &CDs) and decreased total antioxidant status in the HIV positive individuals in this 
asymptomatic phase of the disease confirms what has been described in previous studies. 
D-dimers have been shown to be an important marker of underlying inflammation and have 
strong predictive value for adverse outcomes in HIV infection [28]. The median value of D-
dimers in HIV positive individuals was higher than in control group indicating increased levels 
of inflammation in HIV infection. In addition, there was a negative correlation between D-
dimers and catalase (r = -0.701; P<0.05); suggesting that the higher the levels of 
inflammation, the more oxidative stress is placed on the system; which results initially in an 
increase in protective antioxidant enzymes in this asymptomatic phase of the infection but 
decreases later as the disease progresses. 
In this study we found a positive correlation between total antioxidant status and CD4s (r = 
0.79; P<0.01), GPx and viral load (r = 0.73; P<0.05), SOD and fibrinogen (r = -0.68; P<0.05), 
and SOD and redox status (r = -0.63; P<0.05). Antioxidant enzymes belong to a group of 
thiol enzymes. In order to function effectively, they require the presence of thiols. Therefore 
they utilize free glutathione-SH group for their catalytic activity. Glutathione also supplies -SH 
groups during redox reactions to protect the cells against hydroxyl radicals and other ROS, 
explaining the finding of the negative correlation between SOD and redox status in the 
current study. 
Demonstration of decreased TAS, increased catalase activity and lipid peroxidation in 
asymptomatic untreated HIV infection, indicates that catalase enzyme is essential in 
protection of cells against severe oxidative stress. The findings also indicate that TAS might 
be critical in protecting the immune system from oxidative damage as a result of ROS insult. 
A limitation of this study was its cross-sectional nature, which provides ‗snap-shot‘ insight 
into oxidative stress levels at the time of patient sampling; nevertheless it was of value in 
demonstrating the significant differences in HIV at this stage compared with the uninfected 
group. In addition, we were not able to do specific tests for diagnosing underlying subclinical 
infections and smoking and alcohol habits were not documented. Another limitation of the 
study was the fact that ages spanned 22 - 42 years and antioxidant status is known to 
change with age [31]. Nevertheless, the majority of the participants fell between the ages of 
25 and 35, with median ages for the two groups being very close (P = 0.187). 
It will be important to follow up these markers in longitudinal cohort studies to determine their 
true surrogate value with treatment intervention strategies. 




The current study showed in this South African study population, an increased oxidative 
stress as evidenced by increased catalase activity, MDA and CDs‘ with corresponding 
decrease in antioxidant capacity in untreated HIV-infected individuals with lower CD4 count. 
MDA levels were inversely correlated with glutathione redox status in asymptomatic 
untreated HIV infection. There was also a direct correlation between total antioxidant status 
(ORAC) and CD4 count. In addition, a higher viral load was linked to a lower GSH redox 
potential. 
This has important implications for patients not yet on treatment who have relatively well-
maintained CD4 counts who are already showing effects of oxidative stress. 
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Immune activation is a hallmark of HIV infection. Chronic immune activation is implicated in 
the depletion of CD4+ T-lymphocytes via apoptosis and therefore contributes to disease 
progression. LPS as a result of the breakdown of the intestinal mucosa is an important 
contributing factor in the on-going stimulation of the immune system. Annexin V/7-AAD 
viability dye has been used previously as a way of discriminating early apoptosis from late 
apoptosis and necrosis. 
The aims of this study were to investigate and optimize the in vitro effects of time, 
temperature and concentration on LPS-induced immune activation in asymptomatic 
untreated HIV infection. The effect of varying concentrations of selected antioxidants (vitamin 
C & NAC) on LPS-induced activation was also determined. This was achieved by stimulation 
of whole blood samples (n = 20) with different concentrations of LPS ranging from 100 ng/ml 
to 5 µg/ml, and incubation of the samples with vitamin C (10 µM to 50 µM) or N-acetyl 
cysteine (5 mM) to 50 mM) for 1 hour or 24 hours. This was to develop a functional assay for 
LPS-induced activation and apoptosis measurement using flow cytometry. 
The optimum concentration of LPS which gives maximum in vitro activation of whole blood 
was determined to be 2 µg/ml after overnight incubation with LPS. LPS-induced activation 
was shown to be inhibited at low temperatures (working on ice) when compared to room 
temperature. Low doses of vitamin C (10 mM) and NAC (5 µm) individually or as a cocktail 
were shown to confer protection to LPS-induced activation. Higher concentrations of 




antioxidants above these optimum concentrations were shown to cause more activation and 
apoptosis than protection to these cells. 
Antioxidants in high concentrations may be toxic to CD4+ T-cells; however at optimum doses 
they inhibit LPS-induced immune activation thereby protecting the cells from activation 
induced apoptosis.  
Keywords: Optimization, LPS, Annexin V, 7-AAD, vitamin C, N-acetyl cysteine, whole blood 
activation. 
5.1 Introduction 
HIV infection is associated with chronic and aberrant activation of both the innate and 
adaptive immune systems. The resultant chronic inflammation and oxidative stress 
predispose patients to inflammation-associated complications and progression to AIDS. 
Chronic inflammation induces the up-regulated expression of markers of activation on 
immune cells and these become detectable on the surface of these cells as early and late 
immune activation markers (Gil et al., 2003; Deeks et al., 2004). The breakdown of the 
gastrointestinal barrier resulting in translocation of microbial products such as LPS into the 
systemic circulation is thought to be an important contributing factor underlying immune 
activation in HIV infection. LPS is known to activate various signalling pathways including the 
extracellular signal-regulated protein kinase (ERK), P38 and stress activated protein 
kinase/c-Jun N terminal kinase (SAPK/JNK), in addition to phosphoinositide 3 kinase (PI3) 
kinase and inhibitor of kappa B kinase/nuclear factor of kappa B (IKK/NF-kB) pathways in 
peripheral blood via toll-like receptor 4 (TLR4) complexes (Chow et al., 2005; Shankey et al., 
2006; Hedley et al., 2008). The effects of activation of these pathways can be measured by 
flow cytometry. The same approach can be used to study or monitor the impact of targeted 
inhibitors of these activation pathways.  
CD45 also known as leukocyte common antigen (LCA) is a member of the protein tyrosine 
phosphate family expressed on all hematopoietic cells except mature erythrocytes and 
platelets (Braford, 1994). Different isoforms of CD45 arising from splicing of variable splicing 
of exon 4, 5, and which are specific to the activation and maturation state of the cells and cell 
type exist (Virts et al., 1997). It plays an important role in TCR and BCR signal transduction. 
The use of CD45 fluorochrome conjugated monoclonal antibody has allowed the maximizing 
of gate purity and lymphocyte recovery, thus immunophenotyping, characterization, and 
enumeration of lymphocytes in HIV/AIDS and other immune system disorders can be done 
using flow cytometry (WHO, 2007). 
 
CD4 is a single-chain transmembrane glycoprotein expressed on T-helper lymphocytes. It is 
a member of the immunoglobin g (Ig) superfamily. It is present on most thymocytes, where it 




is co-expressed with CD8 (Littman, 1987). It is also expressed on all 
monocytes/macrophages and dendritic cells though dimly. It acts a co-receptor with the TCR 
during T-cell activation and thymic differentiation by binding MHC class II. CD4 is the main 
receptor for HIV-1 envelope protein gp-120 (Hannet, 1992). The use of CD4 fluorochrome 
conjugated monoclonal antibody has allowed the phenotyping, characterization, and 
enumeration of T-helper lymphocytes (CD4 antigen expressing cells) in HIV/AIDS and other 
immune system disorders using flow cytometry (WHO, 2007). Macrophages/monocytes, 
neutrophils as well as CD4+ T-cells express TLR4, the receptor for LPS on their surfaces, 
thus can be activated directly by LPS (Kabelitz, 2007; Xu et al., 2005; Caramalho, et al., 
2003).  
 
CD69 is a 60 kDa cell surface glycoprotein also known as activation inducer molecule. CD69 
antigen is one of the earliest activation markers to be expressed. It is found on activated T, B 
lymphocytes and platelets, but is absent on resting lymphocytes (Testi, 1994; Sanchez-
Madrid, 1995). It is also expressed by activated macrophages, NK cells and other cells such 
as neutrophils, eosinophils and platelets (Testi, 1994). The use CD69 fluorochrome 
conjugated monoclonal antibody has allowed the phenotyping, characterization, and 
enumeration of activated cells in HIV/AIDS and other immune system disorders using flow 
cytometry (Maino et al., 1995). 
 
CD25 antigen is a 55 kDa single chain glycoprotein, which in association with CD122 and CD 
132 is the receptor for IL-2. It is found on activated T and B-cells, on activated monocytes, 
macrophages and T-cell clones (Anderson et al., 1995). The use of CD25 fluorochrome 
conjugated monoclonal antibody has allowed the phenotyping, characterization, and 
enumeration of activated cells in HIV/AIDS and other immune system disorders using flow 
cytometry (Aandahl et al., 2004). 
 
Annexin V/7-AAD have been used previously as markers of early and late apoptosis. 
Annexin V is Ca+ dependent, phospholipid binding protein that is capable of binding 
specifically to PS even when conjugated with a fluorochrome such as FITC (Raynal & 
Pollard, 1994; Vermes et al., 1995). The ability of Annexin V to bind to PS and specificity of 
7-AAD to bind DNA guanine-cytosine base pair, enables them to be used in combination to 
discriminate between early apoptosis, late apoptosis and necrosis (Zelenin et al., 1984; 
Koopman et al., 1994). The interaction of Annexin V and PS is calcium-dependent, thus it is 
critical to avoid buffers containing EDTA or other calcium chelators during Annexin V 
staining. The baseline levels of apoptosis and necrosis varies widely within a population and 
therefore, even in the absence of induced apoptosis, most cell populations will show a small 
percentage of cells that are positive for apoptosis. Unstained or an untreated cell population 




is included to define the baseline levels of apoptotic cells and dead cells (Vermes et al., 
1995; Koopman et al., 1994). 7-AAD emits light in the far-red of the spectrum and can be 
separated from phycoerythrine (PE) or FITC or other tandem dyes, thus monoclonal 
antibodies conjugated with these fluorochromes can be used to identify different cell types 
simultaneously (Rabinovitch, 1986). It is important to note that cells lose their viability if left in 
the presence of 7-AAD dye for too long. It is therefore recommended that the incubation with 
Annexin V and 7-AAD be carried out on ice in order to maintain cell viability (Keeney, 1999).  
Previous studies involving LPS-induced activation of cells have utilised varying 
concentrations of LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and vitamin C (25 - 50 nM), 
therefore it was important to optimize the concentrations for use in the current study 
(Dobmeyer et al., 1996; Shang et al., 2003; Yamanda et al., 2006). Annexin V/7-AAD, CD4, 
CD25 and CD69 have been used previously as markers of early and late apoptosis and 
immune activation. In this study, we evaluated and optimized the in vitro effects of 
temperature and concentrations of LPS and selected antioxidants on LPS-induced immune 
activation in asymptomatic HIV infection. 
5.2 Materials and techniques 
5.2.1 Blood sample preparation 
Twenty blood samples of consenting, untreated HIV positive individuals and 20 uninfected 
controls were used for optimization of LPS-induced activation assay and to assess the ability 
of selected antioxidants to inhibit this activation. Whole blood samples were stimulated with 
increasing concentrations of LPS (100 ng/ml - 5 µg/ml) at room temperature, 35 oC or on ice, 
incubated with or without antioxidants such as vitamin C (10 - 50 nM), and glutathione 
precursor (NAC) (5 - 50 µM), for 1 hour or 24 hours. CD69, CD25, Annexin V and 7-AAD 
expression on CD4+ T-cells were measured by flow cytometry.  
5.2.2 Materials and methods 
5.2.2.1 Study population and design 
In this preliminary study, twenty untreated, asymptomatic HIV positive individuals and 20 
uninfected controls (32 females and 8 males) were sourced from a single HIV testing and 
prevention primary health clinic in Crossroads, Cape Town (South Africa). The median age of 
the participants was 32 years (range 24 - 42). There was no significant difference (P = 0.27) 
in age between the two groups. The HIV-infected group had a significantly (P = 0.0003) lower 
CD4 count compared to the control group. The patients‘ demographics are summarised in 
Table 5.1. Informed consent was taken from all the participating subjects. Inclusion criteria 
for the study participants were 21 years or older, individuals with HIV infection and CD4 
count>200; not on antiretrovirals (ARV‘s) or any other chronic medication or antioxidant 
supplements. Exclusion criteria included patients with tuberculosis (TB) or other co-infections 




and those receiving antiretroviral therapy, anti-TB treatment or other antibiotic treatment, 
antioxidant supplementation, mineral and vitamins supplements, aspirin or any other drug 
e.g. anti-inflammatory. 
An FC 500 flow cytometer (Beckman Coulter, Miami, Florida, USA) with two lasers, five 
fluorescence channels, CXP and FCS express V3 software were used in this study. Flow-
check Fluorospheres, flow-set Fluorospheres, CD4-PE, CD4-APC CD69-APC, CD25-PE, 
Annexin V-FITC/7AAD-PE kit were obtained from Beckman Coulter, Miami, Florida (US.A). 
Vitamin C, NAC and LPS stock solution (from Salmonella at 1 mg/ml) were all purchased 
from Sigma Aldrich (S.A). A working solution of LPS (1 mg/ml) was made from the powder 
(Stock) by adding 1 ml PBS and reconstituting it by mixing well. Different concentrations of 
LPS were then made from this working solution. 
5.2.3 Instrument set up 
Alignment of the lasers was performed with a mixture of Flow-check and Flow-check beads. 
The appropriate voltages were determined and standardized with a mixture of Flow-set and 
Flow-set beads. Full matrix colour compensation (as shown in Table 5.3) was done using 
FITC, PE, APC & PerCP/PC5 stained whole blood cells prepared using the lyse and wash 
method as described below. A panel was created for test analysis using the cytometer 
settings established with Flow-Set and full matrix colour compensation. 




Instrument settings for optimization (LPS, Annexin V/7-AAD, activation& apoptosis assay) 
FC 500 instrument settings 
Table 5:1: Detectors for FC 5OO 
 
Table 5:2: Acquiring set up; discriminator 
 
Table 5:3: Compensation 
 
5.3 Laboratory investigation 
5.3.1 Effects of concentration of LPS on activation and apoptosis 
LPS is known to activate multiple signalling pathways in cells through its interaction with 
TLR4. The effects of different concentrations of LPS (100 ng/ml, 1 µg/ml, 2 µg/ml & 5 µg/ml) 
was evaluated to determine the optimal concentration that induces maximum activation and 
apoptosis (measured as %CD25 or %CD69 and Annexin V/ 7-AAD expression on CD4+ T-




cells). The samples were incubated for varying durations ranging from 10 minutes, 1 hour 
and overnight incubation to determine the optimum incubation time that would give the best 
results. In order to achieve this, 50 µl of blood was added into labelled tubes after which 20 
µl of the different concentrations of LPS with or without the antioxidants were added. After 
the 10 minutes, 1 hour or overnight incubation, the samples were processed using either of 
the two different staining protocols (on ice and at room temperature) as discussed below. 
5.3.2 Effect of temperature on LPS and 7-AAD activity 
In order to determine the effects of temperature on LPS and 7-AAD activity, three different 
protocols were tested on a number of samples to determine the optimal method for activation 
and apoptosis analysis of cells. In the first protocol, the samples were always kept on ice 
during processing. The staining buffer was prepared by adding 1.25 ml foetal bovine saline 
(FBS) in 500 ml of phosphate buffered saline (PBS). The lysing solution was prepared by 
diluting 10 X fluorescein activated cell sorting (FACS) lyse solution. This was done by mixing 
5 ml of the stock lyse solution with 45 ml reagent grade water. The FACS tubes were labelled 
appropriately and to each of the tubes 50 µL of whole blood was added. The antibodies mix 
(10 µl) of CD4, CD69 or CD25, Annexin V and 7-AAD were added to the tubes, vortexed 
gently, kept on ice and incubated for 15 minutes in the dark. The RBC‘s were lysed by 
adding 500 µl of FACS lysing solution, vortexed gently, kept on ice and incubated for 15 
minutes in the dark. After lysing, 250 µl of ice cold staining buffer and 250 µl of binding buffer 
were added and the mixture centrifuged at 300 g for 5 minutes at room temperature. From 
the mixture 750 µl of supernatant was removed, pellets resuspended and 200 µl of staining 
buffer and 200 µl Annexin V binding buffer added. The preparation was analysed on flow 
cytometer within 30 minutes.  
In the second protocol, the samples were not kept on ice but the processing was carried out 
at normal room temperature. The staining buffer and lysing solution were prepared as 
described above. The samples were processed for flow cytometer analysis as previously 
described. In this protocol, the 7-AAD was added only 5 - 15 minutes before analysis on flow 
cytometer due to adverse effects on the viability of cells if left in the presence of 7-AAD for 
too long. The first two protocols tested the effects of temperature and different concentration 
of LPS on T-cell activation. 
In the third protocol, the effects of different concentration of antioxidants (vitamin C and NAC) 
on LPS stimulation of T-cells were tested. The reaction mixture consisting of whole blood, 
LPS and antioxidants was incubated at 37 oC for varying durations of time. 




5.3.3 Effects of time on LPS-induced activation and apoptosis and antioxidant 
intervention 
The samples were incubated at 37 oC with selected antioxidants for different duration ranging 
from 1 hour and overnight incubation to determine the optimum incubation times that give the 
best results. In order to achieve this, 50 µl of blood was added into the labelled tubes and 20 
µl of vitamin C or 20 µl of NAC or 40 µl of both vitamin C and NAC were added, vortexed 
gently and incubated for 20 minutes. Different concentrations of the vitamins (vitamin C; 10 
µM, 25 µM, 35 µM, 50 µM, and for NAC; 5 mM, 10 mM, 25 mM & 50 mM), were analysed to 
determine the optimum concentration of the antioxidants for inhibition of activation and/or 
apoptosis. After 20 minutes incubation of the whole blood with antioxidants, 20 µl of different 
concentrations (100 ng/ml, 1 µg/ml, 2 µg/ml, 5 µg/ml) of LPS was added. After the 1 hour or 
overnight incubation the samples were processed with the two different staining protocols (on 
ice and at room temperature) as discussed earlier and analysed on flow cytometer. 
5.4 Data acquisition 
5.4.1 Data acquisition and analysis for LPS optimization 
For LPS optimization, plot quadrants were set using unstained cells for every sample such 
that the negative Annexin-V cells and 7-AAD negative population lay in the first decade of the 
Y and X axis. A sequential gating strategy, by first gating on lymphocytes for CD4+ T-cells 
and then gating on CD4 T-cells for the other markers as shown on figures 5.1 and 5.2 below 
was employed. This was in order to detect CD4+ T-cells expressing CD69, CD25, Annexin V 
or 7-AAD. A total of 300,000 events were acquired in order to analyse a minimum of 2000 
CD4+ T-cells. CXP and FCS express V3 softwares were used to analyse flow cytometry 
data. 
5.4.2 Data acquisition and analysis for vitamin C and N-acetyl cysteine 
A sequential gating strategy on lymphocytes was employed in order to count at least 2000 
CD4+ lymphocytes. The gating strategy is shown in figure 5.1 below. A minimum of 300 000 
events were acquired to ensure consistency and a statistically relevant number of CD4+ T-











The participants‘ demographics are summarized in table 5.1. The group included 20 HIV-
infected and 20 uninfected controls most of whom were females (Fisher‘s test P = 0.36). 
There was no significant (P>0.05) difference between the two groups in terms of age. The 
mean age was 35.4 years for HIV-infected group and 29 years for the HIV negative group. 
The HIV-infected group had a significantly (P = 0.006) lower CD4 count compared to the 
uninfected control group. The HIV-infected group had a well maintained CD4 count 
averaging 417 cells/mm3 and were clinically well. Median viral load was 45705 copies/mL. 
The HIV negative group had a high CD4 count with an average of 809 cells/mm3 and was 
also clinically well. 






Male: Female  9:11 5:15  
Mean age (yrs.) 35.4 29.0 0.27 
Range 24-56 23-46  
Mean CD4 cells/mm3 ± 
SD 
417±182 809±197.9 0.006*** 
Median Viral load 
(copies/ml) 




All the values in columns are means ± S.D of HIV-infected (n = 20) individuals and HIV negative 
controls (n = 20). *** Statistically significant at P<0.05. 
 
The protocols used in the optimization, gating strategies employed and examples of dot plots 
are shown in the figures below. The dosage response curves of LPS, Vitamin C and NAC are 
also shown below; 





Figure 5:1: Apoptosis protocol. The figure shows the panel that was used to analyse 
the samples for activation and apoptosis. Lymphocytes were gated in the first plot 
(Plot A), then a CD4 gate (Plot B) was created based on the initial lymphocyte gate and 
the cells expressing either Annexin V, 7-AAD or both (Plot C) were analysed. 300, 000 











Figure 5:2: Gating strategy. The figure shows the gating strategy employed in the 
acquisition of data for forward side scatter (Fig. A), CD4 lymphocytes (Fig. B), Annexin 
V/ 7-AAD (Fig. C) A negative control/unstained sample (For 7-AAD and Annexin V) that 
was used with every sample to set the quadrants is also shown (Fig. C). A total of 
300,000 events were analysed. 7-AAD being a bright flourochrome is brightly 
expressed as seen in the negative control (Figure 5.0.2 above) and thus the quadrant 











Figure 5:3: Activation panel. The figure shows the panel that was used for LPS (2 
µg/ml) induced activation (1 hour) of whole blood. Plot A shows the Side Scatter vs. 
Forward Scatter. The lymphocytes were gated and CD4+ T lymphocytes gated from 
the lymphocyte gate. The third plot shows the percentage of CD4+ T cells expressing 
CD69. A similar panel (except that CD25 was used as the activation marker in place of 
CD69) that was used for overnight activation is not shown.  
 
After analyzing several samples activated with increasing concentration (100 ng/ml, 1000 
ng/ml, 2000 ng/ml and 5 µg/ml) of LPS, 2 µg/ml showed maximum activation and was 
chosen as the optimum concentration to use for LPS induced activation of whole blood. 7-
AAD viability dye has adverse effects on cells when left for too long with cells. It is 




recommended that the samples be on ice when working with 7-AAD (Keeney, 1999). 
However, working on ice is known to arrest activation progress through stages of viability, 
apoptosis and necrosis of the cells (Maya & Meyer, 2011). Therefore, the effect of activating 
the cells on ice and at room temperature was investigated. After choosing 2 µg/ml as the 
appropriate concentration to use for LPS activation, the effect of activation of whole blood on 
ice and at room temperature was investigated. 
 
Figure 5:4: Comparison of LPS activation of whole blood on ice and at room 
temperature. The figure shows arrest/Inhibition of LPS-induced activation by Ice 
compared to room temperature. The figure shows a higher inhibition of activation at 5 
µg/ml LPS concentration. LPS concentration at 2 µg/ml (in both ice and at room 
temperature) showed maximum activation and therefore was selected as the optimum 
concentration to use for LPS activation. A total of 300,000 events were analyzed. 
 
The monoclonal antibodies were added at the beginning (protocol of activation on ice), while 
with the activation at room temperature protocol, 7-AAD was added after the lysing and 
washing of the cells stage and the cells analyzed as soon as possible. This was to minimize 
the adverse effects on the viability of the cells left in the presence of the 7-AAD dye for too 
long. 




Vitamin C and NAC on their own (without LPS) and at high concentrations induced cell 
activation and death. This indicates that although in low doses, antioxidants are capable of 
inhibiting LPS-induced activation, on their own and in high concentrations they can be toxic 
to the cells. 
 
 
Figure 5:5: Example of dot plots used for LPS induced cell activation and death dot 
plot. Figures A, B, C & D show various markers of activation and apoptosis using 
unstimulated sample). 
 
The dose-response curve of LPS-induced activation and vitamin C and NAC response curve 
are shown below; 





Figure 5:6: LPS dose response curve; the figure shows response of whole blood to 
different concentrations of LPS. At 2 µg/ml LPS concentration Annexin V expression, a 
marker of apoptosis was considerably increased. There was also a high level of 
activation (%CD69 expression). 
 
 
Figure 5:7: NAC dose response curve; the figure shows the LPS induced cell 
activation and apoptosis in response to various concentrations of NAC. At 5 µM, NAC 
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Figure 5:8: Vitamin C dose response curve: The figure shows the LPS induced 
activation and apoptosis in response to various concentrations of Vitamin C. At 
concentrations above 10 mM activation (%CD69 expression) and cell death (%7-AAD 
expression) was substantially increased. 
5.6 Discussion 
In this phase of the study, the effects of temperature, time and concentration of LPS on 
activation and apoptosis of whole blood was determined, as well as the optimal 
concentrations of antioxidants for inhibition of these processes. Studies on humans infected 
with HIV indicated that most of the depletion of the CD4+T-cells occurs in the mucosal 
tissues during the acute phase of the infection either as direct targets of the cytopathic 
effects of the virus or indirectly by immune activation induced-apoptosis (Veazey et al., 2003; 
Brenchley et al., 2004; Haynes, 2006). The loss of gastrointestinal mucosal integrity results 
in the translocation of microbial products such as LPS into the systemic circulation and is 
thought to be an important contributing factor to the on-going immune activation in HIV 
infection. LPS is a polysaccharide, cell wall component expressed by gram negative bacteria. 
It is a strong immuno-stimulatory molecule associated with T-cell and monocyte activation 
(Brenchley et al., 2006). Macrophages/monocytes, neutrophils as well as CD4+ T-cells 
express TLR4 (Xu et al., 2005; Kabelitz, 2007), the principle signaling component of the LPS 
receptor complex (CD14, LBP & TLR4) on their surfaces, thus these cells can be activated 
directly by LPS or indirectly by pro-inflammatory cytokines from activated monocytes or 
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The use of fluorescently labelled monoclonal antibodies to assess protein and antigen 
expression enables the identification of cellular patterns and activation states (Alvarez et al., 
2009). Monoclonal antibodies such as CD45, CD25, CD69, CD4, Annexin V & 7-AAD were 
used in the LPS, NAC and vitamin C optimization processes. The effect of various 
concentrations of LPS on the activation of CD4+ T-cells in whole blood was explored. The 
results indicated that the optimal LPS concentration for inducing activation in whole blood 
was 2 µg/ml. Thereafter, the duration for maximum LPS induced activation and apoptosis 
was investigated. Previously authors have used varying duration of time ranging from 15 
minutes to 20 hrs (Schafer et al., 1999; Gercia-Verdugo et al., 2007). In this study, incubation 
durations of I hour and 24 hours were investigated. Overnight incubation of whole blood for 
20 hours was shown to induce optimum cell activation and apoptosis as determined by 
expression levels of CD25, Annexin V and 7-AAD; in comparison with 1 hour as expressed 
by CD69, Annexin V and 7-AAD. Previous studies involving LPS-induced activation of cells 
have utilised varying concentrations of LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and 
vitamin C (25 - 50 nM) therefore optimization was needed for the current study (Dobmeyer et 
al., 1996; Shang et al., 2003; Yamanda et al., 2006). Kim et al. in their study on analysis of 
cellular senescence induced by LPS, demonstrated a significant (P<0.005) decrease of 
cellular viability at 15 µg/ml or greater concentration of LPS (Kim et al., 2012). 
Antioxidants such as NAC and vitamin C have been shown to inhibit cytotoxicity; free radical-
induced DNA damage, ROS generation, immune activation and apoptosis (Alul et al., 2003). 
Therefore, optimizing a functional assay for LPS-induced activation and amelioration with the 
use of by antioxidants was important. The optimal antioxidant concentrations for inhibition of 
the LPS-induced cell activation and apoptosis were also determined. It was shown, that the 
optimal concentrations of vitamin C and NAC capable of in vitro inhibition of LPS-induced cell 
activation and apoptosis were 10 mM and 5 µM respectively. Concentrations higher than 
these were shown to be toxic to the cells as they induced greater levels of apoptosis and cell 
death. Antioxidants such as vitamin C and NAC at higher concentrations are known to be 
pro-oxidants and therefore may become toxic to cells, possibly as a result of greater levels of 
activation-induced death. (Halliwell & Gutteridge, 1989; Godin & Wahaieb, 1988; Bayday et 
al., 2007). Incubation of cells with 0.2 mg/ml of vitamin C for 24 hours was shown to cause a 
39% increase in apoptotic cells; suggesting toxicity of vitamin C (Bergman et al., 2004). 
Therefore, it was vital to optimize the concentrations of vitamin C and NAC used in this 
functional assay. NAC and vitamin C independently and as a cocktail were shown to induce 
activation of the cells in the absence of LPS, but had an inhibitory effect on activation when 
cells were incubated with LPS. This showed that selected antioxidants such as NAC and 
vitamin C are capable of inhibiting LPS induced immune activation and apoptosis. This study 
has demonstrated that higher concentrations were toxic and able to cause activation and 




even death of the cells. Thus, at higher doses vitamin C is likely to have a pro-oxidant effect 
which causes activation and even death of cells. 
It is also recommended that the incubation with Annexin V and 7-AAD be carried out on ice 
to sustain cells viability (Keeney, 1999). Therefore, two different protocols were tested on a 
number of samples (in duplicates) to determine the optimal method for activation and 
apoptosis analysis of cells. The first protocol was carried out on ice while the other protocol 
was at room temperature. The protocol which was carried out at room temperature worked 
best for this study. Working on ice was shown to inhibit LPS activation which we were trying 
to induce when compared to working at room temperature. The recommended protocol is to 
work at room temperature, but to add 7-AAD, 5 - 15 mins. before analysis on flow cytometer 
due to adverse effects on the viability of cells if left in the presence of 7-AAD for too long 
A limitation of this study was the lack of a specific marker for regulatory T-cells (T-regs) such 
as FoxP3 to distinguish the activated CD4 cells from the T-regs.  
5.7 Conclusion and recommendation 
In summary, this study showed that at high concentrations, antioxidants may be toxic to cells 
as shown by increased levels of activation and apoptosis. The study indicated that LPS in 
low concentrations, though capable of inducing activation of immune cells, may not be 
sufficient to induce apoptosis of the cells. Therefore, the optimum concentration of LPS that 
induced both activation and apoptosis in this assay was determined. In addition, antioxidants, 
though important for good health, may be potentially toxic to cells in high doses and 
therefore, optimal concentrations are important to establish for the limitation of cell activation 
and death.  
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Modulation of LPS-induced CD4+ T-cell activation and 
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Abstract 
Persistent immune activation characterises HIV infection and is associated with depletion of 
CD4+ T-cells and increased risk of disease progression. Early loss of gut mucosal integrity 
results in the translocation of microbial products such as LPS into the systemic circulation. 
This is an important source of on-going immune stimulation. 
The purpose of this study was to determine levels of CD4+ T-cell activation (%CD25 
expression) and apoptosis (%Annexin V/7-AAD) in asymptomatic, untreated HIV infection at 
baseline and after stimulation with LPS and incubation with or without vitamin C and N-acetyl 
cysteine.  
LPS induced a significant (P<0.03) increase in %CD25 expression, Annexin V and 7-AAD in 
HIV positive individuals. NAC in combination with vitamin C, significantly (P = 0.0018) 
reduced activation and early apoptosis of CD4+ T-cells to a greater degree than with either 
antioxidant alone. 
Certain combinations of antioxidants could be important in reducing the harmful effects of 
chronic immune activation and thereby limit CD4+ T-cell depletion. Importantly, we showed 
that CD4+ T-cells of the HIV positive group responded better to a combination of the 
antioxidants at this stage than the controls. Therefore, appropriate intervention at this 




asymptomatic stage, could rescue the cells before repetitive activation results in the death of 
CD4+ T-cells. 
Keywords: HIV infection; immune activation; lipopolysaccharide, apoptosis, Annexin V 
6.1 Introduction 
HIV infection is characterized by chronic immune activation and inflammatory cytokine 
production [I,2]. The consistent activation of CD4+ and CD8+ T-cells is associated with 
depletion of CD4+ T-cells and increased risk of disease progression to AIDS [3]. 
Furthermore, markers of immune activation have been shown to be stronger predictors of 
progression to AIDS than either the CD4 counts or viral loads [4,5,6]. In particular, increased 
T-cell activation has been associated with AIDS suggesting that activated T-cells are 
susceptible to apoptosis [7]. In addition, elevated levels of CD38, a marker of immune 
activation on CD4 and CD8+ T-cell predicts a rapid decrease of CD4+ T-cells and a shorter 
survival rate, independent of HIV viral loads [8,9]. 
The significant depletion of memory-type CD4+ T-cells lining the GIT mucosa in early HIV 
infection results in the breakdown of the mucosa and on-going translocation of microbial 
products such as LPS across the epithelial surface [10,1]. LPS induces activation of innate 
immune cells such as monocytes and dendritic cells resulting in increased oxidative stress; 
depletion of antioxidant defence mechanisms and an increased susceptibility to apoptosis 
[1,11]. In addition, CD4+ T-lymphocytes have been shown to express toll like-receptor-4 
(TLR4), which is a receptor for LPS [12,13]. Triggering of TLR4 activates various signalling 
pathways such as mitogen-activated protein kinases (MAPK), p38 and JNK, which induce 
activation of transcription factor NF-kB and subsequent production of pro-inflammatory 
cytokines, chemokines, antimicrobial peptides and other defence molecules such as ROS 
[13]. The pro-inflammatory cytokines such as TNF-α, are capable of activating innate 
immune cells to produce more ROS. Reactive oxygen species and pro-inflammatory 
cytokines in turn induce activation of both the extrinsic and intrinsic pathways of apoptosis. 
The role of in vitro stimulation with LPS on T-cell activation in HIV has been explored only 
minimally [14,15]. The first study to date in HIV used CD38 and HLA-DR as the activation 
markers and were conducted on HIV positive patients who were on antiretroviral treatment 
[15]. Few studies have investigated the inhibitory effects by antioxidants on immune 
activation and apoptosis in asymptomatic, untreated HIV infection. In the current study, we 
investigated the effects of vitamin C and NAC on LPS–induced up-regulation of interleukin 
receptor-2 receptor alpha chain, (CD25), as a marker of LPS-induced activation of CD4+T-
cells after overnight incubation, in untreated HIV infection. 
In this study therefore, levels of immune activation and apoptosis were measured before and 
after stimulation with LPS and incubation with selected antioxidants (vitamin C and NAC) in 




untreated HIV positive individuals. These levels were compared to a control group. We 
developed an assay that demonstrates the response of CD4+ T-cells to LPS-induced 
stimulation and further, showed the inhibitory effect of antioxidants in this process. 
6.2 Materials and Methods 
6.2.1 Study population and design 
In this cross-sectional study, twenty untreated, asymptomatic HIV positive individuals and 20 
controls (32 females and 8 males) were sourced from a single HIV testing and prevention 
primary health clinic in Crossroads, Cape Town (South Africa). The median age of the 
participants was 32 years (range 22 - 42). There was no significant difference (P = 0.43) in 
age between the two groups. The HIV positive group had a significantly (P = 0.0003) lower 
CD4 count compared to the control group. The patients‘ demographics are summarised in 
Table 6.1. Informed consent was taken from all the participating subjects. Inclusion criteria 
for the study participants were 21 years or older, individuals with HIV infection and CD4 
counts>200; not on antiretrovirals (ARV‘s) or any other chronic medication or antioxidant 
supplements. Exclusion criteria included patients with tuberculosis (TB) or other co-infections 
and those receiving antiretroviral therapy, anti-TB treatment or other antibiotic treatment, 
antioxidant supplementation, mineral and vitamins supplements, aspirin or any other drug 
e.g. anti-inflammatory. 
Ethics approval was obtained from both the clinical site, University of Cape Town: REC: 
REF: 417/2006 and laboratory site, University of Stellenbosch HREC N07/09/197.  
6.2.1 Reagents 
Flow-check Fluorospheres, Flow-set Fluorospheres, CD4-PE, CD4-APC, CD25-PE, Annexin 
V-FITC/ 7AAD-PE kit were obtained from Beckman Coulter, Miami Florida Inc. (USA). FC 
500 cytometer with two lasers from Beckman Coulter, Miami Florida, (USA) was used to 
acquire the data. L-ascorbic acid stock powder or vitamin C (C6H8O6; Molecular weight 
176.12 g/mol; 25 g powder) and N-acetyl -L- cysteine stock powder (C5H9NO3S; 25 g 
powder) were purchased from Sigma-Aldrich (South Africa).  
6.2.2 Sample preparation 
Blood was drawn into two 10 ml tubes with Heparin, one 5 ml tube with EDTA (for viral load) 
and one 5 ml tube with citrate (for D-dimers). Samples were then couriered from the clinic to 
the laboratory within two hours of collection. 
Heparinized whole blood samples were incubated with antioxidants for 20 min, then 
stimulated with LPS, incubated overnight and analysed on flow cytometer. Briefly, 100 µl of 
blood was added into the labelled tubes and 30 µl of vitamin C (10 mM) or 20 µl of NAC (5 
µM), vortexed gently and incubated for 20 minutes. An additional tube was prepared with the 




‗cocktail‘ of both antioxidants. After 20 minutes incubation of the samples at 37 oC with 5% 
carbon dioxide (CO2), 20 µl of LPS (2 µg/ml) was added. The dosages (2 µg/ml LPS, 10 mM 
vitamin C and 5 µM NAC) used in this study were chosen for these experiments after a 
rigorous optimization study on the effects of temperature, time and concentration on LPS-
induced whole blood activation and antioxidant intervention in asymptomatic untreated HIV 
infection previously done in our lab (data not shown) that these doses were chosen. The 
samples were incubated overnight and analysed on flow cytometer. 
For each sample, 100 µl of blood was added to appropriately labelled Beckman‘s flow tubes 
and 10 µl of monoclonal antibody mix added. The sample was vortexed gently and incubated 
at room temperature for 15 minutes in the dark after which 500 µl of fluorescein activated cell 
sorting (FACS) lysing solution was added. The sample was vortexed gently and incubated for 
15 minutes at room temperature. After incubation, 250 µl of ice cold staining buffer and 250 
µl of binding buffer were added. The sample was spun at 300 g for 5 minutes after which 750 
µl of supernatant was removed. The pellets were re-suspended, 200 µl of staining buffer and 
200 µl of binding buffers added and analysed on flow cytometer.  
6.2.3 Flow cytometry analysis 
An FC 500 flow cytometer (Beckman Coulter, Miami Florida, USA) with two lasers, five 
fluorescence channels and CXP analysis software were used in this study. Alignment of the 
lasers was performed with a mixture of Flow-check and Flow-check beads. The appropriate 
voltages were determined and standardized with a mixture of Flow-set and Flow-set beads. 
Full matrix colour compensation was done using FITC, PE, APC & PerCP/PC5 stained whole 
blood cells prepared using the lyse and wash method. A panel was created for test analysis 
using the cytometer settings established with Flow-Set and full matrix colour compensation. 
CXP and FCS Express V3 softwares were used to analyse the flow cytometry data. 
6.2.4 Data acquisition and analysis for apoptosis 
For apoptosis, plot quadrants were set using unstained cells for every sample such that the 
negative Annexin-V cells and 7-AAD negative population lay in the first decade of the Y and 
X axis. A sequential gating strategy, by first gating on lymphocytes for CD4+ T-cells and then 
gating on CD4+ T-cells for Annexin V vs. 7-AAD. This was in order to detect Annexin V + 7-
AAD negative cells (apoptotic cells), Annexin V negative 7-AAD positive cells (dead cells) 
and Annexin V positive 7-AAD positive (secondary apoptotic or necrotic) CD4+ T-cells. A 
total of 300,000 events were acquired in order to analyse a minimum of 2000 CD4+ T-cells. 
CXP and FCS express V3 softwares were used to analyse flow cytometry data. 
 




6.2.5 Markers of disease and immune activation 
CD4+ T-cell counts were determined by staining whole blood with Becton Dickinson (BD) 
MultiTESTTM CD3-FITC/CD8-PE/CD45-PerCP/CD4-APC reagent in BD TruCOUNTTM tubes 
according to the manufacturer‘s instructions and analysed on a BD FACSCalibur™ flow 
cytometer (BD Biosciences, San Jose, CA, USA). HIV-1 RNA quantifications were performed 
using 1.0 mL of plasma with use of the Nuclisens Easy Q HIV-1 v.1.2 kit (BioMerieux Inc., 
Boxtel, Netherlands). CD38 expression on CD8+ T-cells (CD38/8) was determined by flow 
cytometry. Whole blood samples were incubated with the monoclonal antibodies; CD8-Per-
CP; CD38-APC; CD3-FITC (BD Biosciences, San Jose, CA) and analysed on a BD 
FACSCalibur instrument using BD Cell Quest Pro (Version 2) software. Lymphocytes were 
gated on forward vs. side scatter, CD3 and CD8 expression. 
6.2.6 D-dimers 
D-dimer, a marker of fibrinogen breakdown and clot formation, thus an indirect marker of 
inflammation, was determined by spectrophotometry using the IL-D-dimer method. This is an 
automated immunoassay for quantitative determination of D-dimers in plasma. Plasma from 
sodium citrate blood samples, was mixed with latex reagent and buffer all supplied by 
Beckman Coulter (Miami, Florida, USA) and agglutination, measured as decrease in 
absorbance was read at 405 nm using ACL TOP from Beckman Coulter (Miami, Florida, 
USA). 
6.3 Statistical analysis 
The data was analysed using the Graphpad Prism version 5 statistical analysis software. 
Comparisons between the groups (HIV + and HIV-) were done. Analysis of variance 
(ANOVA) was used to determine whether the means of the two groups (HIV + and HIV-) 
differed significantly. Mann Whitney non-parametric test and spearman‘s correlation were 
applied. Results were reported as medians with interquartile ranges. A 5% or lower 
significance level was used to determine significant findings (P≤0.05).  
6.4 Results 
6.4.1 Demographics of study population 
The participants‘ demographics are summarized in Table 6.1. The group included 20 HIV 
positive and 20 controls most of whom were females (Fisher‘s test P = 0.36). There was no 
significant (P>0.05) difference between the two groups in terms of age. Both groups had 
similar mean ages: 31 years for HIV positive group and 30 years for the control group. The 
HIV positive group had a significantly (P = 0.0012) lower CD4 count compared to the control 
group. The HIV positive group had a well maintained CD4 count averaging 464 cells/mm3 
(median- 411cell/mm3) and was clinically well. Median viral load was 45705 copies/mL. The 




control group had a high CD4 count with an average of 746 cells/mm3 and was also clinically 
well. 
Table 6:1: Demographics characteristics of both the HIV positive and controls 
Parameter HIV positive group 
(n = 20) 
Controls (n = 20) P-values 
Male: Female  5:15 3:17  
Median age (yrs.) 31.8(27-35) 30.3(22-35) 0.43 
Range 21-51 21-48  
Median CD4 cells/mm3 411(265-634) 753(564-870) 0.0012** 
Median Viral load 
(copies/ml) 





All the values in columns are median (Interquartile range) of HIV positive (n = 20) individuals and 
controls (n = 20). ** Median significant at P<0.05. 
 
 
Figure 6:1: Gating strategy for activation (CD25) and apoptosis (Annexin V/7-AAD). 
Plots A (side scatter vs. forward scatter), B (bright CD4+ cells gated from the CD45+ 
leukocytes), C CD25+ cells gated from the CD4 gate & D (early, late apoptosis and 
dead cells gated from CD4+ cells gate) shows dot plots of whole blood used to set the 
quadrants. 





6.4.2 %CD25 expression in the HIV positive and control group 
The %CD25 expression before and after stimulation with LPS and incubation with vitamin C 
and NAC of the forty study participants is shown in Table 6.2 and illustrated in figure 2. 
Baseline (unstimulated) levels of activation were not significantly different between the two 
groups (P = 0.40), however after stimulation the HIV positive group showed statistically 
significant increase in activation (P = 0.03) when compared to the controls, which was not 
significant (P = 0.16). A significant difference was noted with incubation with LPS and vitamin 
C alone and NAC alone: in the control group. Optimal levels of inhibition of activation in the 
HIV group were achieved with the combination of NAC + vitamin C (P = 0.0018). 
Table 6:2: The %CD25 expression before and after overnight stimulation with LPS and 
incubation with vitamin C and/or NAC 
All the values are median (interquartile range) percentages of cells expressing CD25 of the HIV 
positive and control groups; unstimulated and stimulated with LPS and incubated overnight **Medians 
significant at P<0.05.  
 




P-value for LPS 
activation and 
inhibition by 




unstimulated 7.9(7.1-14.4) 10.2(7.8-14.4) 0.4047   
LPS stimulated 12.5(10.3-17.6) 11.6(9.6-15.2) 0.6823 0.0337** 0.16 
LPS +Vit C 15.2(11.7-17.6) 8.6(7.2-11.9) 0.0003** 0.4 0.01** 
LPS +NAC 9.0(7.1-14.2) 9.9(6.9-13.1) 0.9033 0.0416** 0.07 
LPS + cocktail 6.0(4.2-13.1) 9.1(7.8-14.6) 0.0501 0.0018** 0.22 





Figure 6:2: %CD25 expression on CD4+ T-cells; The figure shows the median %CD25 
expression on CD4+ T-cells under different experimental conditions for both HIV 
positive and control groups. LPS induced a significant increase in CD25 expression in 
HIV infection (P = 0.03) and this increase was similar to that of the controls (P = 0.68). 
Red and black lines at the top of the bars indicate significance. 
6.4.3 The %Annexin V/7-AAD staining for early and late apoptosis between the HIV 
positive and control groups 
The %Annexin/7-AAD staining before and after stimulation with LPS and overnight 
incubation with vitamin C and NAC is summarised in Table 6.3 and figure 3 & 4. For early 
apoptosis, at baseline, the levels of Annexin V+/7AAD- staining were not significantly 
(P>0.05) different between the two groups, however, a significant difference was noted after 
stimulation with LPS (P = 0.007) in the control group. There was a significant difference after 
incubation with LPS, and a combination of NAC and vitamin C in both groups. Importantly the 
combination of vitamin C and NAC significantly (P<0.0001) reduced the Annexin V+/7-AAD- 
staining cells back to its unstimulated levels. NAC and vitamin C in combination significantly 
(P = 0.007, P = 0.002) decreased the staining of Annexin V+/7-AAD- cells. For late 
apoptosis, there was no significant difference (P>0.05) before stimulation with LPS and after 
stimulation with LPS and incubation with the antioxidants individually or in combination, 
meaning that these antioxidants are effective in limiting early apoptosis. This could help in 
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Table 6:3: The %Annexin V+/7-AAD-staining of the HIV positive and the controls 
%Annexin V HIV 
positive 
group 











unstimulated 1.6(0.9-4) 1.9(1.2-2.3) 0.49   
LPS-activated 
cells 
3.3(1.6-5.6) 2.5(2.0-3.2) 0.17 0.11 0.007** 
LPS + VIT C 3.6(1.9-4.2) 2.6(2.1-3.4) 0.26 0.84 0.44 
LPS + NAC 3.4(1.2-4.3) 2.6(2.2–3.4) 0.55 0.54 0.66 
LPS + CKTL 1.8(1.0-3.7) 1.9(1.5-2.4) 0.96 0.02** 0.008** 
All the values are median (interquartile range) percentages of cells staining with Annexin V/7-AAD- of 
the HIV positive and control groups; unstimulated and stimulated with LPS and incubated overnight. 
**Medians significant at P<0.05.  
 
 
Figure 6:3: %Annexin V staining: The figure shows the median %Annexin V staining 
on CD4+ T-cells under different experimental conditions for both HIV positive and 
control groups. LPS induced a significant increase in Annexin V staining in the 
controls (P = 0.007) and this increase was significantly reduced in both HIV positive 
and controls (P = 0.02; P = 0.008 respectively) by a combination of vitamin C and NAC. 
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Table 6:4: The %Annexin V+7-AAD+ staining of the HIV-positive and control group 



















1.9(0.7-3.2) 0.6(0.4-0.7) 0.0029** 0.10 0.14 
LPS + VIT C 1.2(0.7-2.7) 0.7(0.4-1.0) 0.0048** 0.89 0.27 
LPS + NAC 2.4(1.0-3.4) 0.6(0.4-0.8) 0.0003** 0.64 0.79 
LPS + CKTL 1.8(1.3-2.1) 0.7(0.6-1.2) 0.0001*** 0.76 0.56 
The values are medians (interquartile range) percentages of cells staining for both Annexin V and 7-
AAD of the HIV positive and control groups; unstimulated and stimulated with LPS and incubated 




Figure 6:4: %Annexin V+/7AAD+ staining on CD4+T-cells: The figure shows the 
median %Annexin V+/7-AAD+ staining on CD4+ T-cells under different experimental 
conditions for both HIV positive and control groups. LPS did not induce a significant 
increase in Annexin V+/7-AAD+ staining in both groups (P>0.05). 
6.4.4 Other markers of disease in HIV infection 
Table 6.5 shows the values of other markers of disease and immune activation in the cohort. 
When compared with the controls as expected, the HIV positive individuals had significantly 
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formation) marker of inflammation was significantly (P<0.05) higher in HIV positive patients 
than in controls.  
Table 6:5: Other markers of disease in HIV infection in both the HIV-positive and control 
group 
 HIV positive group Control group P-value 
D-dimers (mg/L) 0.23(0.2-0.3) 0.21(0.20-0.26) <0.0001** 
CD38/8 (%) 27.6(17.5-44.0) 11.6(7.3-15.8) <0.0001** 
The table shows the D-dimers and %CD38/8 in these groups expressed as median (interquartile 
range): ** indicates that the medians were significantly different at P<0.05. CD38/8 was significantly 
different (P<0.0001). 
 
There was a strong inverse correlations between CD4 count and viral load (r = -0.62; P = 
0.03) and negative correlation between CD4 count and %CD38/CD8+ (r = -0.48; P = 0.05). 
However, there was no correlation between CD4 counts and D-dimers 
6.5 Discussion 
Persistent immune activation characterises HIV infection and is associated with the depletion 
of CD4+ T-cells, increased risk of disease progression and higher mortality. The breakdown 
of gut mucosal integrity in early HIV infection results in translocation of microbial products 
such as LPS into the systemic circulation. This is an important source of on-going immune 
stimulation. In this study therefore, we developed an assay to determine the ability of CD4+ 
T-cells in HIV to be activated by LPS in vitro and further, to be inhibited by selected 
antioxidants.  
LPS induced a significant increase in CD25 (activation marker) expression in HIV infection 
when compared to that of the controls (P = 0.68). Thus, at this stage of the infection, with 
relatively well maintained CD4 counts and no clinical symptoms; CD4+ T-cells in HIV 
infection retains the ability to be activated, which was significantly reduced by NAC and a 
combination of NAC and vitamin C. After incubation with antioxidants and stimulation with 
LPS, interestingly, the HIV positive group showed good responses to NAC alone and a 
―cocktail‖ of NAC and vitamin C; with CD25 levels returning to below baseline values; 
however, a similar effect could only be demonstrated in the control group with vitamin C 
alone. The combination of vitamin C and NAC was required to; achieve optimal inhibition of 
the LPS induced-activation.  
LPS induces activation of innate immune cells such as monocytes and dendritic cells 
resulting in increased production of pro-inflammatory cytokines consequently inducing 
oxidative stress. This leads to depletion of antioxidant defence mechanisms and an 
increased susceptibility to apoptosis. CD25 is a relatively late marker of activation [16]. In the 
study by Tincati et al. on the effects of in vitro LPS stimulation on T-cells in patients on 
HAART, significantly higher CD4+ & CD8+ expressing HLA-DR and CD38+ expressing cells 
were detected in low and intermediate responders compared to the HIV negative group 




confirming a sustained immune activation in HIV infection [15]. The current study confirms 
Tincati et al. findings of increased LPS-induced immune activation as measured by CD25 
expression in HIV infection when compared to controls. Furthermore, there was a 
significantly (P<0.05) increased immune activation expressed as CD38 in the HIV positive 
group when compared to the controls. 
Annexin V staining was also significantly increased after stimulation with LPS in HIV-positive 
and control group, but was more pronounced in the HIV positive group. NAC alone and in 
combination with vitamin C, significantly reduced early apoptosis of CD4+ T-cells to a greater 
degree than vitamin C alone. Moreover, LPS induced a significant increase in 7-AAD staining 
in HIV infection, which was significantly reduced by the antioxidants either alone or in 
combination.  
This study demonstrates that LPS was capable of inducing CD4+ T-cell activation and 
apoptosis in vitro as indicated by increased CD25, Annexin V and 7-AAD, which was 
ameliorated by the combination of antioxidants. In addition, NAC alone significantly reduced 
LPS-induced activation and apoptosis of CD4+ T-cells in HIV infection. Early work 
demonstrated that NAC administration to HIV positive individuals was able to slow down CD4 
decline in HIV infection [17]. NAC and glutathione have been shown to completely block 
activation induced death and associated DNA fragmentation in T-cell hybridomas, therefore 
implicating redox regulation in the processes [18]. In addition, NAC has been shown to 
directly scavenge free radicals by decreasing hypochlorus acid produced by neutrophils 
[19,20]. Cell studies have indicated that NAC enhances intracellular killing of bacteria by 
protecting the neutrophils and macrophages from free radicals generated during 
phagocytosis [21]. In support of the current study findings, NAC has been shown previously 
to inhibit LPS-mediated activation; however this work was performed in rats kupffer cells [14]. 
The effect of NAC on T-cell activation and apoptosis particularly in the context of HIV 
infection is not well documented and therefore the findings of this study may be of value in 
the future management of persons living with HIV. 
An important finding of this study was that vitamin C had no effect on LPS-induced activation 
when used alone in HIV; but when used in combination with NAC (cocktail); it showed a 
significant reduction in CD4+ T-cell activation levels. Previous studies have reported clinical 
improvement in AIDS patients who willingly consumed high doses (500 mg, 800 mg and 1 
800 mg) of ascorbic acid [22,23,24,25]. In addition vitamin C has been shown to inhibit NF-
kB activation via multiple stimuli including IL-1 and TNF in endothelial cell lines ECV30VS 
and in primary HUVECS [26]. Several studies have shown that, vitamin C inhibited T-cell 
pathways of apoptosis, which includes up-regulation of the anti-apoptotic B-cell lymphoma-2 
(Bcl-2) protein expression levels [27,28,29]. Although vitamin C exhibits strong antioxidant 
properties, it has been demonstrated in vitro that it can also act as a pro-oxidant in the 




presence of free transition metals [30,31]. In this setting it generates hydroxyl radicals in a 
fenton-like reaction. This could explain the cause of activation of CD4+ T-cells when vitamin 
C was used alone in the current study. In support of this, Bergman et al. demonstrated a 39 
% increase in apoptotic cells when cells were incubated with 0.2 mg/ml vitamin C for 24 hrs 
[32]. Previous data on clinical trials using vitamin C have been conflicting. Some authors 
have suggested that supplementation with vitamin C is toxic [33,34]. In this study, only low 
concentrations (10 mM) of vitamin C were utilized. Previous work in our laboratory (results 
not shown) had demonstrated that higher concentrations were toxic and able to cause 
activation and even death of the cells. Thus, at higher doses vitamin C is likely to have a pro-
oxidant effect which causes activation and even death of cells. 
Therefore, the current study has developed an important assay that demonstrates the 
response of CD4+ T-cells to LPS-induced stimulation and further, showed the effects of 
antioxidants in this process. The study was able to demonstrate that at this stage of HIV 
infection, CD4+ T-cells were able to respond to LPS-induced stimulation and antioxidants; 
therefore do not appear ‗exhausted‘ at this stage of the disease. However, it should be noted 
that LPS induced more death in the form of Annexin V+/7-AAD+staining in the HIV group, 
than the control; suggesting that the cells may have been ―primed‖ for death previously in 
vivo. Vitamin C alone did not inhibit LPS-induced activation in the HIV group as it did in the 
controls; suggesting that the use of vitamin C alone in HIV infection would not be of value. 
The combination of NAC with vitamin C produced the greatest level of inhibition of early 
apoptosis; suggesting a potential beneficial effect of this cocktail in the management of this 
stage of the infection. It is at this early stage of HIV infection that the ‗cocktail‘ is most 
effective and this study has demonstrated beneficial effects of the cocktail in limiting immune 
activation and early apoptosis. This way immune cells can be rescued before irreversible 
damage to the cells occurs. 
Limitations of the study were that specific tests for diagnosing underlying subclinical 
infections could not be performed and smoking and alcohol habits were not documented. 
Longitudinal cohort studies will be important to determine the value of intervention with the 
combination of anti-oxidants as described in this study, in HIV positive persons with CD4 
counts > 350 cells/mm3  
6.6 Conclusion 
This is an important assay that demonstrated the response of CD4+ T-cells to LPS-induced 
stimulation and showed the inhibitory effects of antioxidants. Certain combinations of 
antioxidants could be important in reducing the harmful effects of chronic immune activation 
and thereby limit CD4+ T-cell depletion. Importantly, the study showed that CD4+ T-cells of 
the HIV positive group responded better to a combination of vitamin C and NAC. Therefore 




appropriate intervention at this asymptomatic stage, could rescue the cells before exhaustion 
and senescence sets in. 
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CHAPTER 7  
Modulation of LPS-induced immune activation and oxidative 
stress by vitamin C and N-acetyl cysteine in untreated 
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Chronic immune activation, with resultant inflammation, induced oxidative stress and 
increased susceptibility to apoptosis, characterises HIV infection.  
The purpose of this study was to determine whether a combination of selected antioxidants 
(vitamin C & NAC) were capable of limiting LPS-induced oxidative stress in asymptomatic 
untreated HIV-infected South African participants. 




After treatment with NAC & vitamin C and activation with LPS, ORAC and TEAC values 
significantly decreased, while a significant (P<0.05) increase in CDs was noted in the HIV-
infected group, but with no effect on the MDA levels in this group. NAC and vitamin C 
decreased TBARS levels, which was more significant in controls. A decrease in GSH and 
GSSH with a resultant increase in GSH: GSSG ratio in both the HIV-infected and controls 
was observed after activation with LPS and treatment with NAC & vitamin C.  
The results indicate that treatment with these antioxidants rendered some protection against 
the induced oxidative stress, as supported by the improved redox status of glutathione and 
that ex vivo treatment of HIV-infected whole blood with vitamin C and NAC could be 
beneficial in that the treatment with LPS did not compromise the total antioxidant status at 
the same level as it did in controls. 
Keywords: Lipopolysaccharide, oxidative stress, antioxidants, vitamin C, N-acetyl cysteine, 
glutathione. 
7.1 Introduction 
HIV infection is characterised by chronic inflammation, immune activation and oxidative 
stress, which predisposes patients to thrombotic complications and progression to AIDS. 
LPS, produced from the breakdown of the gastrointestinal barrier (―leaky gut‖ phenomenon) 
during early HIV infection, induce activation of innate immune cells such as monocytes and 
dendritic cells, resulting in increased production of pro-inflammatory cytokines and 
consequently inducing oxidative stress [1,2]. Reactive oxygen species participate in GIT 
epithelial cell injury, contributing to the breakdown of the GIT barrier. Furthermore, ROS, 
formed as a result of the activation of cells such as neutrophils, macrophages and 
monocytes, promote inflammation and continuous immune activation in HIV infection [1]. 
This leads to depletion of antioxidant defence mechanisms and increased susceptibility to 
apoptosis. 
HIV infection has been shown to affect levels of antioxidant enzymes such as GPx [3]. 
Furthermore, lymphocytes of HIV/AIDS patients are known to be deficient of GSH, an 
important endogenous antioxidant, therefore making them susceptible to oxidative stress [4]. 
HIV protein-Tat has been shown to induce H2O2 signalling, resulting in enhanced T-cell 
activation and death signal expression [5]. Therefore, it is likely that both the depletion of 
endogenous antioxidants such as GSH and the increased production of H2O2 as a result of 
chronic inflammatory processes, contribute to the depletion of CD4+ T-lymphocytes in HIV 
infection [6].  
Whereas several studies have linked a weakened antioxidant defence system to the 
increased oxidative stress found in HIV/AIDS infection whether as a result of increased 
utilization or reduced intakes of antioxidant micronutrients [7], the impact of direct stimulation 




of the innate immune system on CD4+ T-cell death, has not been well described in the 
literature to date. More importantly, stage II of HIV infection has been associated with higher 
free radical production [8,9,10]. Allard et al. showed an increased oxidative stress in HIV-
positive patients than in seronegative control subjects and decreased plasma concentrations 
of various antioxidant vitamins and selenium [11]. Some investigators have suggested that 
the best way to prevent immune depression in HIV infection is to reduce oxidative stress, 
which is key at the earliest stage [12,13]. 
Therefore, reducing oxidative stress, may limit the susceptibility of immune cells to death by 
apoptosis. Dobmeyer et al. presented the evidence that oxidative stress plays a fundamental 
role in initiation of apoptosis in HIV infection [14]. They noted that ROS generated under 
circumstances similar to those that occur during opportunistic infections, promotes apoptosis 
and further, that this effect could be ameliorated by antioxidants. Montagnier theorized that 
the majority of the T-helper (CD4) cell depletion occurs essentially by apoptosis and not by 
direct HIV infection and this has been confirmed in subsequent studies in patients [15,14]. It 
has also been shown that T-cell activation induces death ligand expression and that 
increased superoxide generated in the mitochondria results in up-regulation of Fasl [16]. 
The effects of vitamin C and NAC on LPS-induced stimulation of the immune system and 
oxidative stress in asymptomatic HIV infection have not been well documented. Therefore, in 
this study, baseline levels of oxidative stress markers and antioxidant status after stimulation 
with LPS and incubation with vitamin C and NAC were determined in asymptomatic 
untreated HIV-infected individuals. These markers were compared with those of an HIV 
negative group and correlated with other markers of the disease.  
7.2 Materials and methods 
7.2.1 Reagents 
Monobasic sodium phosphate (NaH2PO4.H2O) and dibasic sodium phosphate 
(Na2HPO4.12H2O), hydrochloric acid (HCl), sodium phosphate, (NaH2PO4), per chloric acid 
(HCIO4), hydrogen peroxide, chloroform, methanol, cyclohexane, sodium di-hydrogen 
orthophosphate dehydrate (NaH2PO4.2H20), di-sodium hydrogen orthophosphate dihydrate 
(Na2HPO4.2H20), metaphoshoric acid (MPA), trichloric acetic acid, 5,5‘ dithiobis-(2-
nitrobenzoic acid) were purchased from Merck Chemicals (South Africa). Fluorescein sodium 
salt (C20H10Na2O5), 2,2‘-azobis (2-methylpropionamidine) dihydrochloride (AAPH) and trolox 
(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), L-ascorbic acid and iron (III) 
chloride salt, GSH, GR, NADPH solution and sodium azide solution, nicotinamide adenine 
dinucleotide phosphate (NADPH), 2,4,6-Tri [2-pyridyl]-s-triazine (TPTZ), 1-methyl-2-vinyl-
pyridinium trifluoromethane sulfonate (M2VP), 6-hydroxydopamine (6-HD), vitamin C, N-
acetyl cysteine (NAC), LPS (from Salmonella) and GSSG were purchased from Sigma-




Aldrich (South Africa). The fluorescence was read on a Fluoroskan plate reader (Thermo 
Fisher Scientific, Waltham, Mass., USA). The absorbance was read in a Multiskan plate 
reader (Thermo Fisher Scientific, Waltham, Mass., USA). 
7.2.2 Study population and design 
In this cross-sectional study, 20 untreated asymptomatic HIV positive participants and 20 
uninfected controls (32 females and 8 females) were recruited from the same HIV testing and 
prevention primary health clinic in Crossroads, Cape Town (South Africa). The clinic uses the 
national HIV counselling and testing (HCT) testing algorithm with accredited rapid tests. The 
median age of the participants was 32 years (range 21 - 57). There was no significant 
difference (P = 0.43) in age between the two groups. The patients‘ demographics are 
summarised in table 7.1. The HIV-infected group had a significantly (P = 0.0003) lower CD4 
count compared to the uninfected control group. Informed consent was obtained from all the 
participants, with inclusion criteria for the study comprised of 21 years or older, individuals 
with HIV infection and CD4 counts of >200 cells/mm3 and not taking ARVs or any other 
chronic medication or antioxidant supplements. Volunteers with tuberculosis (TB) or other co-
infections and those receiving antiretroviral therapy, anti-TB treatment or other antibiotic 
treatment, minerals and vitamins supplements, aspirin or any other drugs e.g. anti-
inflammatory, with established antioxidant properties, were excluded from the study. 
Ethics approval was obtained from both the clinical site, University of Cape Town: REC: 
REF: 417/2006 and laboratory site, University of Stellenbosch: N07/09/197. This sub study 
was added as an addendum to the ethics approval received for the original project 
N07/09/197.  
7.2.3 Sample preparation 
Fresh heparin, EDTA and sodium citrate blood was collected from the antecubital vein and 
transported on ice to the laboratory for immediate processing. For baseline redox status 
determinations, plasma were obtained from 1 ml heparinised whole blood, centrifuged at 
1200 g at 4 oC for 10 minutes. The plasma samples were aliquoted and frozen at -70 oC until 
the day of analysis (within 2 months). Fresh EDTA blood was aliquoted immediately for CD4, 
CD8 counts and viral loads, while citrate blood was used for fibrinogen and D-dimers 
determination, which was done within 4 hours of collection. 
7.2.3.1 GSSG sample preparation 
A 100 µL portion of EDTA-treated whole blood was added to 10 µL M2VP and mixed gently 
and frozen at -80oC. The samples were thawed and mixed immediately and incubated at 
room temperatures for 2-10 minutes thereafter, 290 µL of cold 5% MPA was added to the 
tube and vortexed for 15-20 seconds. The mixture was centrifuged at 10 000 x g for 10 




minutes. A 25 µL portion of this MPA extract was added to the buffer in Eppendorf tubes and 
the extracts were placed on ice until use. 
7.2.3.2 GSH sample preparation 
A 50 µL portion of whole EDTA-treated blood was aliquoted into tubes and frozen at -80 oC. 
On the day of analysis, the samples were thawed and mixed immediately with 350 µL of 5% 
cold MPA and vortexed for 15-20 seconds, centrifuged at 10 000 x g for 10 minutes. A 5 µL 
portion of the MPA extract was added to 300 µL of buffer and placed on ice until use. 
The baseline samples were treated with vitamin C and NAC only and incubated overnight. 
For LPS-stimulated samples, I ml of fresh whole blood, were incubated at 37 oC with 300 µl 
of vitamin C (10 mM) and 300 µl of NAC (5 µM). After 20 minutes, 200 µl of LPS (2 µg/ml) 
was added and samples were further incubated overnight at 37 oC. Thereafter, plasma was 
obtained by centrifugation at 1200 g at 4 oC for 10 min. All plasma samples were aliquoted 
and frozen at –80 oC until analysis, which was done within 2 months. 
7.2.4 Laboratory analysis 
7.2.4.1 CD4 counts and CD38/8 
Heparin blood samples (50 µl) were mixed with 20 µl of the multitest reagent of antibody mix 
(CD4, CD45, CD8, CD38) and incubated for 15 min in the dark at room temperature. Red 
blood cells were lysed with 450 fluorescent activated cell sorter (FACS) lysing solution from 
Beckton Dickinson (San Jose C.A, USA). The cells were washed once in PBS (1300 g), 
resuspended in staining buffer and analysed on flow cytometer (FACSCalibur B.D 
Biosciences., San Jose C. A, USA). The results were expressed as percentage of the gated 
cells. 
7.2.4.2 Viral loads 
EDTA blood was used for the quantification of viral loads. The plasma viral load was 
determined by the amplification of viral RNA on duplicate samples using PCR and detecting 
the real time molecular beacons, according to the assay kit manufacturer‘s (BioMerieux Inc., 
Boxtel, Netherlands) specification. Seropositivity of the participants was determined at the 
HIV counselling and testing prevention clinic, which uses the national HCT testing algorithm, 
with accredited rapid tests. Based on WHO/CDC clinical and immunological classification 
(CD4 ≥ 350cells/mm3 and no symptoms), the participants were classified asymptomatic, with 
12 participants having a CD4 count of ≥350cells/mm3, while 8 had a CD4 count lower than 
350 but >200 cells/mm3. 
7.2.4.3 Fibrinogen 
Fibrinogen, a marker of inflammation, was determined by the Hemos IL-fibrinogen C method 
using ACL TOP (Beckman Coulter SA), which utilises excess thrombin to convert fibrinogen 




to fibrin in diluted plasma. Sodium citrate blood was centrifuged at 2000 g for 15 min to 
obtain plasma which was aliquoted. Plasma samples were mixed with fibrinogen reagent and 
the absorbance was read at 405 nm. The results were expressed in g/L with normal ranges 
being 2.0 – 4.0 g/l [17]. 
7.2.4.4 D-dimers 
D-dimer, a marker of fibrinogen breakdown and clot formation, thus an indirect marker of 
inflammation, was estimated by spectrophotometry using the IL-D-dimer method (Legnani et 
al., 2010). This method is an automated immunoassay for the quantitative determination of 
D-dimers in plasma. Plasma from sodium citrate blood samples, was mixed with latex 
reagent and buffer, (Beckman Coulter, Miami, Florida USA), allowing for agglutination and 
measured as a decrease in absorbance read at 405 nm using ACL TOP (Beckman Coulter, 
Miami, Florida, USA). The results were expressed in mg/L and the normal ranges are 0.00 – 
0.25 mg/l [18]. 
7.2.5 Biochemical measurements 
The total antioxidant status of the participants was determined using a battery of assays 
including; ORAC, TEAC, lipid peroxidation products (MDA/TBARS & CDs) and redox status 
of GSH. 
7.2.5.1 Oxygen radical absorbance capacity 
The oxygen radical absorbance capacity (ORAC) was determined using the modified 
fluorescein method by Ou et al. which is based on the principle that the fluorescence of an 
oxidizable substrate e.g. fluorescein, changes with respect to time upon damage caused by a 
peroxyl radical [19]. Calculations were performed using a Microsoft Excel® spreadsheet. 
7.2.5.2 Trolox equivalent antioxidant capacity 
The Trolox equivalent antioxidant capacity (TEAC) was determined using the method 
described by Re et al. [20]. The ABTS radical (prepared by reacting 8 mM ABTS salt with 
140 mM potassium peroxodisulphate) was prepared 24 hours before the assay while stored 
in the dark. The ABTS radical; solution was diluted with distilled water (1:20) to give an 
absorbance of 1.5 at 734 nm.  
7.2.5.3 Lipid peroxidation 
Lipid peroxidation was assessed by measurement of CDs and MDA. The level of plasma 
conjugated dienes was estimated according to the method of Recknagel & Glende [21]. 
Plasma MDA was determined using a HPLC method adapted from Khoschsorur et al. based 
on the reaction of thiobarbituric acid (TBA) with MDA [22]).  




7.2.5.4 Glutathione redox status analysis (GSH:GSSG) 
The total glutathione (GSH and GSSG) was measured according to the method described by 
Asensi et al. [23]. The glutathione redox analysis is based on the enzymatic recycling method 
with GR. 
7.3 Statistical analysis 
The data was analysed using the Graphpad Prism version 5 statistical analysis software. 
Analysis of variance (ANOVA) was used to determine whether the means of the two groups 
(HIV + and HIV-) differed significantly. No assumptions were made; Mann Whitney non-
parametric test and Spearman‘s correlation were applied. Results were reported as medians 
(interquartile range). A 5% or lower significance level (P<0.05) was used to judge significant 
findings. 
7.4 Results 
7.4.1 Demographics of study population 
Participant information and baseline clinical characteristics are summarized in table 7.1. The 
group included 20 HIV-infected and 20 uninfected controls, most of whom were females. The 
mean age of HIV-positive participants were 31 years and 30 years for the control group. The 
HIV-infected group had a well maintained CD4 count, averaging 464 cells/mm3 (median 411 
cells/mm3), asymptomatic according to WHO classification and clinically well with a median 
viral load of 45705 copies/ml. The uninfected group had a significantly (P = 0.0012) higher 
CD4 count, with an average of 746 cells/mm3 (median 753 cells/mm3) and also clinically well. 
Table 7.2 shows the values of two markers of inflammation, of the two participant groups 
measured before treatment with antioxidants and activation with LPS. When compared with 
the HIV negative participants, the HIV positive group had significantly (P<0.05) lower CD4 
counts. CD38/8 was significantly (P<0.005) higher in the HIV positive participants than in the 
















Table 7:1: Demographic characteristics of both the HIV-infected and HIV-negative 
participants  
Parameter HIV Infected group 
(n=20) 
Controls (n=20) P-value 
Male: Female  5:15 3:17  
Median age (yrs.) 31.8(27-35) 30.3(22-35) 0.430 
Age range (yrs.) 21-51 21-57  
Median CD4 cell count 
(cells/mm3 ) 
411(265-634) 753(564-870) 0.001 
CD4 count (<350, >200) n=9   
CD4 count (>350) n=11   
CD38/8 
 
Median Viral load 
(copies/ml) 









Some of the values in columns are medians (Interquartile range) of HIV-infected (n = 20) and controls 
(n = 20). 
7.4.2 Other markers of disease in HIV infection measured in these participants 
When considering D-dimers, an indirect marker of fibrinogen breakdown and clot formation, 
the levels were significantly (P<0.05) higher in the HIV-infected participants than in the 
uninfected control study participants, while fibrinogen, a marker of inflammation, a well-
described acute phase reactant, was not significantly (P>0.05) different between the two 
groups (Table 7.2). 
Table 7:2: Baseline levels of inflammatory markers (both direct and indirect) of the HIV-
infected and uninfected controls 
 HIV-positive Controls P-value 
Fibrinogen (g/L) 2.7(2.3 3.1) 2.8(2.4-3.2) 0.32 
D-dimers (mg/L) 0.23(0.2–0.3) 0.21(0.20–0.20) 0.02** 
  Values in columns are medians (Interquartile range).** Medians significant at P<0.05. 
7.4.3 Plasma total antioxidant status 
The TAS measured as ORAC and TEAC of the forty study participants are shown in table 
7.3. There were no significant (P>0.05) differences in baseline ORAC and TEAC levels 
between the HIV positive and uninfected control group. However, after treatment with NAC 
and vitamin C and LPS activation, the baseline TAS (both ORAC & TEAC) decreased 
significantly (P≤0.005) between the two groups and between experiments i.e. baseline levels 
before and after stimulation with LPS. The decrease in TAS after treatment with NAC and 
vitamin C and activation with LPS was more pronounced (P<0.05) in the uninfected control 
group when compared with the HIV-infected group. 
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P-value 0.5 0.003  0.4 0.020  
All values in columns are medians (interquartile range) (all samples analysed in triplicates and repeated. P<0.05 
considered significant, P>0.05 considered not significant. 
7.4.4 Lipid peroxidation markers 
Plasma levels of both lipid peroxidation markers, MDA and CDs are shown in table 7.4. The 
baseline levels of CDs in the two groups were similar and did not differ significantly (P>0.05). 
However, the CD levels significantly (P = 0.0075) increased in HIV positive participants after 
treatment with NAC and vitamin and overnight stimulation with LPS, while the levels in the 
uninfected controls did not increase significantly (P = 0.88). The increase, after LPS 
activation and antioxidant treatment, between the two groups was significantly (P = 0.0002) 
higher in the HIV-infected participants. When considering the baseline levels of MDA, there 
was no significant differences between the two groups (P = 0.32). Interestingly, after 
overnight stimulation with LPS and incubation with antioxidants, the MDA levels decreased 
significantly (P<0.0001) in the uninfected controls and only slightly, although not significant 
(P = 0.15) in HIV–infected individuals. 
Table 7:4: Changes in participants lipid peroxidation markers after treatment with 
antioxidants (NAC & vit. C) and LPS activation 










HIV + 121.1(101.9-142.1) 141.6(133.2-149.9) 0.007 3.4(3.0–4.0) 3.1(2.8–3.3) 0.150 














The values in columns are medians (Interquartile range), (all samples analysed in triplicates). ** 
Medians significant at P<0.05. 
7.4.5 Erythrocyte glutathione redox status 
Concentrations of erythrocyte GSH and GSSG as well as the ratios of these two glutathione 
forms (indicative of the redox status) of the study population are shown in the table 7.5. The 
baseline GSH and GSSG levels of the HIV positive and uninfected controls were similar and 
did not differ significantly (P>0.05). However, after treatment with NAC and vitamin C and 
LPS activation, both these levels, significantly (P<0.0001) reduced in both groups, which was 




more pronounced in the HIV–infected group (P = 0.0001). When considering the baseline 
GSH:GSSG ratio, it was noted that this ratio was lower in the HIV-infected participants, 
although not significant. After treatment with NAC and vitamin C and activation with LPS, the 
glutathione ratios significantly increased in both groups, as a result of the significant 
decrease in GSSG levels.  
Table 7:5: Levels of erythrocyte reduced (GSH) and oxidized (GSSG) glutathione and 
the ratios of the two forms in the study population at baseline and after antioxidant 
treatment and LPS activation  
 
Erythrocyte glutathione redox status 
 HIV+ (NAC & Vit. 
C) (unstimulated) 
HIV+ NAC+ Vit.C & 
LPS (stimulated) 
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P- value 


















5.7(3.9–5.8) 7.0(5.2-9.6) 0.010** 5.6(4. -6.1) 8.1(5.6–10.7) 0.005** 











LPS induces the activation of innate immune cells such as monocytes and dendritic cells, 
resulting in increased production of pro-inflammatory cytokines, consequently inducing 
oxidative stress, which could lead to the depletion of the antioxidant defence system and an 
increased susceptibility to apoptosis. Therefore in this study, we determined whether a 
combination of selected antioxidants (vitamin C & NAC) were capable of limiting LPS-
induced oxidative stress, and thus protecting the cells from activation and oxidative stress-
induced cell death, in asymptomatic untreated HIV-infected South African participants. 
Baseline ORAC and TEAC levels in both HIV–infected and uninfected controls were similar, 
however, after treatment with NAC and vitamin C and activation with LPS, the baseline TAS 
(both ORAC & TEAC) decreased significantly (P≤0.005) in both groups. When comparing the 
two groups after antioxidant treatment and LPS activation, the uninfected controls showed a 
significantly lower TAS (expressed as TEAC and ORAC). These results indicate that ex vivo 
treatment of HIV-infected whole blood with vitamin C and NAC could be beneficial, in that the 
treatment with LPS did not compromise the total antioxidant status at the same level as it did 
in the uninfected controls blood. It is not known whether this phenomenon will be the same in 
HIV-infected individuals and will still need to be confirmed. There were no significant 
(P>0.05) differences between baseline plasma CD & MDA levels in HIV positive participants 
when compared to the uninfected group. However, after treatment with NAC & vitamin C and 
activation with LPS, a significant (P<0.05) increase in CDs was noted in the HIV-infected 
group, but with no effect on the MDA levels in this group. The results thus indicate that in this 
study, the treatment with vitamin C and NAC did not protect against the LPS-induced 
oxidative stress when considering the early lipid peroxidation marker, CD. Although a 
protective effect was shown against the LPS-induced oxidative damage for the late lipid 
peroxidation marker, MDA, indicative of some protection against oxidative lipid damage. 
When considering the HIV negative participants, the CD levels remained the same, while the 
MDA levels significantly decreased after the treatment regime, also indicative of a protective 
effect, as expected in non-immuno-compromised cells.  
Vitamin C supplementation has been shown to significantly reduce oxidative stress and 
inflammation, indicated by reduced F2-isoprostanes, prostaglandin E2 and monocyte 
chemotactic protein-1, albeit in healthy individuals [24]. By scavenging free radicals, thus 
preventing them from interacting with low density lipopolysaccharides (LDL), vitamin C was 
shown to inhibit LDL oxidation [25]. As discussed earlier, LPS is a well-known inducer of 
activation of innate immune cells. Immune cells such as monocytes and CD4+ T-
lymphocytes express toll like-receptor-4 (TLR4) which is a receptor for LPS [26,27]. TLR4 
activates various signalling pathways which induce activation of transcription factor NF-kB 





with subsequent production of pro-inflammatory cytokines, chemokines, antimicrobial 
peptides and other defence molecules such as ROS. The pro-inflammatory cytokines such 
as TNF-α produced are capable of activating innate immune cells to produce more ROS, 
therefore causing increased oxidative stress as indicated by increased lipid peroxidation 
markers (CDs and MDA) and depletion of antioxidant defences as indicated by lower ORAC 
and TEAC after stimulation with LPS as seen in both the HIV-infected and uninfected 
controls in this study.  
In the current study, the baseline GSH, GSSG and GSH:GSSG ratios of the two groups were 
similar and did not differ significantly. The high levels of GSH measured in both groups 
before LPS activation, can be explained as these are higher levels than previously reported 
in the literature for specifically South Africans [28]. At baseline the blood samples for the 
current study were treated with NAC, which is a cysteine analogue and a glutathione 
precursor and can account for the increased levels measured. After LPS-induced oxidative 
stress, the levels of oxidised glutathione significantly decreased in both groups, indicative of 
less oxidative damage to glutathione. This decrease was more pronounced in the HIV-
infected cells, indicating that treatment with these antioxidants rendered some protection 
against the induced oxidative stress, as supported by the improved redox status of 
glutathione (measured as the ratio of reduced to oxidised glutathione). Deficiency in 
glutathione has been associated with increased mortality in HIV infection [29]. Furthermore, 
apoptosis depends on caspases, a class of cysteine-dependent and glutathione redox status 
sensitive enzymes. It has previously been reported that the cytochrome release from the 
mitochondrial is associated with exhaustion of glutathione and that Bcl-2 driven blockage of 
cytochrome C release, hinders depletion of glutathione concentration, thus modifying the 
redox environment towards a reducing one which is unfavorable for apoptosis [30,31]. NAC, 
a well-recognized thiol antioxidant which is converted to glutathione after uptake as well as 
glutathione have been shown to completely block activation induced death and associated 
DNA fragmentation in T-cell hybridomas, therefore implicating redox regulation in the 
processes [32]. The HIV positive individuals who had a lower antioxidant capacity (measured 
as ORAC and TEAC) and GSH as a consequence of which they had higher CDs and MDA 
after LPS stimulation and incubation with antioxidants. This indicates that higher antioxidant 
capacity is important in modulation of LPS-induced activation. Therefore the higher the 
immune activation the more the depletion of CD4+ T-cells. 
A high correlation between MDA and viral load (r = 0.58; P = 0.03), CD4 and v/load (r = -
0.62; P = 0.03), CD4 and CD38 (r = - 52; P = 0.04). As expected, the CD4 count was 
significantly (P = 0.0012) different between the HIV-infected and uninfected controls. In 
addition, the D-dimers were significantly higher in HIV-infected group when compared to the 





uninfected controls. Interestingly, the CD38/8 was significantly (P = 0.001) higher in HIV-
infected group and correlated with CD4 count. 
This study also demonstrated that a combination of vitamin C or NAC was capable of 
reducing the LPS-induced oxidative stress in both groups, probably via NF-kB signalling 
pathways. NF-kB is a ubiquitously expressed transcription factor that regulates the 
expression of hundreds of genes involved in cell survival, differentiation, growth, apoptosis 
and inflammation. It occurs as an inactive complex in the cytosol, bound to inhibitor of kappa 
B α (IkB-α) which masks the NF-kB‘s DNA binding domains. Reactive oxygen species are 
capable of directly activating IkB kinase (IKK), which phosphorylates the C-terminal ankylin 
repeats of the IkB-α proteins bound to NF-kB at serine residuals 32 and 36 [33]. This leads to 
ubiquitination and degradation of the IkB-α unmasking the DNA binding sites subsequently 
causing translocation of the NF-kB to the nucleus, where it binds to kB sites and activates 
the transcription of genes involved in cellular processes such as production of pro-
inflammatory cytokines, inflammation, thereby promoting oxidative stress [34].  
In HIV infection, oxidative stress may cause damage to immune cells, impairing the immune 
response to the virus and lead to faster disease progression [35,36]. Therefore, protection 
from oxidative damage in HIV infection might slow down the disease progression [36]. 
Antioxidants such as vitamin C and NAC have been shown to inhibit this NF-kB activation in 
vivo and in vitro, thereby ameliorating oxidative stress [37,38,39,40]. In this study, NAC and 
vitamin C were able to reduce MDA levels in both groups. CDs, being early markers of 
oxidative stress during lipid peroxidation process increased after stimulation and incubation 
with antioxidants. In a controlled clinical trial involving patients with HIV infection, Akerlund et 
al. showed a reduction in TNF levels in serum and interestingly a decreased rate of decline 
of CD4+ T-cell counts [41].  
A limitation of this study was its cross-sectional nature which provides ‗snap-shot‘ insight into 
oxidative stress levels at the time of patient sampling; nevertheless it was of value in 
demonstrating the significant differences in HIV at this stage compared with uninfected 
group. In addition, we were not able to do specific tests for diagnosing underlying subclinical 
infections and smoking (however, smoking did not affect serum TAS in untreated and treated 
patients [42] and alcohol habits were not documented. 
It will be important to follow up these markers in longitudinal cohort studies to determine their 
true surrogate value with treatment intervention strategies. 
7.6 Conclusion 
The results of this study indicate that ex vivo treatment of HIV-infected whole blood with 
vitamin C and NAC could be beneficial in protecting against oxidative stress in HIV infection. 





This ex vivo investigation was also able to demonstrate that at this stage of HIV infection, a 
response to oxidative stress is almost similar in HIV-infected and uninfected control groups. 
Although TAS was lower in HIV-infected group than that of uninfected controls, the response 
to LPS stimulation and incubation with antioxidants of both groups was in a similar manner. 
This suggests that antioxidant defence mechanisms of the HIV-infected group do not appear 
to be ‗exhausted‘ or severely compromised at this stage of the disease and appropriate 
interventions at this stage might be protective against oxidative damage, as indicated by 
decreased MDA and increased glutathione redox ratio in this group. The increase in 
glutathione redox ratio might be important in protecting immune cells from oxidative stress–
induced apoptosis.  
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CHAPTER 8  
General discussion, conclusions, and recommendations 
 
 




8.1 General discussion, conclusions, and recommendations 
8.1.1 A model of inflammation-induced oxidative stress and potential ameliorating 
interventions in HIV 
As mentioned previously, a key occurrence in HIV infection is the continuous activation of the 
immune system and inflammation as a result of microbial translocation across the GIT 
mucosal lining during early HIV infection (Brenchley et al., 2006). Microbial products such as 
LPS moving across the epithelial surface induce activation of the innate immune cells such 
as macrophages, neutrophils, monocytes and dendritic cells causing increased oxidative 
stress. As a result, activated immune cells especially macrophages and neutrophils produce 
high levels of ROS and TNF. Consequently, antioxidant defence mechanisms are depleted, 
which causes increased susceptibility of the CD4+ T-cells to apoptosis. The arising overload 
of ROS (specifically H2O2 ) and TNF in conjunction with deficiencies in enzymatic antioxidant 
defence mechanisms such as SOD, CAT and GPx and other antioxidants such as GSH, 
vitamin C and E are thought to promote the increased apoptosis and depletion of CD4+ T-
lymphocytes seen in HIV infection (Hockenbery et al., 1993; Kotler, 1998; Gil et al., 2003; 
Reinehr et al., 2008; Morris et al., 2012). 
Although more than 10 million people in low and middle income countries are currently 
receiving ARV‘s, 10 million more people living with HIV and who are qualified for treatment 
according to the new WHO guidelines, are still on a waiting list (UNAID, 2010). Currently, it is 
recommended internationally to commence ARVs at CD4 count of between 350 – 500 
cells/mm3 (WHO, 2013). However, in resource-poor countries this may be difficult to 
implement, since significant numbers of patients with CD4 count of less than 200 cells/mm3 
have not yet had access to antiretroviral therapies. Despite more than three decades of 
efforts, the discovery of a cure for HIV/AIDS has remained elusive and a challenge for 
scientists, especially in our geographical region of sub-Saharan Africa. It is becoming clear 
that immune activation and inflammation may be stronger indicators or predictors of HIV 
pathogenesis and prognosis than CD4 count and viral load (Giorgi et al., 1993; Fahey et al., 
1998; Liu et al., 1998; Brenchley et al., 2004; Cassol et al., 2010). An insight into the immune 
activation, inflammatory and oxidative stress status of patients will enable long term profiling 
of each patient with a view to individualized therapy. This approach may have a direct impact 
on patient care in resource-limited settings like sub-Saharan Africa.  
In order to determine the impact of inflammation, immune activation and oxidative stress in 
asymptomatic untreated HIV infection, firstly, a preliminary study was conducted to establish 
baseline levels of oxidative burst and immune stimulation. In this preliminary study, the role 
of the neutrophil respiratory burst in asymptomatic untreated HIV infection as an in vitro 
indication of response to immune stimulation was investigated. The results of this study 
indicated that neutrophils from HIV-infected persons at rest and in response to low 




stimulating agent (fMLP), had significantly (P = 0.041) higher levels of oxidative burst 
response compared to uninfected controls. These results suggested ‗pre-activation‘ or 
priming by ROS or pro-inflammatory cytokines in vivo, which may indicate that patients with 
asymptomatic HIV-infection have higher levels of oxidative stress in vivo, as demonstrated 
by significantly higher baseline resting levels and a ‗primed‘ response to a low stimulating 
agent. In addition to this, the significantly (P = 0.0069) higher expression of the cellular 
immune activation marker, CD38/8, may indicate that patients with asymptomatic HIV 
infection have higher immune activation and higher levels of oxidative stress in vivo. Based 
on results of this preliminary study, ROS and in particular the neutrophil respiratory burst, 
was considered to be a contributing factor in the persistent immune activation, inflammation 
and oxidative stress common in HIV infection. This may initiate or activate signalling 
pathways involved in apoptosis. The oxidative burst elicits a vicious cycle of oxidative stress, 
inflammation, immune activation and apoptosis leading to faster disease progression to 
AIDS. 
One of the hypotheses of this study was that a dysfunctional enzymatic antioxidant defense 
system (SOD, CAT & GPx) would lead to an overall increase in H2O2 levels, which have 
been implicated in apoptosis of cells from HIV-infected individuals (Dobmeyer, et al., 1996). 
The H2O2, which is membrane soluble can easily enter the cells and cause apoptosis 
(Dobmeyer, et al., 1996). In addition, it has been reported that HIV–infected individuals are 
under chronic oxidative stress (Allard et al., 1998; Jaruga et al., 2002; Gil et al., 2003; 
Wanchu et al., 2009). Some previous studies have reported a dysfunctional enzymatic 
antioxidant activity, while others reported increased levels of the activity (Stephensen et al., 
2007; Kuller et al., 2008; Pasupathi et al., 2009: Suresh et al., 2009). Therefore in the second 
phase of the study, we investigated how baseline levels of total antioxidants status relate 
with other markers of disease in asymptomatic, untreated HIV infection. There was increased 
oxidative stress as evidenced by increased catalase activity, MDA and CDs with 
corresponding decrease in antioxidant capacity in the HIV-infected individuals with lower 
CD4 count. This has important implications for patients not yet on treatment who have 
relatively well-maintained CD4 count and who are already showing the effects of oxidative 
stress.  
This study also found a significant increase in catalase activity and a similar trend with the 
other enzymes (SOD & GPx) in this asymptomatic phase of HIV infection. From these results 
and supported by other studies, it is likely that the antioxidants enzymes increase initially in 
response to increased oxidative stress to protect the cells from induced oxidative damage. 
Later, as the disease progresses, the enzymatic antioxidant defenses are overwhelmed by 
ROS and thus become dysfunctional (Delmas-beauvieux et al., 1996; Stephensen et al., 
2007; Kostyushov et al., 2009). Therefore, in this asymptomatic phase of HIV infection, the 




enzymatic antioxidant defenses are still functional and only become dysfunctional at a later 
stage of the infection, depending on other factors such as levels of oxidative stress, 
nutritional and immune status of individuals.  
Previous studies involving LPS-induced activation of cells have utilised varying 
concentrations of LPS (100 ng/ml - 5 µg/ml), NAC (5 - 50 µM), and vitamin C (25 - 50 nM) 
therefore the need for optimization of the current study functional assay (Dobmeyer et al., 
1997; Shang et al., 2003; Yamanda et al., 2006). A decrease of cellular viability at higher 
concentrations (>15 µg/ml) of LPS as well as pro-oxidant activity of vitamin C have been 
reported (Carr & Frei, 1999; Lee et al., 2001; Kim et al., 2012). Antioxidants have been 
shown to have an effect in inhibition of T-cell activation and apoptosis (Meier, 2002). 
Different concentrations of N-acetyl cysteine, vitamin C and E have been shown to have 
different effects on T-cell activation (Dobmeyer et al., 1997; Shang et al., 2003; Yamanda et 
al., 2006). Thus, it was important to determine the dosage that was the most effective or had 
the desired effects. Combinations of different antioxidants at different concentrations also 
needed to be tested in order to determine their possible synergistic effects on T-cell 
activation and apoptosis. This may justify why dietary antioxidants rather than antioxidant 
supplements have been recommended previously (Krauss et al., 2000; Norman et al., 2003). 
Therefore, in the third phase of study we determined the optimal concentrations of LPS, NAC 
and vitamin C. The optimum concentration of LPS, which gave maximum in vitro activation of 
whole blood, was determined to be 2 µg/ml after overnight incubation with LPS. LPS-induced 
activation was shown to be inhibited at low temperatures (working on ice) when compared to 
room temperature. Low doses of vitamin C (10 mM) and NAC (5 µm) individually or as a 
cocktail, were shown to confer protection on LPS-induced activation. Higher concentrations 
of antioxidants above these optimum concentrations were shown to cause more activation 
and apoptosis than protection in these cells. 
Our second hypothesis was that specific antioxidant intervention could ameliorate HIV 
inflammation-induced oxidative stress and thereby limit the death of the cells from HIV- 
infected individuals and may represent a valuable adjunct to the management of patients 
with earlier stages of HIV infection. Therefore, in the fourth phase of the study we 
investigated the potential of selected antioxidants (NAC and vitamin C) to ameliorate LPS 
induced-immune activation and oxidative stress in asymptomatic untreated HIV infection. 
The results of this study demonstrated a significantly (P = 0.0075) decreased antioxidant 
status, a dysfunctional glutathione redox status and significantly higher (P = 0.03) LPS-
induced CD4+ T-cell activation in HIV-infected group when compared to uninfected 
participants. 




8.1.2 What are the effects of vitamin C and the glutathione precursor (NAC) on immune 
activation, oxidative stress and apoptosis of CD4 T-cells in HIV infection? 
Vitamin C had no effect on LPS-induced activation when used alone; but when used in 
combination with NAC (cocktail) it showed significant (P = 0.001) reduction in CD4+ T-cell 
activation levels. NAC significantly (P = 0.04) reduced LPS-induced activation of CD4+ T-
cells in HIV infection. Stimulation of the whole blood with LPS induced a significant increase 
in the expression of Annexin V and 7-AAD. NAC and vitamin C individually and in 
combination were able to decrease the expression of Annexin V and 7-AAD significantly.  
The antioxidant combination (NAC & vitamin C) decreased MDA values in HIV-infected 
individuals. A significant (P<0.0001) decrease in MDA levels was noted in the uninfected 
control group after LPS stimulation and incubation with antioxidants when compared to HIV-
infected individuals. Another important finding of this study was the significant (P = 0.01) 
increase in glutathione redox ratio after incubation with NAC and vitamin and stimulation with 
LPS. There was a decrease in tGSH and GSSH, which was more pronounced in the HIV-
infected group, however glutathione redox status ratio (GSH:GSSG ratio) in both the HIV-
infected and uninfected control groups increased significantly after stimulation with LPS and 
incubation with antioxidants. A change in this ratio or decrease in GSH indicates an increase 
in GSSG, which in turn indicates lipid peroxidation and thus cellular oxidative stress (Sen, 
1997; Schafer & Buettner, 2001). 
In addition, this study demonstrated that a combination of vitamin C and NAC could reduce 
the LPS-induced activation in vitro. Importantly, this study demonstrated a significantly 
increased glutathione redox ratio after treatment with NAC and vitamin C and activation with 
LPS indicating that NAC, a precursor of glutathione and vitamin C might be important in the 
replenishment of GSH in HIV infection. This might be of specific importance in correction of 
the glutathione redox imbalance, which has been implicated in apoptosis. The ability of NAC 
to restore normal glutathione levels in lymphocytes and in so doing, reduce oxidative stress, 
has been associated with its health benefits in HIV (Malorni et al., 1993). Oxidative stress 
and in particular ROS is linked to depletion of glutathione resulting in redox imbalance. As a 
result, the redox imbalance facilitates opening of permeability transition pore in the 
mitochondria leading to release of cytochrome C and activation of initiator caspases (3 & 7). 
It has been reported previously that cytochrome C released from the mitochondria is 
associated with exhaustion of glutathione and that Bcl-2 driven blockage of cytochrome C 
release hinders depletion of glutathione concentration, thus modifying the redox environment 
towards a reducing one which is unfavorable for apoptosis (Circu et al., 2010). 




8.1.3 Why do lymphocytes from HIV-infected people show increased susceptibility to 
oxidative stress? 
Throughout this study, lower median values of glutathione redox status (GSH: GSSG ratio) 
were found in HIV positive individuals compared to negative controls, indicating decreased 
GSH levels. As previously mentioned, plasma membranes of the cells of immune system 
contain high levels of polyunsaturated acyl lipids, which are vulnerable to peroxidation 
making them highly sensitive to oxidative stress. Furthermore, lymphocytes of HIV/AIDS 
patients are known to be deficient in glutathione, therefore making them susceptible to 
oxidative stress (Willcox et al., 2004; Guerra et al., 2011). 
LPS induces activation of innate immune cells such as monocytes and dendritic cells 
resulting in increased oxidative stress; depletion of antioxidant defence mechanisms and an 
increased susceptibility to apoptosis. As CD4+ T-lymphocytes express toll like-receptor-4 
(TLR4), this receptor for LPS activates various signalling pathways such as mitogen-
activated protein kinases (MAPK), p38 and JNK, which induce activation of transcription 
factor NF-kB with subsequent production of pro-inflammatory cytokines, chemokines, 
antimicrobial peptides and other defence molecules such as ROS (Kabelitz, 2007). The pro-
inflammatory cytokines such as TNF-α that are produced, are capable of activating innate 
immune cells to produce more ROS. Reactive oxygen species and pro-inflammatory 
cytokines in turn induce activation of both the extrinsic and intrinsic pathway of apoptosis. 
This could explain in part the susceptibility of CD4+ T-lymphocytes to oxidative stress and 
persistent depletion of the cells during HIV infection. 
8.1.4 Does increased SOD activity and reduced GPx activity in immune cells and 
RBC’s in HIV infection, lead to increased oxidative stress and thus promotes 
enhanced apoptosis? 
In the present study, there were no significant differences between the two groups 
investigated, although the mean SOD activities were higher in HIV-infected than in 
uninfected individuals. Although lower GPx mean values in HIV-infected individuals were 
shown in the present study, it was not statistically significant. 
Catalase activity was shown to be increased during this asymptomatic phase of HIV-
infection; possibly in response to heightened levels of oxidative stress as evidenced by the 
increased levels of lipid peroxidation markers demonstrated in this study. As discussed 
previously, results of this study and from others indicated that antioxidant enzymes initially 
increase in response to increased oxidative stress to protect the cells from induced oxidative 
damage, however as the disease progresses, the enzymatic antioxidant defenses are 
impaired by oxidative stress at a later stage of the infection depending on other factors such 
as the levels of oxidative stress, nutritional and immune status of individuals (Delmas-
beauvieux et al., 1996; Stephensen et al., 2007; Kostyushov et al., 2009). Based on the 
WHO immunological and clinical classification of HIV infection, the participants of this study 




were at stage 1 (asymptomatic) with relatively well maintained CD4 count (averaging 460 
cells/mm3 and clinically well). Therefore, this study demonstrated that in this asymptomatic 
phase of HIV infection, the enzymatic antioxidant defenses were still functional and not 
overwhelmed by ROS. In addition, the neutrophil burst arm of this study demonstrated the 
ability of immune cells at this stage of HIV infection to respond similarly to that of uninfected 
controls in response to various stimulating agents. 
Nevertheless, decreased antioxidant status was already evident in this clinically well group of 
HIV-infected individuals, suggesting that early intervention with selected antioxidants may 
serve a protective function against further oxidative damage to immune cells. Catalase and 
antioxidant defenses are likely to be important protective factors in inflammation-induced 
oxidative stress during asymptomatic HIV infection. 
As previously mentioned, the initial objective of HIV treatment was to manage opportunistic 
infections and simply keep the individual alive, which then later shifted to suppressing HIV 
replication and managing drug side effects and complications that may arise. Today‘s 
emphasis is on improving overall health and enabling people with HIV to live long productive 
lives (Highleyman, 2010). Highleyman (2010) proposed three ways in which this can be 
approached: reducing T-cell activation, altering production and activity of cytokines and 
inflammatory mediators such as ROS and changing underlying risk factors through lifestyle 
modifications. In line with this, probiotics to reduce pro-inflammatory microbiota and increase 
anti-inflammatory bacteria in the gut have been proposed as a viable option to address the 
microbial translocation (―leaky gut phenomenon‖) (Kwon et al., 2011). Consistent with this, 
the present study proposes and recommends a personalised/individualised model 
(summarised in Figure 8.1) of managing the persistent immune activation, inflammation and 
oxidative stress at the earliest possible time-point, before oxidative damage to the immune 
cells becomes pronounced. This way, the integrity of the immune cells can be maintained 
and the risk of progression to AIDS minimised. The present study recommends intervention 
with a ―cocktail‖ of antioxidants vitamin C and NAC at this point, which were found to have 












Figure 8:1: A model of inflammatory induced oxidative stress and potential 
ameliorating intervention (Adapted from Appay & Sauce, 2008). 
8.2 Conclusions 
In summary, this study has shown higher oxidative burst response in neutrophils of HIV-
infected individuals at rest and in response to a low simulating agent, significantly higher 
catalase activity and lipid peroxidation with decreased total antioxidant status and increased 




immune activation in asymptomatic untreated HIV infection, indicating increased oxidative 
stress in these individuals. This study has also shown increased baseline and LPS-induced 
immune activation, and that LPS-induced activation and oxidative stress can be modulated 
by specific combinations of antioxidants (vitamin C and NAC) in this untreated, clinically well 
HIV study population. The literature study indicated that most of the depletion of CD4+ T-
cells occurs during the acute phase (Bundres et al., 1993; Favier et al., 1994; Jarstrand & 
Akerlund, 1994; Pugliese et al., 2005). Our study has shown that even at this asymptomatic 
phase and with relatively well-maintained CD4 count, adverse effects of oxidative stress such 
as decreased TAS, increased lipid peroxidation, dysfunctional antioxidant enzymes, reduced 
glutathione redox potential and increased immune activation were already evident in 
individuals. Therefore, early intervention at this clinically asymptomatic stage of infection may 
be protective against further oxidative damage to immune cells. 
Although ROS are produced constitutively by living systems to serve vital biological 
functions, evidence suggests that they play an important role in apoptosis and thus depletion 
of the CD4+ T-cells in HIV infection. They also fuel the process of inflammation, which 
induces immune activation, perpetuating a vicious cycle of inflammation and immune 
activation. Reactive oxygen species and inflammation act like ‗fuel added to the immune 
activation fire‘, whose source is the HIV and thus very difficult to put out. At the moment ART 
remains the best treatment option for HIV/AIDS. The model described in this thesis is not a 
replacement therapy to ARV‘s, but a supplementary therapeutic strategy that targets 
lowering or minimizing immune activation, inflammation and oxidative stress responses in 
HIV infection. Through data from this study, it is hoped that individualised or personalised 
management and care strategies can be devised for HIV patients in resource-limited 
settings. 
To the best of our knowledge, this study is the first to use an integrated approach involving 
not only plasma levels of antioxidant status, but also RBC antioxidant enzyme activities, 
oxidative damage (lipid peroxidation), inflammation, cellular levels of immune activation and 
potential ameliorating interventions in evaluating the problem of inflammation-induced 
oxidative stress in HIV infection. In addition, this is the first study to our knowledge that 
combines the effect of oxidative stress on apoptosis, total antioxidant status, the enzymatic 
antioxidant defence system and antioxidant intervention models in one study. The results 
from this study will certainly contribute to the current knowledge in the field of HIV and 
oxidative stress by addressing important mechanisms by which dietary antioxidants (in 
combination) can modulate oxidative stress in specific immune cells (CD4+ T-lymphocytes) 
from HIV-infected individuals. Therefore, this work represents a novel contribution to the 
field. Through data from this study, possible management strategies may be devised for HIV 
patients. 




Currently, CD4 count and viral load remain the golden standard tests in HIV management. 
Recommendations for the commencement of ART are currently at a CD4 count of ≤500 
cell/mm3; however, the roll-out of these medications has only reached 50-60% (about 8, 
million by 2011) of those requiring therapy in Africa (WHO, 2013; WHO, 2012; UNAIDS, 
2012). Furthermore, the current expansion of eligibility of commencement of ART criteria to 
≤500 cell/mm3 has added 10 million more patients to the waiting list of 15 million eligible 
patients, hence making universal access to ART difficult to attain in resource-poor settings 
(WHO, 2013). Therefore, other tests, particularly of inflammation, may be required to identify 
those patients at increased risk of disease progression or other inflammation-associated 
complications. In line with the findings of this study, it is recommended that integration of 
other tests such as inflammatory markers (fibrinogen) activation markers (CD38/8) redox 
status markers (tGSH, GSSG, GSH: GSSG ratio) total antioxidant status (TEAC), RBC 
antioxidant enzyme activity (SOD, CAT & GPx) lipid peroxidation (MDA/TBARS or CDs) with 
the routine CD4 count and viral load tests in HIV management and care be considered. In 
resource-limited settings such as sub-Saharan Africa, these tests, some of which have 
commercially available assay kits, are accessible and can give a quick insight into the 
inflammatory, immune activation and oxidative stress status of an individual. Based on the 
results, tailor-made personalised HIV care and management may be possible. 
8.3 Future study recommendations 
The preliminary nature of this study only provided ‗snap-shot‘ insight into inflammation, 
immune activation and oxidative stress status of the participants at the time of patient 
sampling. Although it was of value in demonstrating the significant differences in HIV at this 
stage compared with uninfected group, it will be important to follow up these markers in 
longitudinal cohort studies to determine their true surrogate value with treatment intervention 
strategies. Future research can also be directed at investigating the role of genetic 
polymorphism in genes coding for apoptosis such as TRAIL, Bim, Fas and FasL, which are 
involved in the depletion of CD4+ T-cells and thus rapid progression to AIDS in certain 
individuals and not others. It would also be important to look at whether mRNA or genes 
involved in the increased surface expression of antigens are also up-regulated or down-
regulated or whether their functions are affected at molecular level. In addition, 
polymorphisms in genes encoding for pro-inflammatory cytokines such as IL-6, TNF-α, INF-α 
that predispose individuals to inflammation and immune activation, should also be explored. 
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